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ABBREVIATIONS 
 
AaDO2 : alveolo-arterial difference in partial pressure of oxygen 
ACD: alveolar capillary dysplasia 
? -SMA: ? -smooth muscle actin 
AT%: adventitial thickness expressed as percentage of the external diameter 
BAEP: brainstem auditory evoked potential 
cHb: intravascular concentration of haemoglobin (in mmol/L) 
cHHb: concentration of deoxyhaemoglobin (in µmol/100 g) 
cO2Hb: concentration of oxyhaemoglobin (in µmol/100 g) 
ctHb: concentration of total haemoglobin (in µmol/100 g) 
CBF: cerebral blood flow 
CBFV: cerebral blood flow velocity 
CBV: cerebral blood volume (in mL/100 g) 
CDH: congenital diaphragmatic hernia 
CPP: cerebral perfusion pressure  
CVL method: central venous line method 
CVP: central venous pressure  
CT-scan: computer tomography scan 
DLVV-ECMO: double lumen catheter veno-venous extracorporeal membrane oxygenation 
ECLS: extracorporeal life support  
ECMO: extracorporeal membrane oxygenation  
ED: external diameter 
EEG: electroencephalogram 
ELSO: extracorporeal life support organization  
FiO2 : fraction of inspired oxygen  
Flow AP: flow in the ECMO system between the bridge and the arterial catheter 
Flow VP: flow in the ECMO system between the venous catheter and the bridge 
HR: heart rate 
i-PPHN: idiopathic persistent pulmonary hypertension of the newborn 
IRDS: idiopathic respiratory distress syndrome 
kPa: kilo Pascal 
MABP: mean arterial blood pressure 
MAS: meconium aspiration syndrome 
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MRI: magnetic resonance imaging  
MT%: medial thickness expressed as a percentage of the external diameter 
NIRS: near infrared spectrophotometry 
OI: oxygenation index 
paO2: arterial partial pressure of oxygen 
paCO2: arterial partial pressure of carbon dioxide 
PBS: phosphate buffered saline 
PPHN: persistent pulmonary hypertension of the newborn  
Qao: blood flow in the aorta 
Qcar: mean blood flow in the left common carotid artery 
Qduct: ductus arteriosus blood flow 
Qecmo: ECMO flow 
Qpa: blood flow in the common pulmonary artery 
Qsyst: systemic blood flow 
RCCA: right common carotid artery 
RIJV: right internal jugular vein 
saO2: arterial oxygen saturation 
sd: standard deviation 
SEM: standard error of the mean 
SMC: smooth muscle cell 
Sp-B: surfactant protein B 
SSSP: superior sagittal sinus pressure 
svO2 : mixed venous oxygen saturation 
svO2 method: mixed venous oxygen saturation method 
svO2line: inline 'mixed venous' oxygen saturation  
VA-ECMO: veno-arterial extracorporeal membrane oxygenation 
VV-ECMO: veno-venous extracorporeal membrane oxygenation 
WT%: total wall thickness expressed as a percentage of the external diameter 
? : change in a variable 
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GENERAL INTRODUCTION 
 
 
BACKGROUND 
 
Extracorporeal life support (ECLS) provides a prolonged but temporary support of cardiac 
and/or lung function, using mechanical devices. When ECLS is used for respiratory failure, it 
is called ExtraCorporeal Membrane Oxygenation (ECMO). The ECMO circuit consists of 
vascular access catheters, connecting tubing, a blood pump, an artificial lung (“oxygenator”), 
a heat exchanger and monitoring devices. In ECMO in newborns, venous blood is passively 
drained from the right atrium via a venous catheter inserted into the right internal jugular vein 
(RIJV). The blood then passes through a pump that maintains adequate flow in the ECMO 
system. For safety purposes, an intermediate bladder box with servo- system prevents 
pumping if venous drainage is inadequate. Next, the blood passes the membrane oxygenator 
where it is oxygenated and the carbon dioxide pressure is regulated. In the membrane 
oxygenator, a gas mixture of air, oxygen and carbon dioxide passes in the opposite direction 
to the blood flow. After rewarming in the heat exchanger, oxygenated blood is returned to the 
patient. This can either take place via the right common carotid artery (RCCA), in veno-
arterial extracorporeal membrane oxygenation (VA-ECMO) (figure 1), or via the RIJV into 
the right atrium, in veno-venous extracorporeal membrane oxygenation (VV-ECMO).  
With mechanical support of circulation and gas exchange, the lungs and heart are given a rest 
period, during which the intensity of artificial ventilation and vaso-active drug administration 
can be diminished. Partial bypass is continued until the heart or lung function improves, after 
which blood flow through the extracorporeal circuit is decreased (weaning) and ECMO is 
ended.  
Generally, ECMO is indicated as a rescue treatment in patients with acute reversible 
respiratory failure, when there is a high risk of dying (50-100%) from the primary disease, 
despite optimal conventional treatment. The most important indications for ECMO treatment 
in newborns are respiratory failure and pulmonary hypertension caused by meconium 
aspiration syndrome (MAS), congenital diaphragmatic hernia (CDH), sepsis and idiopathic 
persistent pulmonary hypertension of the newborn (i-PPHN) (1). 
As ECMO is only used in patients who are likely to die without ECMO, the results are usually 
described in terms of survival. Current survival rates with ECMO treatment reported in the 
registry of the Extracorporeal Life Support Organization (ELSO) are 80% for neonatal 
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respiratory failure, 60% for paediatric respiratory failure and 50 % and for adult respiratory 
failure (1). 
 
Figure 1. Scheme of the VA -ECMO circuit  
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ECMO has increased survival in selected newborns with severe respiratory insufficiency. 
Unfortunately, this treatment modality has important complications that cause major 
morbidity and also determine survival rates. Ten to 30% of patients have major haemorrhagic 
and/or ischaemic intracranial lesions (2-9). Concern about the short and long-term negative 
effects of ligation of the RCCA in VA-ECMO led to the development of the VV-ECMO 
technique, in which ligation of the RCCA is avoided by cannulating a vein to return the 
oxygenated blood. However, VV-ECMO has the disadvantage of limited oxygenation, as 
recirculation of oxygenated blood from the ‘arterial’ infusion side of the cannula into the 
‘venous’ drainage side does not contribute to patient oxygenation.  
In addition to cerebral complications, survival rates are also determined by the occurrence of 
pulmonary complications (10). Severe intracranial abnormalities and pulmonary 
complications are highly correlated with disturbed neurodevelopmental outcome (2,5,8,11-
13). Abnormal developmental outcome was present in 11-24% of the patients in these studies. 
The presence of major abnormalities in neuro- imaging studies and chronic lung disease 
increased the risk of adverse neurodevelopmental outcome 27 and 2.6 times respectively. 
Patients with intracranial abnormalities on neuro- imaging were 27 times likely to have a 
delayed development (12,13).  
Persistent respiratory problems during ECMO can interfere with weaning the patient from 
ECMO. Although it is generally possible to wean the patient from ECMO, it remains unclear 
by which mechanism ECMO improves the underlying disease. 
Some technical aspects of ECMO treatment may be related to the occurrence of 
complications. Our group published about the effects on cerebral oxygenation and 
haemodynamics of cannulation and VA-ECMO initiation and of opening of the bridge, a 
safety connection between the arterial and venous side of the ECMO circuit (14,15). 
Furthermore, our group demonstrated the presence of a patent ductus arteriosus with left to 
right shunt during VA-ECMO and its relation with a prolonged ECMO duration (run-time) 
(16). Hereby the time period during which ECMO related complications might occur 
increases. 
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STUDY OBJECTIVES 
 
ECMO as a rescue treatment for newborns with severe respiratory insufficiency improves 
survival. However, the technique is complex and two major aspects determine short and long 
term outcome: cerebral and lung complications. 
It is very important to understand the effects of ECMO on the brain and lungs, in order to be 
able to optimize its use and prevent complications related to this technique.  
 
 
Therefore, this thesis had the following aims: 
1. To study clinical results, in terms of survival and complications, of VA-ECMO 
treatment in newborns with severe respiratory failure.  
2. To study the effect of VA-ECMO on cerebral oxygenation and haemodynamics. 
3. To devise a method to quantify the amount of recirculation during VV-ECMO. 
 
 
DETAILED OBJECTIVES OF THE STUDY 
 
Part 1 describes the clinical results of ECMO treatment at the University Medical Centre 
Nijmegen.  
1. More than 18,000 newborns have been treated with ECMO worldwide. Since the 
introduction of ECMO at our centre in 1999, 186 newborns have received treatment 
because of severe respiratory failure. Are our results comparable with those obtained 
at other centres? (Chapter 2). 
2. The beneficial effect of ECMO is generally described as “lung rest”, but it is unclear 
what this concept represents. Newborns with severe pulmonary hypertension have an 
abnormal morphology of the lung vasculature. What is the difference in the 
morphology of the lung vasculature in patients with pulmonary hypertension treated 
with ECMO and those not treated with ECMO? (Chapter 3). 
 
Part 2 addresses cerebral oxygenation and haemodynamics during ECMO. 
1. VA-ECMO causes changes in cerebral oxygenation and haemodynamics. Does the 
induction of VA-ECMO have different effects on the left and right cerebral 
hemispheres? (Chapter 5).   
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2. Opening of the bridge during VA-ECMO results in changes in cerebral oxygenation 
and haemodynamics. What causes these changes? What is the effect of opening the 
bridge at different ECMO flow rates and for different opening times, and can the 
changes in cerebral oxygenation and haemodynamics be prevented? (Chapter 6). 
 
3. A patent ductus arteriosus with left to right shunt can be present during VA-ECMO. 
How does a ductus arteriosus with left-to-right shunt during VA-ECMO affect 
cerebral oxygenation and haemodynamics? (Chapter 7). 
 
Part 3 addresses VV-ECMO 
In VV-ECMO, ligation of the RCCA is avoided by cannulating a vein to return the 
oxygenated blood. Oxygenation is limited with this technique, because recirculation 
does occur. Is it possible to quantify recirculation during VV-ECMO using an easily 
applicable, bedside method? (Chapter 9). 
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ECMO IN NEWBORNS WITH RESPIRATORY FAILURE: INTRODUCTION 
 
 
HISTORY 
 
The first extracorporeal cardiopulmonary bypass system was developed by John Gibbon in 
the 1930s (1). In this system, direct blood-gas contact was necessary for oxygenation, which 
limited the bypass time to about 6 hours because of cell haemolysis, platelet consumption and 
protein denaturation (2). In 1963, Theodore Kolobow developed the silicone rubber 
membrane lung, which today is still the oxygenator mainly used for long-term bypass (3). 
In 1976, Bartlett was the first to use ECMO successfully in a newborn with respiratory failure 
due to MAS (4,5). In 1982, Bartlett’s group reported on the use of ECMO in 45 newborns (6). 
These patients were suffering from pulmonary disease, often exacerbated by pulmonary 
hypertension, and were generally moribund when ECMO was started. ECMO and the short-
term follow-up results were considered so encouraging that many others started to apply 
ECMO treatment for newborn respiratory failure (7-10). Different authors tried to identify 
patients who would benefit most from rescue treatment with ECMO. Krummel et al, Ortiz et 
al and Beck et al published criteria to select patients for ECMO treatment (11-13). However, 
no scientific prove was available that demonstrated better survival with ECMO treatment. For 
obvious reasons it was not feasible to perform a blind randomised controlled trial comparing 
conventional treatment to ECMO treatment, because blinding as well as sham operations were 
impossible in the controls. Experience with ECMO treatment convinced people about its 
effectiveness. Opportunities were searched for in trials to limit the number of patients who 
had to be randomised to conventional treatment. Physicians could not accept that children 
from were dying while an alternative treatment was available. 
Two “adapted” randomised studies were published that seemed to prove the benefit of ECMO 
therapy over conventional therapy in newborns with severe respiratory failure (14,15). 
However the randomization design of these studies was disputed, which led to the opinion 
that no approved clinical trials had been undertaken (16). 
The ELSO, founded in 1989, participated in a National Institute of Health conference in 1990. 
It was concluded that ECMO use should be continued and that ECMO centres should 
participate in the ELSO registry, thus making it possible to monitor efficacy and effectiveness 
(17). Today, the ELSO has 110 centres in 14 countries.  
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In 1989, ECMO was applied for the first time at our hospital (University Medical Centre 
Nijmegen) in two newborns with MAS and sepsis, both survived (18). Between 1991 and 
1994, ECMO treatment was used within the "Evaluation project for innovative developments 
in medicine" entitled Extra Corporeal Membrane Oxygenation in newborns (no OG 90-001). 
As randomisation was considered to be unethical, the ECMO group was compared to a 
control group of newborns with severe respiratory failure who fulfilled the criteria for ECMO 
treatment but had not received ECMO because it was not yet available (1988-1991), the so-
called historical control group. Results of this project are summarized in table 1: survival in 
the ECMO group was better than that in the historical control group. The best survival was 
seen in the group of patients with MAS, while the greatest increase in survival was achieved 
in the group of patients with CDH. 
 
Table 1. Results of the “Evaluation project for innovative developments in medicine”: Extra Corporeal 
Membrane Oxygenation in newborns (OG-90-001) 
Diagnosis  ECMO survival Conventional 
therapy survival 
Odd’s ratio p value 
MAS 87% (n=31) 50% (n=22) 0.15 0.005 
CDH 65% (n=23) 4% (n=24) 0.02 <0.001 
Other 72% (n=25) 39% (n=38) 0.25 0.02 
Total 76% (n=79) 32% (n=84) 0.15 <0.001 
MAS = meconium aspiration syndrome, CDH = congenital diaphragmatic hernia 
 
In 1996, the UK collaborative ECMO group published a large randomised trial on survival in 
ECMO in newborns in (19). Newborns with severe respiratory failure were randomised to 
either ECMO treatment at one of the five ECMO centres or conservative treatment at the 
participating centres. The results are summarized in table 2. Survival until discharge in all the 
diagnoses groups of newborns with severe respiratory failure was better in the ECMO group 
than in the conventional treatment group. Cost-effectiveness was also evaluated and it was 
concluded that ECMO was likely to be as cost-effective as other life-extending technologies 
(20). 
The Cochrane group evaluated the trials of Bartlett et al, O’Rourke et al, the UK trial and also 
a fourth trial the results of which were presented at a conference (14,15,19,21,22). There were 
fewer deaths before discharge in ECMO patients than in controls (Relative Risk 0.44, 95% 
CI: 0.31-0.61, p<0.00001). Mortality rates differed by -0.32 (95% CI: -0.44 to -0.20), which 
meant that ECMO in three newborns was needed to prevent one death. The risk of death 
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before discharge was reduced the most in infants without the diagnosis CDH (RR 0.33, 95% 
CI: 0.21-0.53, p<0.00001), but even in infants with CDH the risk of death was reduced (RR 
0.72, 95% CI: 0.54-0.96, p=0.03). The Cochrane group concluded that the use of ECMO in 
newborns with severe, but potentially reversible, respiratory insufficiency resulted in 
significantly improved survival, without an increased risk of severe disability in survivors. 
However, in terms of death or disability, the advantage of ECMO treatment over conventional 
treatment in CDH patients had disappeared at 4 years follow-up in the UK trial (23). 
Over the past 28 years, ECMO has evolved from an experimental therapy for moribund 
newborns to a life-saving technology for a selected group of newborns with reversible or 
treatable disorders and intractable hypoxaemia, hypotension and/or clinical deterioration that 
is unresponsive to maximal conservative treatment (24). 
 
Table 2. Results of the UK collaborative randomised trial of extracorporeal membrane oxygenation in newborns 
 Deaths*/number treated  
Primary diagnosis  ECMO Conventional 
management 
Relative risk (95% CI); p value 
CDH 13/18 17/17 0.72 (0.54-0.96); p<0.05 
MAS 6/32 16/37  
I-PPHN 2/15 10/16 0.41 (0.24-0.67); p<0.001 
Other 7/28 11/22  
Total 28/93 54/92 0.52 (0.36-0.73); p<0.001 
 * = Death before discharge, MAS  = meconium aspiration syndrome, CDH  = congenital 
diaphragmatic hernia, i-PPHN = idiopathic persistent pulmonary hypertension of the newborn 
 
 
PATIENT SELECTION 
 
Patient selection for ECMO treatment is based on the principle that the risk of death or severe 
morbidity with conventional therapy is greater than the risk associated with ECMO treatment. 
In general, underlying lung disease must be reversible within the ECMO run-time. The most 
important disorders in newborns with severe respiratory failure are MAS, sepsis/pneumonia 
and CDH, often aggravated by severe persistent pulmonary hypertension of the newborn 
(PPHN). This latter disorder may be present without any of the other underlying disorders: 
idiopathic persistent pulmonary hypertension of the newborn (i-PPHN). ECMO allows time 
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for recovery and avoids the risks associated with prolonged intensive mechanical ventilation 
(24). 
ECMO treatment is not offered to patients with a compromised health state, i.e. patients with 
pre-existing cerebral defects, irreparable congenital heart disorders, non-functional kidneys, 
lethal and untreatable metabolic diseases, malformation syndromes, major anatomical 
anomalies and severe chromosomal aberrations (trisomy 13 and 18). Patients with pre-
existing irreversible organ damage are also excluded (24). 
ECMO is not offered to patients born at a gestational age of less than 34 weeks or with a birth 
weight of less than 2 kg, because of the increased risk of intracranial haemorrhage (25-27).  
As it is necessary to administer heparin during ECMO treatment, uncontrollable bleeding or 
coagulopathy is considered a relative contra- indication (24). Intensive artificial ventilation for 
longer than 10 days is also a relative contra-indication, because it may have caused 
irreversible lung damage. 
In their original paper, Bartlett et al used ECMO as a last resort treatment in moribund 
patients (4). Over the years, different physiological and clinical variables have been used to 
select patients who might benefit from ECMO treatment for their high mortality rate diseases 
(11-13). Currently, two main variables are used as criteria for ECMO treatment: the 
oxygenation index (OI) and the alveolar-arterial difference in partial pressure of oxygen 
(AaDO2), (table 3). Additionally, there are criteria based on acute deterioration of the patient 
and criteria related to pH, mainly for sepsis patients who might not develop severe 
hypoxaemia, but do have severe acidosis and poor organ perfusion (24).   
A set of generally used criteria have emerged in the meantime, which are summarized in the 
ELSO guidelines for the application of ECMO to newborns (28). The selection criteria at our 
institute are based on these guidelines (table 3). 
Although the original criteria predicted 80% mortality, nowadays these criteria would 
probably not predict this. In the UK trial, an OI of over 40 for 3 hours was used as a selection 
criterion for ECMO treatment. Thus, survival rates with conventional therapy (61%) in that 
study were based on this criterion and did not predict 80% mortality as originally suggested 
(13,19). Our own study demonstrated mortality rates of 50 to 96% in the control group, 
depending on the primary disease (table 1). Mathias et al published a study on newborns who 
met the ECMO criteria and found a mortality of 19% (29). Studies like these emphasize the 
need to re-evaluate ECMO criteria once new treatment modalities become available for 
respiratory failure. 
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Table 3. Selection criteria for ECMO at the University Medical Centre Nijmegen in newborns with severe 
respiratory failure  
 
Indications 
 
1. AaDO2>80 kPa (600 mm Hg) for more than 8 hours. 
2. AaDO2>80.6 kPa (605 mm Hg) for more than 4 hours with peak inspiratory pressure  = 38 mbar or 
mean airway pressure  = 22 mbar. 
3. Acute deterioration for at least 2 hours with pH<7.15 and PaO2<5.3 kPa (40 mm Hg). 
4. No clinical improvement on maximal conventional therapy for 3 hours with PaO2<5.3 kPa (40 mm Hg). 
5. Signs of barotrauma (at least 4): lung emphysema, pneumothorax or pneumomediastinum, 
pneumopericardium, pneumoperitoneum, subcutaneous emphysema, air leak >24 hours, mean airway 
pressure >15 mbar. 
6. OI>40 for 3-5 hours. 
7. In patients with CDH, at least one PaO2>10.6 kPa (80 mm Hg) must be documented. 
 
Contra-indications 
 
1. Gestational age <34 weeks or birth weight <2000 grams. 
2. Underlying lung disease or cause of respiratory insufficiency, that is not reversible within 10-14 days. 
3. Mechanical ventilation >10 days. 
4. Chromosomal or other congenital or acquired abnormalities incompatible with life. 
5. Intraventricular or cerebral parenchymal haemorrhage = grade II. 
6. Coagulopathy or bleeding complication for which heparin administration is contra-indicated. 
AaDO2 = Alveolo-arterial difference in partial oxygen pressure difference (mm Hg). 
AaDO2 = Patm - PH2O - (paO2+paCO2)FiO2, where Patm = atmospheric pressure, PH2O = vapour pressure 
(being 47 mm Hg at 37oC), paO2 = arterial partial pressure of oxygen, paCO2 = arterial partial pressure of 
carbon dioxide, FiO2 = fraction of inspired oxygen. 
OI = Oxygenation index  = [Mean Airway Pressure x FiO2 x 100]/paO2. MAP in mbar, paO2 in mm Hg. 
 
 
CLINICAL MANAGEMENT OF NEWBORNS ON VENO-ARTERIAL ECMO 
 
After a patient has been found to fulfil the ECMO criteria in the absence of contra- indications, 
the paediatric surgeon inserts appropriate cannulas. In VA-ECMO, the arterial cannula is 
inserted through the RCCA into the junction of the innominate artery and aortic arch. The 
venous cannula is inserted through the RIJV into the right atrium. The cannulas are then 
connected to the ECMO system and ECMO can be started. ECMO flow is increased gradually 
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until adequate oxygenation of the patient has been reached and ventilator settings can be 
reduced to so-called “rest-settings”, typically a frequency of 17-24/min, inspiratory pressure 
22-26 mbar, positive end-expiratory pressure 4-8 mbar and FiO2 of 0.30. Usually 
haemodynamic stability improves to such an extend after ECMO initiation that cardiotonic 
drug administration can be weaned and stopped. 
In the initial phase of ECMO, the goal of treatment is to maintain an adequate ECMO flow. 
This will ensure adequate oxygenation of the patient (arterial blood gas and “mixed venous” 
saturation) and normal organ function (pH, blood pressure, diuresis). It may be necessary to 
maintain a high ECMO flow rate in many patients initially, because the chest radiograph 
shows deterioration during the first 1-2 days (white-out). After 24 to 48 hours, the lung 
function generally improves, as indicated by increases in arterial partial pressure of oxygen 
(paO2) values, lung compliance, end-tidal partial pressure of carbon dioxide values and in 
paO2 after increasing the fraction of inspired oxygen (FiO 2) of the ventilator to 100% (“the 
hyper-oxygenation test”). Then by decreasing the ECMO flow rate, weaning can be started by 
10-20 mL/min per hour as long as paO2 values remain adequate. When an ECMO flow of 50 
mL/min has been reached and adequate oxygenation of the patient can be maintained for 6-8 
hours (idling), the patient is decannulated. If the ECMO flow cannot be diminished to 50 
mL/min, some adaptation of the ventilator settings with higher frequency, pressures and FiO 2 
may have to be accepted, in order to enable decannulation of the patient. 
In CDH patients, the diaphragmatic defect is closed during ECMO treatment, once an ECMO 
flow of 50 mL/min is reached. During and directly after surgery, the ECMO flow is 
maintained at a higher level for 24-36 hours to prevent recurrent pulmonary hypertension, 
where after the patient was weaned again and decannulated. 
Newborns with respiratory failure usually have two distinct abnormalities: pulmonary 
parenchymal disease with a mismatch in ventilation and perfusion, and pulmonary vascular 
disease with pulmonary hypertension. The latter disorder can cause right to left shunt at the 
ductus arteriosus and at the atrial level thereby causing hypoxaemia (30,31). 
The syndrome of PPHN is associated with abnormalities in the structure of the small arteries 
in the lung (32-26). It is important to understand the effects of ECMO on the neonatal lung, 
the recovery of PPHN and the underlying parenchymal lung disease. Generally, the beneficial 
effect of ECMO is described as lung rest (37-38). Despite the large number of newborns 
treated with ECMO worldwide, only a few data are available about the evolution of the 
abnormal vascular wall structure during ECMO. Shehata et al studied vascular morphology in 
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CDH patients after ECMO treatment and found partial regression of the abnormal vascular 
wall structure.  
The next two chapters describe the results of ECMO treatment in newborns at the University 
Medical Centre Nijmegen, and those of a study on lung vascular morphology after ECMO 
treatment.  
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ABSTRACT 
 
Between 1991 and 2003, 186 newborns were treated with extracorporeal membrane 
oxygenation at the University Medical Centre Nijmegen, the Netherlands. Diagnoses were 
meconium aspiration syndrome (n=78, survival 95%), congenital diaphragmatic hernia (n=58, 
survival 65%), sepsis/pneumonia (n=28, survival 79%), idiopathic persistent pulmonary 
hypertension of the newborn (n=20, survival 75%) and idiopathic respiratory distress 
syndrome (n=2, survival 100%). Extracorporeal membrane oxygenation was started at an 
earlier postnatal age in congenital diaphragmatic hernia than in meconium aspiration 
syndrome, sepsis and idiopathic persistent pulmonary hypertension of the  newborn, and 
earlier in meconium aspiration syndrome than in idiopathic persistent pulmonary hypertension 
of the newborn. There were no statistically significant differences in extracorporeal 
membrane oxygenation run times between diagnosis groups.  
Thirty-five newborns died (19%), due to respiratory failure (n=21), intracranial haemorrhage 
(n=8), alveolocapillary dysplasia (n=3) and surfactant protein B deficiency (n=1). There were 
two late deaths (> 6 weeks after extracorporeal membrane oxygenation treatment) related to 
the underlying abnormality. Survivors and non-survivors differed on entry diagnosis, 
extracorporeal membrane oxygenation run time and birth weight. 
Important complications during extracorporeal membrane oxygenation treatment were 
disseminated intravascular coagulation (19%), need for circulatory support with inotropic 
medication (16%) and problems with the cannula position (15%). 
Important factors related to death were pH < 7.20 and cerebral haemorrhage. 
Thirteen patients had a cerebral haemorrhage, while 17 had an ischaemic lesion, without 
predominance for either cerebral hemisphere. 
In 8 patients, a patent ductus arteriosus with left to right shunt was detected during or after 
extracorporeal membrane oxygenation. 
Conclusion: extracorporeal membrane oxygenation is a rescue treatment for a selected group 
of newborns with cardiorespiratory insufficiency that is unresponsive to maximal 
conventional treatment. Overall survival at our centre was 81%, which is comparable with 
other centres. Complications form an important limiting factor for favourable outcome. 
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INTRODUCTION 
 
ECMO is a rescue treatment for newborns with severe cardiorespiratory insufficiency when 
conventional treatment, including artificial ventilation, inotropic support, surfactant 
administration and nitric oxide inhalation, has failed to maintain adequate oxygenation and 
there is a high predicted mortality (1-3). ECMO was introduced at our clinic in 1989 (4). So 
far, we have been using the VA-ECMO technique on all newborns treated with ECMO. 
Venous blood is drained from the right atrium and pumped a by roller pump to a membrane 
oxygenator. Gas exchange takes place in the membrane oxygenator: venous blood is 
oxygenated and the carbon dioxide pressure of the blood is regulated. Be fore the oxygenated 
blood is returned to the arterial circulation, it passes a heat exchanger to normalize the blood 
temperature. VA-ECMO offers temporary support for lung function and cardiac function, 
generally over a maximum period of 2 to 3 weeks. The most important indications for ECMO 
treatment in newborns with respiratory failure are MAS, CDH, sepsis/pneumonia and i-
PPHN. 
We describe the results of VA-ECMO treatment in 186 newborns at the University Medical 
Centre Nijmegen over the period 1991 and 2003.  
 
 
PATIENTS AND METHODS 
 
Patients 
 
The first two newborns were treated with ECMO at our centre in 1989 (4). From 1991 to 
1994, ECMO treatment was offered within the "Evaluation project for innovative 
developments in medicine"  ExtraCorporeal Membrane Oxygenation in newborns (no OG 90-
001) and later as a regular treatment method. Between 1991 and 2003, 186 newborns that 
fulfilled one or more of the selection criteria for ECMO treatment and did not have any 
contra- indications were treated with ECMO (5,6). 
After the initiation of ECMO, there was a stabilization period of 24-48 hours. Then the 
newborn was weaned until an ECMO flow of 50 mL/min was reached. When oxygenation 
was adequate at this flow rate, the patient was decannulated. In CDH patients, the 
diaphragmatic defect was closed during ECMO treatment, once an ECMO flow of 50 mL/min 
was reached. During and directly after surgery, the ECMO flow was maintained at a higher 
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level for 24-36 hours to prevent recurrent pulmonary hypertension, where after the patient 
was weaned again and decannulated (7). Heparin administration during ECMO to prevent 
clotting in the ECMO circuit was dosed based on determination of the activated clotting time 
or heparin activity in the blood. 
 
Registration of the results of ECMO treatment 
 
To report our results of ECMO treatment to the ELSO we have been using the ELSO 
Documentation Form (8). On this form, the diagnosis for ECMO treatment, gestational age, 
sex, age at the start of ECMO and ECMO run time are documented. In CDH patients, time of 
diagnosis, prenatal or postnatal, is recorded. Survival rates until discharge or transfer are 
calculated. Complications that occur during ECMO treatment are also documented in this 
form. Furthermore, in CDH patients, we record the place of birth. In non-surviving infants, 
causes of death are described. During the ECMO run, ultrasound of the head is performed 
daily. Also computer tomography (CT) scanning or magnetic resonance imaging (MRI) scan 
of the brain are performed in survivors after ECMO treatment. Lesions can be classified as 
haemorrhagic or ischaemic. They were further classified by us according to their localization: 
left or right hemisphere, bilateral, or in the posterior fossa.  
 
 
STATISTICS 
 
Survival rates were compared between the different diagnoses groups and also with those 
reported by the ELSO (Fisher’s exact test). Survival rates were compared in prenatally and 
postnatally diagnosed CDH patients (Fisher’s exact test) and survival was also calculated 
according to place of birth (Fisher’s exact test/Chi-square test). Mean ages at the start of ECMO 
were compared between the different diagnosis groups (Kruskall Wallis non-parametric 
ANOVA test with Dunn’s multiple comparison test). ECMO run times were compared between 
the different diagnosis groups (one way ANOVA). Survivors and non-survivors were compared 
on ECMO run time, birth weight and gestational age (unpaired t-test). The distribution of 
haemorrhagic and ischaemic cerebral lesions over the left and right hemisphere was compared as 
well as these two lesions combined (Fisher’s exact test). The relation between diagnosis and the 
occurrence of haemorrhagic or ischaemic lesions was tested (chi-square test). Infants with and 
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without cerebral lesions were compared on gestational age and birth weight (unpaired t-test). P 
values = 0.05 were considered significant. 
 
 
RESULTS 
 
Diagnosis and survival 
 
Results are presented as mean ± sd. 
The total group of 186 newborns treated with ECMO comprised 116 boys and 70 girls. Table 
1 summarizes all the diagnoses and survival rates after ECMO treatment in our patients and 
survival data according to the ELSO. Survival varied from 65% in CDH to 95% in MAS and 
was significantly better in MAS than in CDH, sepsis and PPHN.  
The diagnosis of CDH was made prenatally in 15 patients and postnatally in the remaining 43. 
Survival rates in the CDH patients diagnosed prenatally and postnatally were 60% and 67%, 
respectively (p=0.75). Place of birth had no effect on the survival of CDH patients. Survival 
rates of patients born at home, at a general hospital and at a 3rd level centre were 75%, 59% 
and 71%, respectively (p=0.53). Survival rates of CDH patients born at our ECMO centre 
(62%) were comparable with those born elsewhere (67%; p=0.80). 
 
Age at the start of ECMO 
 
ECMO was started significantly earlier after birth in CDH patients (24±17 hrs, mean ± 
standard deviation (sd)) than in patients with MAS (46±46 hrs; p<0.001), sepsis (78±90 hrs; 
p<0.001) and i-PPHN (77±78 hrs; p<0.001), while in MAS patients it was started earlier than 
in i-PPHN (p<0.05). All the CDH patients, except for one, were on ECMO on day 3 after 
birth. In two patients, ECMO was started after surgical correction of the diaphragmatic defect; 
in all the others ECMO was initiated in order to achieve pre-operative cardiorespiratory 
stabilization before surgery. In the other diagnosis groups, 74% of the patients were on 
ECMO on day 3 after birth. 
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Table 1. Diagnosis and survival in 186 newborns treated with ECMO for respiratory insufficiency 
Diagnosis Number Survival  (nr) Survival (%) ELSO (%) 
MAS 78 74 95* # 94 
CDH 58 38 65 53 
Sepsis  28 22 79 75 
i-PPHN 20 15 75 79 
IRDS 2 2 100 84 
Total 186 151 81 - 
MAS = meconium aspiration syndrome, CDH = congenital diaphragmatic hernia, i-PPHN = idiopathic persistent 
pulmonary hypertension of the newborn, IRDS = idiopathic respiratory distress syndrome, ELSO = 
Extracorporeal Life Support Organization, Survival = survival to discharge or transfer 
*: p<0.05 MAS compared to sepsis and PPHN,  #: p<0.01 MAS compared to CDH 
nr = number, % = percentage 
 
ECMO run time 
 
There were no significant differences in ECMO run time between the different diagnosis 
groups: 153±56 hours in MAS, 176±71 hours in CDH, 166±67 hours in sepsis and 172±48 
hours in i-PPHN patients. Differences in ECMO run times between the diagnosis groups were 
however not significant (p=0.17). 
ECMO run time was significantly shorter in survivors (154±50 hours) than in non-survivors 
(214±93 hours; p<0.01). 
 
Mortality  
 
Thirty-five newborns died. Causes of death are summarized in table 2. Persistent respiratory 
insufficiency was the major cause of death, especially in the group of CDH patients. These 
patients often had severe rebound pulmonary hypertension and signs of multi-organ failure, 
such as hypotension and oliguria. In the CDH group, 2 patients died more than 6 weeks after 
ECMO treatment (late deaths), one because of ischaemic intestinal necrosis with perforation 
and another one because of respiratory insufficiency. In 8 patients with intracranial 
haemorrhage, ECMO was withdrawn to prevent progression of the haemorrhage during 
heparin administration or because of expected poor prognosis. In the i-PPHN group, 4 out of 
the 5 patients that died had rare, untreatable diseases: 3 patients had alveolar capillary 
dysplasia (ACD) and 1 had surfactant protein B (Sp-B) deficiency.  
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Apart from the differences in diagnosis and ECMO run time, survivors differed from non-
survivors on birth weight (3393±591g and 3094±496g, respectively; p<0.01). There was no 
difference in gestational age between survivors (276±15d) and non-survivors (274±17d; 
p=0.41).  
 
Table 2. Causes of death in 36 newborns treated with extracorporeal membrane oxygenation for 
cardiorespiratory insufficiency 
 
Diagnosis 
 
Number 
 
Persistent 
respiratory 
insufficiency 
ICH 
 
Sp-B def 
 
ACD 
 
Late death 
 
MAS 4 1 3    
CDH 20 15 3   2 
Sepsis  6 4 2    
i-PPHN 5 1  1 3  
IRDS 0      
Total 35 21 8 1 3 2 
MAS = meconium aspiration syndrome, CDH = congenital diaphragmatic hernia, i-PPHN = idiopathic persistent 
pulmonary hypertension of the newborn, IRDS = idiopathic respiratory distress syndrome, ICH = intra-cranial 
haemorrhage, Sp-B def  = surfactant protein B deficiency, ACD = alveolar capillary dysplasia, late death = 
patients that died more than six weeks after ECMO treatment from primary disease related causes. 
 
Complications 
 
The most frequent complications of ECMO treatment in our population are listed in table 3. 
Disseminated intravascular coagulation was the most common (19%). Other major 
complications were the need for circulatory support with inotropic medication during ECMO, 
problems with the cannula position, surgical site bleeding, hypo- or hyperglycaemia, culture 
proven infections and clots in the ECMO system, especially in the bridge. The most important 
factors related to death were the occurrence of metabolic acidosis with pH<7.20 during the 
ECMO run, cerebral haemorrhage, infections and surgical site bleeding. The latter 
complication occurred in 45% of the CDH patients. 
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Table 3. Complications of ECMO treatment 
Complication % Survival (%) 
DIC 19 70 
Inotropes on ECMO 16 77 
Cannula problems  15 79 
Surgical site bleeding 45* 56 
Clots in bridge 14 73 
Glucose > 13.3 mmol/l 14 74 
Glucose < 2.2 mmol/l 11 81 
Culture proven infection 11 57 
Cerebral infarction 9 59 
Cerebral haemorrhage 7 38 
pH < 7.20 4 14 
% = percentage of ECMO runs, DIC: disseminated intravascular coagulation 
*: percentage of surgical site bleeding in CDH patients, as this only occurred in CDH patients. 
 
Cerebral imaging   
 
Ultrasound investigations of the brain were performed daily in all 186 patients. A CT-scan or 
MRI-scan was not done on 33 patients that died. In another 18 patients, care providers 
decided not to do a CT-scan or MRI-scan because they had normal ultrasound findings. 
Results of head ultrasound, CT-scan and MRI-scan studies of the brain are presented in table 
4. Haemorrhagic lesions were observed in 13 patients (7.0%) and infarctions in 17 patients 
(9.1%). There was no significant difference between the occurrence of lesions in the left and 
right hemispheres; in both hemispheres 8 lesions (4.3%) occurred (p=1.0). Also, there was no 
significant difference in the distribution of haemorrhagic and ischaemic lesions over the right 
and left cerebral hemispheres (p=0.72 for both). Bilateral lesions were present in 11 patients 
(5.9%) and posterior fossa lesions in 3 patients (1.6%). Altogether 16.1% of the patients had a 
haemorrhagic or ischaemic lesion during or after ECMO treatment. In the survivors, 3.3% had 
a cerebral haemorrhage, while 6.6% had an infarction.  
There was no relation between diagnosis and the occurrence of haemorrhagic or ischaemic 
lesions (p=0.09 and p=0.36, respectively). Infants with and without cerebral haemorrhage did 
not differ on gestational age (276±16d versus 271±18d; p=0.31) or birth weight (3287±671g 
versus 3343±577g; p=0.77). Also infants with and without ischaemic lesions were 
comparable on gestational age (275±16d versus 281±15d; p=0.13) and birth weight 
(3353±586g versus 3357±575g; p=0.91). 
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Table 4. Localization of cerebral haemorrhagic and ischaemic lesions  
Nr: number, withdrawn: patients from whom ECMO treatment was withdrawn because of the cerebral lesion that 
occurred 
 
Patent ductus arteriosus 
 
Although echocardiography investigations were not performed routinely dur ing or after 
ECMO, 8 patients (4.3%) were found to have a patent ductus arteriosus with left-to-right 
shunt, which was considered to be haemodynamically important. Six of these patients had a 
diagnosis of CDH. In 5 patients the patent ductus was detected during the ECMO run and in 3 
it was detected afterwards. The ductus closed with conservative treatment (fluid restriction 
and adequate oxygenation) in 3 patients, it was ligated in 4 patients and in 1 patient it was 
closed with indomethacin.  
 
 
DISCUSSION 
 
Number of patients 
 
We treated 186 patients between 1989 when ECMO treatment in the Netherlands was 
introduced, and 2003. As we only had 1 set of ECMO equipment until 1995, the annual 
number of patients treated with ECMO has remained fairly constant. Other ECMO centres 
have reported a decrease in numbers since the introduction of new treatment modalities, such 
as surfactant administration, high frequency ventilation and nitric oxide inhalation (9-12). The 
worldwide annual number of neonatal respiratory ECMO runs peaked in 1992 at 1517 
treatments, but decreased to 853 treatments in 2001 (13). The constant number of patients 
treated over the years at our centre is possibly explained by an increase in referrals from other 
neonatal intensive care units after the official recognition of ECMO centres in the 
Netherlands.  
Haemorrhage Nr Survi val Withdrawn Infarction Nr Survival 
Left hemisphere 5 2 3 Left hemisphere 3 0 
Right hemisphere 3 1 2 Right hemisphere 5 4 
Bilateral 3 0 3 Bilateral 8 6 
Posterior fossa 2 2 0 Posterior fossa 1 0 
Total 13 5 8 Total 17 10 
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The proportion of newborns with idiopathic respiratory distress syndrome (IRDS) worldwide 
has decreased markedly from 15% in 1988 to 4% in 1997. As a consequence, the proportion 
of CDH patients has increased from 18% to 26% (12). In our population, there were only 2 
patients with IRDS; the last one was treated in 1998. MAS was the most frequent indication 
for ECMO treatment in our group, which is in agreement with the international literature (12). 
Wilson et al reported changing patient demographics in the ECMO population and suggest an 
increasing need for cardiac ECMO (9). This is supported by the ELSO data: 165 cardiac runs 
in 1990 compared to over 500 in 2000. Over the past few years, we have treated 12 cardiac 
patients apart from the 186 newborns with respiratory failure described here, mainly 
following cardiac surgery. With the increasing complexity of cardiac surgery, in our ECMO 
centre we can confirm the trend suggested by Wilson. 
 
Survival rates 
 
Survival rates in our group are comparable with those reported by other centres and registered 
by the ELSO. In our CDH group, survival of patients with a prenatal diagnosis born at a 3rd 
level centre was comparable with that of the group born elsewhere. However, confounding 
factors can have been present. In the Netherlands, there is no routine prenatal screening 
programme. Thus, the prenatal diagnosis of CDH is mainly made on the basis of incidental 
screening for other diseases, or on so-called ‘fun scans’. Consequently, these cases are not 
necessarily the ones with the most severe CDH abnormalities and worst outcome. The fact 
that only a minority of the CDH patients were detected prenatally also determined the place of 
birth and might have influenced survival in relation to birth location as well. Also, it is not 
clear which percentage of the CDH patients, born in other centres, were referred for ECMO.  
  
Age at the start of ECMO  
 
Significant differences were found between the different diagnoses groups in the postnatal  
age at which ECMO was started. In CDH patients, ECMO was started earlier than in all the 
other diagnosis groups while in MAS patients it was started earlier than in patients with 
PPHN. Schoeman et al reported that the median age at the start of ECMO in CDH patients 
was 2 days (14). The fact that in the CDH group all the patients except for one were on 
ECMO on the third day of life in our opinion confirms the presence of respiratory 
insufficiency at an early stage in many CDH patients and necessitates the early referral of 
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these patients. This is supported by our previous study on ECMO criteria in CDH patients. 
Our group suggested that ECMO should be started earlier than is currently stipulated in 
classical ECMO criteria (5). Kössel et al stated that in newborns pretreated with high 
frequency ventilation and nitric oxide inhalation the decision to start ECMO based on an 
OI>40 needs to be adapted to an OI>25 after 72 hours of such treatment (15). 
 
ECMO run time 
 
There was no significant effect of diagnosis on ECMO run time. However, ECMO run time 
was significantly increased in non-survivors compared to survivors, with a difference in the 
mean ECMO run time of almost 60 hours. Apart from the difference in ECMO run time, 
survivors and non-survivors differed in birth weight and entry diagnosis, as was also 
described by Stolar et al (14). 
 
Causes of death 
 
Watson et al described that the major cause of death in ECMO patients is the underlying 
disease process leading to cardiopulmonary failure and that mortality is not affected by 
technical complications (16). We also observed this in our patients. Short and Walker stated 
that the major cause of death in infants who are receiving ECMO is cerebral injury (17). In 8 
of our patients, ECMO was withdrawn because of severe intracranial haemorrhage at a time 
when they were not actually weanable and therefore died. In this study, the cause of death in 
these patients was then classified as intracranial haemorrhage. Late death, more than 6 weeks 
after ECMO treatment, can occur especially in CDH patients. Schoeman et al reported five 
late deaths, secondary to chronic lung disease (n=3) and infection (n=2) in 11 CDH patients 
treated with ECMO (18). In our group of CDH patients, we had 2 late deaths related to the 
underlying disease. Patients with i-PPHN may have underlying diseases, such as Sp-B 
deficiency, ACD and congenital pulmonary lymphangiectasia, that are not treatable with any 
form of therapy (19-22). Four of the 5 deaths in our i-PPHN group were due to these diseases: 
3 from ACD, 1 from Sp-B deficiency. There were 5 sets of siblings with ACD in the 45 
patients described by Tibbals and Chow, which suggests that the disease can have a genetic 
basis (23). We had 2 siblings with ACD, one was treated with ECMO and one was not. In 
patients with ACD, oxygenation status improved during ECMO, but this did not lead to their 
survival (20,21). Sp-B deficiency is also considered to be lethal; it is usually caused by a 
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121ins2 mutation in the Sp-B gene. Ballard et al described a patient with a form of Sp-B 
deficiency that had a milder course. This patient demonstrated a point mutation in exon 7 of 
the Sp-B gene (24). 
 
Complications 
 
ECMO treatment has potentially severe complications. The most important are haemorrhagic 
complications. It has been suggested that these are related to the administration of heparin and 
to an increase in fibrinolytic activity after the initiation of ECMO (25). Heparin is 
administered because the contact of blood with foreign surfaces causes activation of the 
clotting system. Despite the use of heparin, thrombus formation still occurs. Nineteen per cent 
of our patients showed signs of disseminated intravascular coagulation. Glass et al reported 
that about 50% of the patients that died after ECMO treatment had haemorrhagic 
complications (26). 
We also observed haemorrhagic complications, especially in CDH patients. In these patients, 
the defect in the diaphragm is closed during the ECMO run and bleeding may occur from the 
surgical site. Haemorrhages can be so severe that the ECMO run has to be ended to control 
the blood loss. If this is necessary before the underlying respiratory problem has been 
completely resolved, the patient will die of respiratory failure. The introduction at our centre 
of the anti- fibrinolytic drug tranexaminic acid in the peri- and early post-operative phase to 
CDH patients resulted in a significant decrease in haemorrhagic complications (27). 
Mechanical complications occurred less frequently and could always be solved. Owing to the 
invasive character of this treatment with the insertion of catheters into blood vessels and 
decreases in plasma immunoglobulin concentration, there is an increased risk of infections 
(28,29). Cultures were positive in 11% of our patients but many more were suspected of 
having an infection based on laboratory investigations and clinical symptoms.  
Infections may contribute to rebound pulmonary hypertension and multi-organ failure and are 
a risk factor for non-survival (30,31). Steiner et al found that the risk of acquiring a 
nosocomial bloodstream infection on ECMO was increased in patients treated for longer than 
10 days (32). Other important factors related to death were haemodynamic instability, 
presenting as metabolic acidosis, and cerebral haemorrhage. Cheung et al demonstrated that 
plasma lactate levels and a low pH were both related to death and neurodevelopmental 
disability or delay (33). Low survival rates in patients with a cerebral haemorrhage are 
partially determined by the withdrawal of ECMO therapy to prevent progression of the 
 48
haemorrhage during heparin administration or because it is expected that the patient has a 
poor prognosis. 
 
Cerebral lesions 
 
Lazar et al reported a range of between 10 and 35% for intracranial lesions, while Bulas et al 
mentioned an incidence of even 52% for intracranial haemorrhage and infarction (34,35). In 
contrast, the ELSO registry documented 9.2% for central nervous system infarctions and 5.4% 
for haemorrhages (13).  The latter rates are comparable with our data. We did not find a 
predominance of cerebral lesions in either hemisphere. Some authors found differences 
between the left and right hemispheres, whereas others did not (36-42). Haemorrhages in the 
posterior fossa have also been described by others (40,42,43-45). Several authors found that 
the majority of cases of intracranial haemorrhage occurred within 72 hours after the start of 
ECMO (43,46,47). 
It has been reported that preterm infants and infants with a low birth weight treated with 
ECMO are at increased risk for intracranial haemorrhage (42,48). However, in our group 
there was no difference in gestational age or birth weight between the patients with and 
without intracranial haemorrhage. Bulas et al found that an increase in time spent on ECMO, 
increased the risk for ischaemic lesions (42). This could not be confirmed in our group 
(ischaemic lesions: 161±65hrs, others 162±67hrs; p=0.85, unpaired t-test). They also 
observed an increased risk of haemorrhagic lesions in sepsis patients and an increased risk of 
non-haemorrhagic lesions in CDH patients. These findings were not confirmed in our 
population. In addition, we also could not demonstrate a relation between ischaemic lesions 
and gestational age or birth weight. 
 
Patent ductus arteriosus 
 
As mentioned above we did not study the presence of a patent ductus arteriosus with left to 
right shunt systematically during ECMO. However, 5 patients were found to have a patent 
ductus with left-to-right shunt during ECMO and 3 more afterwards. In these latter patients, it 
is likely that the ductus was present during ECMO treatment. In an earlier study on 29 
newborns, we observed a patent ductus with left to right shunt in 62% at some time during the 
ECMO run. These patients had a significantly longer ECMO run time than the patients 
without a ductus with left to right shunt (49). Also the potential stealing effect on the cerebral 
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circulation of a patent ductus with left to right shunt warrants further studies on this theme 
(50). Furthermore, it is not clear how a haemodynamically important ductus arteriosus should 
be treated, conservative, surgically or with medication. 
 
 
CONCLUSION 
 
ECMO is a rescue treatment for newborns with severe respiratory insufficiency. It improves 
survival rates in a selected group of patients. However, the occurrence of complications 
impairs the outcome. 
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ABSTRACT 
 
The morphology of persistent pulmonary hypertension in the newborn is represented by 
increased medial and adventitial thickness in the lung vasculature. This study describes the 
morphometry of the lung vasculature after extracorporeal membrane oxygenation treatment in 
newborns with persistent pulmonary hypertension due to meconium aspiration syndrome, 
sepsis, or idiopathic.  
Three groups were studied: newborns with persistent pulmonary hypertension treated with 
extracorporeal membrane oxygenation (n=9), newborns with persistent pulmonary 
hypertension not treated with extracorporeal membrane oxygenation (n=12), and age matched 
controls without persistent pulmonary hypertension of the newborn (n=11). Formalin fixed 
and paraffin embedded lung specimens obtained at autopsy were stained with Elastic von 
Gieson or Masson trichrome staining followed by morphometric measurements. In intra-
acinar arteries with an external diameter less than 150 µm, the arterial medial, adventitial, and  
total wall thickness, expressed as percentage of the external diameter, and their cross sectional 
areas were calculated.  
Newborns with persistent pulmonary hypertension, compared to controls, demonstrated an 
increased percentage of medial thickness, percentage of adventitial thickness and percentage 
of total wall thickness and an increased medial, adventitial and total wall cross sectional area. 
Newborns treated with extracorporeal membrane oxygenation, compared those not treated so, 
showed a decreased percentage of medial thickness and medial cross sectional area in arteries 
with an external diameter less than 75 µm, and a decreased percentage of medial thickness 
and a decreased medial, adventitial, and total wall cross sectional area in arteries with an 
external diameter between 75 and 150 µm. 
Extracorporeal membrane oxygenation treatment for persistent pulmonary hypertension of the 
newborn, due to meconium aspiration syndrome, sepsis, or idiopathic, reduces the abnormal 
morphometry of the small intra-acinar arteries. The underlying mechanisms contributing to 
this improved morphometry are yet unknown.  
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INTRODUCTION 
 
The clinical syndrome of PPHN is characterized by central cyanosis due to right-to-left 
shunting through the oval foramen and/or ductus arteriosus (1). Right-to-left shunting 
develops as consequence of persistence of a high pulmonary vascular resistance. Classically, 
and mainly based on morphologic data, three different anatomic types of lung vascular 
abnormalities have been documented in case of PPHN; underdevelopment, maldevelopment 
and maladaptation (2-4). First, underdevelopment of the lung vasculature in combination with 
hypoplasia of the lung occurs in CDH. The second type of pulmonary vascular abnormalities 
is present in maldevelopment of pulmonary vessels in utero, like in MAS and i-PPHN. 
Finally, vascular abnormalities can be present in maladaptation of the pulmonary arteries to 
postnatal life, where there is a failure to decrease pulmonary vascular resistance after birth, 
like in sepsis and pneumonia (2,3,5).  
Despite the different aetiologies, the lung vascular morphology in all three forms of 
pulmonary hypertension in newborns is similar, showing an increased medial and adventitial 
thickness (3,5-9). In MAS, i-PPHN, and sepsis the  number of intra-acinar arteries is normal 
and the vessels have a normal external diameter (ED). There is however extension of the 
muscle coat into normally non-muscular arteries (5,7,10). However, in CDH the situation is 
far more complicated because of lung hypoplasia with a decreased number of bronchial 
generations in which the vasculature is also hypoplastic with a decreased number of intra-
acinar arteries. These intra-acinar arteries have a decreased ED in which the medial wall 
thickness is increased. Extension of the muscle coat in the smaller arteries can either be 
normal, or increased to distal into normally non-muscular arteries (2).  
The treatment of PPHN consists nowadays of a combination of different therapies including 
artificial ventilation, either conventional or high frequency oscillatory ventilation, inhalation 
of nitric oxide, and recently the use of phosphodiesterase inhibitors like sildenafil (4,11-13).  
ECMO can be used as a rescue treatment for PPHN, when conservative therapy fails (14). 
Generally, the effect of ECMO is described as ‘lung rest’ (15-17). Although the beneficial 
effect of ECMO with regard to changes in the pulmonary vasculature is unclear, it is thought 
that ECMO therapy “breaks” the circle of increasing pulmonary hypertension and right-to-left 
shunting (18).   
In a series of CDH cases that, following successful decannulation from ECMO, died 12-48 
hours later because of therapy resistant or recurrent pulmonary hypertension, our group 
formerly found a decrease in adventitial thickness of small pulmonary arteries after ECMO 
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treatment. The medial smooth muscle cell (SMC) hyperplasia was however not altered (8). As 
described, the vascular changes in CDH patients can be different from those in patients with 
MAS, sepsis, or i-PPHN. To our knowledge the effect of ECMO treatment in newborns with 
pulmonary hypertension due to MAS, sepsis or idiopathic has not been documented in a 
systematic way before. We hypothesized that ECMO has an effect on the abnormal 
morphology of the vascular wall in patients with pulmonary hypertension (2,3,5). We studied 
the morphology of the lung vasculature after ECMO treatment in patients with PPHN due to 
MAS, sepsis or idiopathic, and compared this with patients with PPHN that were not treated 
with ECMO and control patients without PPHN. 
 
 
PATIENTS AND METHODS 
 
Study group 
 
We studied thirty-two consecutive lung autopsy specimens of newborns. Materials were 
retrieved from the archives of the Institute of Pathology, University Medical Centre 
Nijmegen, Nijmegen and the Department of Pathology, Josephine Nefkens Institute Erasmus 
MC, Rotterdam. Tissue specimens were obtained from patients after parental consent for 
autopsy during the period 1991-2001. All newborns had a gestational age above 34 weeks and 
a birth weight of at least 2,000 gram.  
Patients were divided into three groups: (a) patients suffering from pulmonary hypertension 
due to MAS (n=3), sepsis (n=5) or i-PPHN (n=1) treated with ECMO after conservative 
treatment had failed (ECMO group, n=9); (b) patients suffering from pulmonary hypertension 
due to MAS (n=6), sepsis (n=3) or i-PPHN (n=3) treated with conservative therapy only (non-
ECMO group, n=12); (c) a control group of patients (n= 11) who died shortly after birth from 
asphyxia due to placental abruption and did not receive intensive therapy. 
In all patients of the ECMO group and the non-ECMO group the presence of pulmonary 
hypertension was confirmed by cardiac ultrasonography with right-to-left shunting together 
with the existence of a difference of 10% or more between pre-ductal and post-ductal 
transcutaneous oxygen saturation (8). 
In four patients of the ECMO group, ECMO was withdrawn because of cerebral 
complications, the other five patients all were early post-ECMO deaths, median value 9 days, 
range 1-17 days after decannulation. The patients in the non-ECMO group all suffered from 
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severe pulmonary hypertension but were not treated with ECMO because of the presence of a 
contra- indication for ECMO treatment: intracranial haemorrhage (n=7) or asphyxia with 
resulting brain damage (n=5). The patients in the control group showed no clinical features of 
pulmonary hypertension and had no lung abnormalities on histological examination. In these 
patients therapy was withdrawn at the median age of 2 days, range 1-4 days, because of the 
severe neurologic abnormalities and poor prognosis. 
The entry-criteria for ECMO treatment were: gestational age of at least 34 weeks, birth weight 
at least 2000 g, artificial ventilation for less than 10 days, AaDO2 greater than 600 mm Hg for 
more than 8 hours. 
Ventilation modes in the non-ECMO group and ECMO group were either conventional 
ventilation (peak inspiratory pressures of 30-38 mbar, positive end-expiratory pressures of 4-8 
mbar, frequency 45-85/min, FiO 2 1.0) or high frequency oscillation ventilation (mean airway 
pressure 16-22 mbar, amplitude 30-60 cm H2O, frequency 10 Hz, FiO 2 1.0). The control 
group was ventilated with mild conventional ventilation; peak inspiratory pressure of 12-16 
mbar, positive end-expiratory pressure of 3-5 mbar, frequency 20-40/min, FiO 2 0.21-0.40. 
Inhalation of nitric oxide became available as a treatment mode for pulmonary hypertension 
in 1996 and was used in 5 patients of the ECMO group and in 7 patients of the non-ECMO 
group. 
All autopsy lung specimens, obtained within 24 hours after death, were routinely fixed by 
immersion in 4% buffered formalin, and embedded in paraffin. Serial 4 µm sections were 
processed for histopathological and immunohistochemical examination. As our study material 
was routinely harvested at the time of autopsy, no predetermined protocol including inflation 
fixation was used (19-22).  
All slides were evaluated for diagnosis by an independent investigator, blinded for the clinical 
history of the individual patients. 
 
Histological staining 
 
Serial sections were mounted on polylysine-coated glass slides and stained with Masson 
trichrome staining, which stains elastic fibers dark blue/black, collagen fibers green and 
smooth muscle red or Elastic von Giesson’s staining, which stains elastic fibers dark violet, 
collagen fibers red, and smooth muscle brownish yellow. 
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Immunohistochemistry 
 
Formalin fixed, paraffin embedded sections of lung tissues, were mounted on super-frost glass 
slides. Immunohistochemistry was performed using a standard avidin-biotin complex method. 
Deparaffinised slides were treated with 3% hydrogen peroxide in phosphate buffered saline 
(PBS, 30 minutes) to block the endogenous peroxidase activity, followed by rinsing with 
PBS. Slides were then placed in a Sequenza Immunostaining Workstation (Shandon Scientific 
Ltd, Astmoor, Runcorn, USA). Slides were pre- incubated for 10 minutes with 20% normal 
horse serum to block non-specific binding, then incubated for 60 minutes at room temperature 
with mouse monoclonal anti-human ? -smooth muscle actin (a-SMA) antibodies (clone 1A4: 
Sigma, St. Louis, MO, USA) as a primary antiserum in dilution of 1:15,000 in monoclonal 
diluent (DPC, Los Angeles, USA). After rinsing with PBS, slides were incubated for 30 
minutes with biotinylated horse-anti-mouse antibody 1:200 (Vector Laboratories) in 
polyclonal diluent (PLD-100, DPC, Los Angeles, USA). After further rinsing with PBS, 
slides were incubated for 45 minutes with peroxidase conjugated avidin-biotin complex 1:50 
(Vector Laboratories) in PLD-100 (DPC, Los Angeles, USA), and visualised with 
diaminobenzidin in PBS (5 minutes) as the chromogen. Slides were counter-stained with 
Mayer’s haematoxylin for 20 seconds. Negative controls were prepared by omission of the 
primary antiserum. 
Masson trichrome staining or Elastic von Giesson’s staining and ? -SMA immunostaining 
were compared on serial sections to check that the media is co- localised with ? -SMA in 
pulmonary arteries before starting the morphometric measurements. 
 
Morphometry 
 
Pulmonary arteries were identified based on their position and structure. They mainly run 
along the terminal and respiratory bronchioles and at the alveolar duct level and are 
characterized by a distinct inner and outer elastic lamina (9,23). Arteries fulfilling these 
criteria, and with an external diameter (ED) measured between the external elastic laminae of 
up to 150 µm, and having a complete muscular coat, were measured. The diameter of less 
than 150 µm was chosen, because these arteries are considered to be the pressure regulating 
arteries (2). Only arteries that were cut at approximately right angles, so that the maximal ED 
exceeded the minimal ED by less than 50%, were analysed with the use of a calibrated 
 62
eyepiece. Measurements of the arterial wall layers in microns were done on Masson trichrome 
or elastic von Gieson’s stained sections. Medial thickness in microns was calculated as the 
distance from the external elastic lamina to the internal elastic lamina along the shortest 
diameter of the artery. Adventitial thickness in microns was calculated along the shortest 
arterial diameter. Total wall thickness in microns consisted of medial thickness plus 
adventitial thickness, since the thickness of the intima was minimal in all cases. Total wall 
thickness, medial thickness and adventitial thickness, were expressed as a percentage (%) of 
ED (respectively WT%, MT% and AT%), to relate them to the arterial vessel size (19-22). To 
exclude the effect of vasoconstriction on medial, adventitial and total wall thickness, the cross 
sectional areas of medial, adventitial and total wall thickness were therefore also calculated 
(expressed as µm2) (22,24). The measured variables are demonstrated in figure 1. 
 
Figure 1. Diagram of the measured morphometric variables 
 
IEL: internal elastic lamina; EEL: external elastic lamina; WT: total wall thickness in µm; MT: medial thickness 
in µm; AT: adventitial thickness in µM; ED: external arterial diameter. In this study, MT, AT and WT are 
expressed as (1) percentage (%) of the ED, where MT% = [MT x 2 x 100]/ED, AT% = [AT x 2 x 100]/ED and 
WT% = [WT x 2 x 100]/ED and (2) cross sectional area in µm2. The medial cross sectional area is defined as the 
area contained by the EEL minus the area contained by the IEL. The adventitial cross sectional area is defined as 
the area contained by the entire artery minus the area contained by the EEL. The wall thickness cross sectional 
area is defined by the area contained by the entire artery minus the area contained by the IEL. 
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Because in previous studies, the most dramatic vascular wall changes were demonstrated in 
arteries with an ED less than 75 µm, the small arteries were divided in two groups; a group of 
arteries with ED less than 75 µm and a group with ED between 75 and 150 µm (2,5,22).  
 
Statistical Analysis 
 
Study groups were compared for gender, gestational age and birth weight with Chi-square test 
and unpaired Student’s t-test respectively. Furthermore the age at the moment of death in the 
non-ECMO group was compared with the age at start of ECMO treatment in the ECMO 
group (unpaired Student’s t-test).  
Values of WT%, MT%, AT%, and total wall cross sectional area, medial cross sectional area, 
and adventitial cross sectional area from the three study groups were calculated and presented 
as mean (?  standard deviation). Data from the three study groups were compared using the 
unpaired Student’s t-test. P values ?  0.05 were considered statistically significant. 
 
 
RESULTS  
 
There were no significant differences in demographic data between the stud ied groups, as 
they were comparable for gender, gestational age, and birth weight (table 1). Mean (? sd) 
ECMO treatment duration was 182 (±114) hours. The non-ECMO group was ventilated for 7 
(±8) days and the control group for 1 (±1) day. There was no significant difference in post-
natal age at the moment of death in the non-ECMO group (7±8 d) and the moment of start of 
ECMO treatment in the ECMO group (4±4 d). 
 
Table 1. Gender, gestational age, birth weight for the 3 study groups 
 Gender 
(F:M) 
Gestational age 
(days) 
Birth weight 
(grams) 
Control group 4:7 277 ?  18 3284 ?  486 
Non-ECMO group 4:8 273 ?  15 2978 ?  558 
ECMO group 3:6 275 ?  16 3248 ?  520 
Values for gestational age and birth weight: mean ?  standard deviation. F = female, M = male. 
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The mean number of investigated arteries per case was 34. The mean values (? sd) for WT%, 
MT%, AT%, total wall cross sectional area, and medial and adventitial cross sectional area of 
the small pulmonary arteries with an ED<75 µm and an ED between 75 and 150 µm are 
presented in figures 2 and 3. 
 
Pulmonary arteries with an ED<75 µm (figure 2) 
 
There were differences in WT%, wall thickness cross sectional area, AT%, and adventitial 
cross sectional area between the studied groups. The highest values were found in the 
pulmonary arteries of infants in the non-ECMO group, and the lowest values in the control 
group. However, these differences were not statistically significant. 
The MT% and the medial cross sectional area in the non-ECMO group were significantly 
increased compared to the control group. In the ECMO group, the MT% and the medial cross 
sectional area were significantly decreased compared to the non-ECMO group (p<0.05).  
 
Pulmonary arteries with an ED 75-150 µm (figure 3) 
 
In the non-ECMO group, all studied variables were increased significantly compared with the 
control group (p<0.01, except for AT%, p<0.05). The ECMO group demonstrated a decreased 
WT% and wall thickness cross sectional area compared to the non-ECMO group, where the 
decrease in wall thickness cross sectional area was significant (p<0.01). WT% in the ECMO 
group was not significantly different from that in the control group. 
The MT% in the ECMO group was decreased compared to the non-ECMO group, but not 
significantly, and was still increased compared to the control group (p<0.05). The medial 
thickness cross sectional area in the ECMO group was significantly decreased compared to 
the non-ECMO group (p<0.01).  
Finally, the AT% in the ECMO group was comparable with that of the control group, but did 
not demonstrate a difference with the non-ECMO group. However, the adventitial cross 
sectional area in the ECMO group was significantly decreased compared to the non-ECMO 
group (p<0.05). 
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Figure 2. Morphometric parameters in pulmonary arteries with external diameter<75 µm 
 
 
Bars represent mean values, error bars represent standard deviation. Percentage: variable expressed as percentage 
of the external diameter. 
Control: control group, non-ECMO: patients with pulmonary hypertension not treated with ECMO, ECMO: 
patients with pulmonary hypertension treated with ECMO. 
*; p<0.05 Non-ECMO group versus control group. #; p<0.05 ECMO group versus non-ECMO group.  
 66
Figure 3. Morphometric parameters in pulmonary arteries with external diameter between 75 and 150 µm 
 
Bars represent mean values, error bars represent standard deviation. Percentage: variable expressed as percentage 
of external diameter. Control: control group, Non-ECMO: patients with pulmonary hypertension not treated with 
ECMO, ECMO: patients with pulmonary hypertension treated with ECMO. 
*; p<0.05 Non-ECMO group versus control group, **; p<0.01 Non-ECMO group versus control group, #; 
p<0.05 ECMO group versus Non-ECMO group, ##; p<0.01 ECMO group versus Non-ECMO group, ^; p<0.05 
ECMO group versus control group. 
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DISCUSSION 
 
In this study we demonstrated that in patients with severe pulmonary hypertension, either 
idiopathic or secondary to MAS or sepsis, there were significant changes in pulmonary 
arterial wall morphology compared to controls with the same postconceptional age. WT% and 
cross sectional area, MT% and cross sectional area, and AT% and cross sectional area in 
pulmonary arteries with an ED 75-150 µm, and also MT% and cross sectional area in 
pulmonary arteries with an ED<75 µm were significantly increased.  
When looking at the vascular wall morphology in these patients after ECMO treatment, there 
was a significant decrease in MT% and cross sectional area in pulmonary arteries with ED<75 
µm and a significant decrease in wall thickness cross sectional area, medial cross sectional 
area and adventitial cross sectional area in arteries with an ED 75-150 µm. In uninjected 
fixated arteries, the media cross sectional area is thought to be a better measurement than 
MT%, because medial area does not vary with the degree of distension of the artery, whereas 
the MT% does (25-27). 
The observed changes suggest a beneficial effect of ECMO therapy on disturbed lung 
vascular morphology in newborns with severe pulmonary hypertension. The decreased 
vascular wall thickness in ECMO treated patients compared to non-ECMO treated patients 
results in an increased arterial lumen in vessels with a comparable ED (10). Since vascular 
resistance is inversely related to the fourth power of the intraluminal radius, even a small 
decrease in the medial diameter, causing a small increase in vascular lumen, may have an 
important effect on arterial resistance and pressure (2,5). Also, decreases in advential 
thickness are suggested to increase the compliance in small pulmonary arteries (2).  
In both this study and that of Shehata et al in CDH patients, adventitial and wall thickness 
thinning was found in infants after ECMO treatment. Shehata et al also suggested that 
adventitial thinning, which is followed by an increase of vascular compliance of the pressure 
regulating small pulmonary arteries, is a possible mechanism for a temporary decrease of the 
vascular resistance in CDH patients (8). 
However, this study reveals an important difference between non-CDH and CDH cases. We 
demonstrated a decrease in medial thickness and cross sectional area after ECMO treatment in 
pulmonary arteries of patients with MAS, sepsis and i-PPHN. Both Shehata et al and 
Thibeault and Haney could not demonstrate an effect of ECMO on medial thickness in CDH 
patients, only evaluating patients that died (8,28). An explanation for differences between our 
study and theirs can be that pulmonary hypertension in CDH has a different pathogenesis than 
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non-CDH causes of pulmonary hypertension. CDH is a developmental disorder with antenatal 
anatomical abnormalities. MAS, sepsis and i-PPHN are considered as maldevelopment or 
maladaptation occurring in the transitional circulation around birth. In CDH as well as in 
MAS, sepsis and i-PPHN, an increase in medial and adventitial thickness is documented. 
However, in MAS, sepsis and i-PPHN there is a normal ED and a normal number of intra-
acinar arteries, in contrast to CDH patients, in whom there is a decrease in ED and number of 
intra-acinar arteries (2,3). The difference in timing of the occurrence of the vascular 
abnormalities in CDH and non-CDH patients with pulmonary hypertension may determine 
the differences between these groups. Lung hypoplasia in CDH is generally considered to 
start in the first trimester of pregnancy. As a consequence, the vascular pathology is 
considered to be the result of an early fetal developmental anomaly (29,30). Although it is 
suggested that the vascular changes in MAS and i-PPHN do already occur before birth, it is 
unlikely that they develop in the first trimester (2,3,7). 
Probably, these differences in lung vasculature and timing influence the reaction to ECMO 
treatment and might explain why in CDH no decrease in medial thickness was seen after 
ECMO treatment. In some CDH cases the absence of changes of the pulmonary vasculature 
probably refers to an already fixed and irreversible pathology of the media. This is supported 
by the lack of response on inhaled nitric oxide therapy in CDH patients (31). 
Our results may represent an underestimation of the real effect of ECMO on lung vascular 
morphology, as nine of 12 patients of the non-ECMO group did not yet fulfil criteria for 
ECMO treatment at the moment of death. This suggests a milder amount of pulmonary 
hypertension in these patients than in patients of the ECMO group when ECMO was started. 
Therefore, lung vascular morphologic abnormalities could be less pronounced at the moment 
of death in these patients than in those of the ECMO group at the moment of start of ECMO 
treatment. If all patients in the non-ECMO group would have fulfilled the ECMO criteria, the 
differences found between the non-ECMO group and ECMO group might have been more 
significant. Another possibility for underestimation of the effect of ECMO treatment may be 
that the patients in the ECMO group died and therefore did not completely “recover” from 
their abnormal vascular morphology. It is impossible to correlate our findings with lung 
vascular morphology in patients after successful ECMO treatment and survival, since all cases 
studied were autopsy cases. No data are available showing the median time on ECMO 
necessary to reverse abnormal vascular morphology in newborns with pulmonary 
hypertension towards a normal pulmonary vascular architecture. Laberge and Wilson, 
discussing the results found by Shehata et al, suggested that reversal of the abnormal vascular 
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morphology in pulmonary hypertension is not an effect of ECMO, but rather of postnatal age. 
These arguments are speculative, as Shehata et al found the same morphometric results in 
CDH patients after a short period of ECMO treatment as after a prolonged period (8). We also 
found no differences in the studied morphometric parameters between newborns that died 
after a short (119±88 hrs) or long (287±57 hrs) ECMO run time, but conclusions are difficult 
to draw because the groups were relatively small.  
From the results in this study it could be argued that ECMO does not cause a reversal of 
abnormal lung vascular morphology, but only prevents a further deterioration, when ECMO 
treatment is not started as could have occurred in the non-ECMO group. As stated above it 
seems unlikely that the vascular abnormalities in patients of the non-ECMO group were more 
severe than in patients of the ECMO group. Therefore it is likely that ECMO influenced the 
medial and adventitial abnormalities in patients with pulmonary hypertension due to MAS, 
sepsis or i-PPHN. 
The regression of the abnormal vascular morphology after ECMO treatment points to a 
mechanism that explains the beneficial effect of ECMO in patients with severe pulmonary 
hypertension. Further studies are needed to unravel the underlying processes involved in this 
regression. To study the exact effects of ECMO on lung vascular morphology, lung biopsies 
are needed before and after ECMO treatment, which is however not possible for obvious 
ethical reasons (32). In patients with pulmonary hypertension sustained hypoxia may be the 
mechanism for abnormal vascular remodeling, as persistent ongoing hypoxia is a trigger for 
cell proliferation (33,34). Experimental models suggest an important role of both SMC’s and 
adventitial fibroblasts during the natural history of vascular remodeling in pulmonary 
hypertension (33,35). Detailed molecular analysis focussing on maturational changes of the 
medial SMC population of the arterial media is warranted.  
An adequate animal model for pulmonary hypertension in which the animals can be subjected 
to ECMO is necessary to obtain a better insight into reversal of the pathologic vascular 
remodeling which exists in pulmonary hypertension (36). An alternative way of evaluating the 
molecular background of the abnormal lung vascular morphology might include laser capture 
micro-array in combination with RNA protein isolation to quantify changes in gene products 
known to be involved in muscle cell proliferation and vascular remodeling (37). 
Genes regulating for instance matrix metalloproteinases might not be switched on or off or at 
an abnormal time point. In animal models, matrix metalloproteinases are involved in vascular 
remodeling during pulmonary hypertension, by influencing collagen deposition, SMC 
proliferation and apoptosis (38,39). To determine differences in matrix metalloproteinases 
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effect between patients in the non-ECMO and ECMO group, extracellular matrix composition 
may be studied (38,40,41). Alternatively, in PPHN there might be an imbalance between 
proliferation and apoptosis, a usually occurring feature in preparation to the ability to dilate at 
the transition for postnatal life. Geraci et al showed an imbalance between genes regulating 
cell growth and genes regulating apoptosis in patients with primary pulmonary hypertension 
(37). 
In summary, we demonstrated that ECMO therapy caused a reduction in abnormal vascular 
morphology in small pulmonary arteries of patients suffering from MAS, sepsis, or idiopathic 
pulmonary hypertension. The effect of ECMO therapy in these patients with pulmonary 
hypertension, often described as lung rest, can be “translated” into a documented reversal of 
the vascular wall abnormalities that are present in pulmonary hypertension. The molecular 
mechanisms underlying this process are currently under investigation in our laboratory. 
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INTRODUCTION TO ECMO AND THE BRAIN 
 
Although ECMO has increased survival in selected newborns with severe respiratory 
insufficiency, it has several complications that can lead to major morbidity. Imaging studies 
revealed major haemorrhagic or ischaemic intracranial abnormalities in 10 to 30% of patients 
(1-8). The presence of intracranial abnormalities is highly correlated with adverse 
neurodevelopmental outcome (4,9-13). It is therefore extremely important to determine risk 
factors for cerebral haemorrhagic and ischaemic lesions. Prevention of these lesions will 
improve survival and neurodevelopmental outcome. 
Pre-ECMO events as well as ECMO-related events may play a role in the occurrence of 
intracranial haemorrhagic and ischaemic lesions (table 1). 
 
Table 1. Risk factors for haemorrhagic and ischaemic intracranial lesions in ECMO treated patients 
 Haemorrhage Ischemia 
Pre-ECMO Birth trauma 
Hypercapnia 
Hypertonic solutions 
Asphyxia 
Hypotension 
Hypocapnia 
Seizures 
ECMO Ligation right internal jugular vein 
Heparinization 
Thrombocytopenia 
Coagulopathy 
Hypertension 
Reperfusion 
Ligation right common carotid artery 
Micro-thrombi 
 
In the pre-ECMO period factors that can contribute to cerebral damage include birth trauma, 
hypoxia, hypercapnia, acidosis, ischaemia, hypotension, seizures and rapid infusions of 
colloid or hypertonic solutions (14). Additional risk factors arise during ECMO treatment, 
such as ligation of the RCCA and RIJV, systemic heparinization, thrombocytopenia, 
coagulopathy, systolic hypertension, and micro-thrombi from the ECMO circuit (15).  
Before starting ECMO, all the patients have hypoxaemia for several hours or even a few days. 
To maintain oxygen transport to the brain and oxygen metabolism of the brain, cerebral blood 
flow (CBF) is increased (16-18) Prolonged hypoxaemia compromises cerebral oxygen 
transport and metabolism, especially when cardiac output is affected by hypoxia. In this 
compromised brain, the RIJV and the RCCA are ligated. Normally, after RCCA ligation, 
blood flow to the right cerebral hemisphere is maintained by collateral circulation via the 
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circle of Willis. Short et al demonstrated that even after exposure to hypoxia, RCCA ligation 
in the newborn lamb did not result in differences in CBF between the left and right 
hemispheres. They also demonstrated that CBF, cerebral oxygen transport and cerebral 
oxygen metabolism remained unchanged (17).  
In order to have adequate CBF over a wide range of cerebral perfusion pressures (CPP), it is 
important that cerebral autoregulation is intact (19). Systemic insults in the pre-ECMO period, 
such as asphyxia, hypoxia and hypercapnia, may disrupt cerebral autoregulation and render 
the microcirculation vulnerable to alterations in systemic blood pressure (20,21).  
In the lamb model, Short et al demonstrated that cerebral autoregulation was disturbed by pre-
ECMO hypoxia combined with blood vessel ligation, and by VA-ECMO itself (18,22). The 
combination of exposure to hypoxia and VA-ECMO treatment disturbed cerebral 
autoregulation even more profoundly than either hypoxia or VA-ECMO alone (23). This 
autoregulation disturbance was characterized by a shift of the lower limit of the autoregulation 
plateau to a higher CPP value (a shift to the right) than in the control animals. The effect of 
the shift in autoregulatory threshold was greater in the right cerebral hemisphere than in the 
left. At this CPP point where autoregulation was lost, this caused differences in CBF between 
the hemispheres. The shift in autoregulatory threshold increases the risk of ischaemic cerebral 
injury at a CPP level where this is not usually expected. Cerebral oxygen consumption was 
indeed decreased at CPP below this higher autoregulatory threshold, thus indicating a 
potential cause for cerebral injury. 
Tweed et al demonstrated in the lamb that after exposure to hypoxia, CBF autoregulation was 
also lost at the higher end of the autoregulatory curve (21). The loss of autoregulation makes 
the brain vulnerable to changes in arterial blood pressure, with hypotension resulting in 
ischaemic lesions and hypertension resulting in hyperaemia and haemorrhages.  
Sell et al and Boedy et al reported hypertension in a high percentage of their patients treated 
with ECMO, in association with the occurrence of intracranial haemorrhages (24,25). 
Pharmacological control of the hypertension resulted in a reduction in the incidence of 
intracranial haemorrhages, suggesting a relation between hypertension and the occurrence of 
intracranial haemorrhages. 
As in the studies of Short et al there were differences in CBF between the right and left 
hemispheres at the point where cerebral autoregulation was lost, RCCA ligation and VA-
ECMO initiation may be risk factors for right-sided cerebral lesions (18,22). Schumacher et al 
found indeed an increase in right-sided cerebral lesions after VA-ECMO treatment (26). 
ECMO patients also have an increased risk of posterior fossa haemorrhages (2,27). Short et al 
 79
demonstrated an increase in CBF in the cerebellum of the lamb after recovery from hypoxia 
and suggested that the increased risk of posterior fossa haemorrhages was related to 
reperfusion injury (18). Taylor and Walker suggested that venous outflow obstruction from 
ligation and cannulation of the right internal jugular vein plays a role in the occurrence of 
posterior fossa haemorrhages (28). Increased venous pressure may disrupt the blood-brain 
barrier and alter the cerebral autoregulation curve by shifting the lower end of the 
autoregulatory curve to a higher level (29,30).  
Besides loss of autoregulation and blood vessel ligation as causes of cerebral lesions in 
newborns treated with VA-ECMO, administration of heparin is another risk factor.  
Although heparin does not cause intracranial haemorrhage directly, it may lead to rapid 
progression of it (6,31). Patients who need ECMO often have pre-existing coagulation factor 
deficiencies while coagulation factor concentrations can decrease further during the first 24 
hours of ECMO (32,33). In addition, activation of the fibrinolytic system, thrombocytopenia 
and altered thrombocyte function during ECMO may aggravate existing haemorrhagic lesions 
(34-36). Hirthler et al found that instability of coagulation variables was an early predictor of 
intracranial haemorrhages (37). This suggests that stability in the clotting system is necessary 
to prevent haemorrhagic complications. 
The ECMO system contains thrombogenic materials. Contact of blood with foreign surfaces 
activates the contact system and the complement system, resulting in thrombus formation, 
which can be suppressed by heparin administration during ECMO (38,39). Nevertheless, 
thrombus formation does still occur. Clots in the ECMO system are reported in 20% of the 
patients (40). If clots in the ECMO system are reinfused into the arterial circulation, they may 
cause ischaemic cerebral lesions. 
Hyperventilation, used to lower pulmonary hypertension, may be another pre-ECMO factor 
that contributes to cerebral damage (41,42). Hyperventilation causes a decrease in the arterial 
partial pressure of carbon dioxide (paCO2) and subsequent vasoconstriction in the cerebral 
circulation, which reduces CBF. Walker et al and Liem et al demonstrated that 
cerebrovascular reactivity to carbon dioxide was intact in animal models, during ECMO 
(43,44). At the start of ECMO, the paCO2 level may show acute normalization and lead to an 
increase in CBF, another potential risk factor for haemorrhages (45).  
In summary, ECMO infants are not only at risk for cerebral injury secondary to their critical 
pre-ECMO state, but also from the ECMO therapy itself. 
The animal studies described above indicate that recovery from hypoxia, with or without 
ECMO, is a vulnerable period in which physiological alterations, such as hypotension or 
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hypertension, may hold risk of brain injury. If these results in animals can be extrapolated to 
the newborn human infant, VA-ECMO may increase this risk. Therefore, stabilization of the 
infants during the initial recovery period on ECMO and treatment of events such as 
hypotension and hypertension should be undertaken in an expedient manner. When using a 
technique as complicated as ECMO, it is necessary to understand the factors that cause 
morbidity, to be able to optimize the use of ECMO and thus improve the long-term outcome 
of ECMO patients. 
In an earlier study, our group demonstrated a marked increase in cerebral perfusion during the 
induction of VA-ECMO, but it was not possible to draw conclusions about differences in 
effect on the left and right cerebral hemispheres (46). This question is studied in chapter 5.  
In addition, our group observed changes in cerebral oxygenation and haemodynamics when 
the bypass bridge was opened during VA-ECMO (47). This bridge is a safety connection 
between the drainage and infusion tubing of the ECMO system. It is used in emergency 
situations, when the patient has to be temporarily disconnected from the ECMO circuit. If 
necessary, the tubings leading to and from the patient can be clamped off and the bridge 
opened, thus allowing to maintain circulation in the ECMO circuit. During ECMO treatment, 
the bridge is opened and flushed every 15 minutes to prevent the development of thrombi due 
to blood stasis. 
Chapter 6 addresses the cause of the changes in cerebral oxygenation and haemodynamics 
when the bypass bridge is opened, effects of opening the bridge at different ECMO flow rates 
and opening times, and ways to prevent these changes.  
In chapter 7, we used an animal model to study how the patent ductus arteriosus with left-to-
right shunt affected cerebral oxygenation and haemodynamics during VA-ECMO. 
Motivation for this study was the presence of a left to right shunt through the ductus in 
newborns during VA-ECMO and its relation with a prolonged ECMO run time (48). In pre-
term infants, a patent ductus with left-to-right shunt may cause stealing of blood from the 
cerebral circulation, which might be related to the occurrence of cerebral lesions (49-52).  
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ABSTRACT 
 
Objective: Oxygenation and haemodynamics in left and right cerebral hemispheres were 
measured during induction of veno-arterial extracorporeal membrane oxygenation. 
Study design: Using near infrared spectrophotometry, effects of right common carotid artery 
and right internal jugular vein ligation and start of veno-arterial extracorporeal membrane 
oxygenation on concentrations of oxyhaemoglobin, deoxyhaemoglobin and the cerebral blood 
volume were evaluated in 10 newborn infants. Mean cerebral blood flow velocity in the major 
cerebral arteries was compared before and after the start of veno-arterial extracorporeal 
membrane oxygenation (pulsed Doppler ultrasonography). 
Results: Right common carotid artery ligation caused a decrease in oxyhaemoglobin 
concentration and an increase in deoxyhaemoglobin concentration. Right internal jugular vein 
ligation caused no changes. Sixty minutes after the start of veno-arterial extracorporeal 
membrane oxygenation, oxyhaemoglobin concentration and cerebral blood volume had 
increased, and deoxyhaemoglobin concentration had decreased. There were no differences 
between the hemispheres. Mean cerebral blood flow velocity had increased in the left internal 
carotid artery, and it increased equally in both middle cerebral arteries. Flow direction was 
reversed in the right internal carotid artery. Three patients had asymmetric cerebral lesions, 
not related to differences in the studied variables between the cerebral hemispheres. 
Conclusion: The initiation of veno-arterial extracorporeal membrane oxygenation causes 
changes in cerebral oxygenation and haemodynamics but without a difference in effect on left 
and right cerebral hemispheres. 
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INTRODUCTION 
 
ECMO is a rescue therapy for newborns with severe cardiorespiratory insufficiency. Major 
complications of this treatment are the occurrence of haemorrhagic and ischaemic cerebral 
lesions, leading to neurological and neurodevelopmental dysfunction (1,2). Since the 
introduction of ECMO there has been concern about the effect of ligation of the RCCA and 
the RIJV on the perfusion of the brain. Conflicting data exist on the predominant occurrence 
of cerebral lesions in the right hemisphere, related to this ligation (3-9). Schumacher et al and 
Campbell et al found an increase in left-sided seizures, lateralized neuromotor findings, and 
right-sided ischaemic cerebral lesions (3,4). Lott et al demonstrated long lasting decreased 
blood flow in the right internal carotid artery and a reduction in the amplitude of right 
hemispheric long latency evoked potentials (5). Mendoza et al demonstrated the preference of 
ischaemic lesions to the right hemisphere and of haemorrhagic lesions in the left hemisphere 
(6). Others demonstrated an equal distribution of cerebral lesions on neuroimaging studies, no 
lateralized neurologic findings, and satisfactory collateral flow on Doppler flow studies (7-9). 
In a lamb model, RCCA and RIJV ligation after 2 hours of hypoxia caused a disturbed 
autoregulation with significant differences in CBF between the right and left hemisphere (10).  
Previously we demonstrated marked changes in cerebral oxygenation and haemodynamics 
during introduction of VA-ECMO, using single-channel near infrared spectrophotometry 
(NIRS) (11). In this present study the effects of ligation of the RCCA and RIJV and the 
initiation of VA-ECMO on left and right cerebral hemisphere perfusion and oxygenation are 
evaluated using a two-channel NIRS.  
 
 
METHODS  
 
Study population and ECMO procedure 
 
After obtaining informed parental consent, we studied 10 VA-ECMO patients who had severe 
cardiorespiratory failure and hypoxaemia despite adequate conventional treatment, using 
mechanical ventilation, sedation, muscle paralysis, vaso-active drugs, surfactant and nitric 
oxide inhalation. All infants met the established entry criteria for ECMO (12). The study 
population consisted of 4 males and 6 females, gestational age 37 to 42 weeks and birth 
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weight 3000 to 3670 g. The underlying diseases were CDH (n=4), MAS (n=3), sepsis (n=2) 
and i-PPHN (n=1). The study was approved by the University Hospital Ethics Committee.  
During cannulation, the infants were anaesthetized using fentanyl and midazolam and 
paralysed with pancuronium. After starting standard VA-ECMO (13), the flow rate on bypass 
was gradually increased over several minutes until an appropriate level was reached (range: 
165-210 mL/kg.min) to maintain the arterial oxygen saturation (saO2) between 90 and 100% 
as measured by pulse oximetry. 
Subsequently, the artificial ventilation was set at ‘rest settings’ and was continued during the 
measurement period, with a peak inspiratory pressure of 22-26 cm H2O, a positive end 
expiratory pressure of 4 cm H2O and FiO2 of 0.30. To prevent clot formation, systemic 
heparinization was established. During the measurement period, medication administered 
before VA-ECMO was continued. 
 
Near Infra-Red Spectrophotometry (NIRS) 
 
This technique is based on the continuous spectrophotometric measurement of oxygenation-
dependent changes in the absorption of near infrared light by haemoglobin (14). Details of our  
NIRS measurement have been described earlier (15). Briefly, three wavelengths of near 
infrared light (905, 850 and 767 nm) were transmitted through the skull with a three-branch 
fiberoptic bundle and received by two separate optodes. Using the described algorithm, 
absolute changes (?) in concentration of oxyhaemoglobin (cO2Hb), deoxyhaemoglobin 
(cHHb) and total haemoglobin (ctHb), as the sum of the changes in concentration of 
oxyhaemoglobin and deoxyhaemoglobin, were calculated from changes in absorption of near 
infrared light at the three wavelengths mentioned (16). To investigate the changes in cerebral 
oxygenation and haemodynamics in both cerebral hemispheres, the 2 receiving optodes were 
placed over the left and right parietotemporal region, one above each hemisphere. The 
transmitting optode was placed over the posterior fontanel. In this way, changes in the 
concentrations of oxyhaemoglobin (?cO2Hb), deoxyhaemoglobin (?cHHb) and total 
haemoglobin (?ctHb) could be registered separately over a substantial part of the left and 
right cerebral hemisphere. In all infants, the interoptode spacing between transmitter and 
receivers was greater than 2.5 cm to ensure a constant path length multiplying factor, which 
was 4.39 (17). ?cO2Hb and ?cHHb reflect changes in cerebral oxygen supply, if perfusion 
and oxygen consumption remain constant. ?ctHb represent changes in cerebral blood volume 
(CBV). 
 92
Doppler ultrasound 
 
Measurements of the mean cerebral blood flow velocity (CBFV) in major cerebral arteries 
were performed using pulsed Doppler ultrasonography (ATL HDI 3000, ATL ultrasound Inc, 
Bothell, WA, USA). CBFV in the supraclinoid internal carotid artery was measured by 
placing the transducer on the anterior fontanel. Measurement of CBFV in the middle cerebral 
artery in the Sylvian sulcus was performed by placing the transducer 1 to 2 cm in front of the 
right  ear above the zygomatic process (18). Using this approach, the insonation angle was 
assumed to be negligible (less than 10o). Mean CBFV was calculated using the built- in 
calculation program. Measurements were performed just before application of the NIRS 
optodes at approximately 30 mins before cannulation and just after removal of the NIRS 
optodes at approximately 60 mins after ECMO was started. The changes in mean CBFV after 
induction of VA-ECMO were expressed as percentages of their precannulation levels. 
 
Measurement of physiological variables 
 
Heart rate (HR), mean arterial blood pressure (MABP) measured by an umbilical arterial 
catheter, and saO2 measured non- invasively by pulse oximetry using the right hand, were 
recorded continuously, using a neonatal monitor (HP Model 68S, Hewlett Packard, 
Boeblingen, Germany). This monitor was connected to a data acquisition system (Poly®, 
Inspector Research System, Amsterdam, The Netherlands) with a sampling frequency of 1 
Hz. Blood samples for determination of paO2, paCO2, and the intravascular concentration of 
haemoglobin (cHb) were drawn from an umbilical arterial catheter just before cannulation and 
at 60 mins after ECMO was started.  
 
Follow-up 
 
In all patients the occurrence of cerebral haemorrhagic and ischaemic lesions was studied 
daily during ECMO treatment using ultrasonography. After ECMO treatment, CT-scan or 
MRI-scan of the brain was performed in all surviving newborns. In addition, brainstem 
auditory evoked potentials (BAEP) and electroencephalogram (EEG) were conducted. 
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Data analysis 
 
From each continuously recorded variable (cO2Hb, cHHb, ctHb, saO2, MABP and HR), we 
selected data for a stable 30-secs period from six episodes: (A) just before the start of the 
cannulation procedure, (B) just before ligation of the RCCA, (C) after RCCA ligation, just 
before insertion of the arterial cannula, (D) just before RIJV ligation, (E) after RIJV ligation, 
just before insertion of the venous cannula and (F) at 60 mins after starting ECMO. 
For each variable, the mean value for this 30-secs period was calculated. The differences in 
the mean values for the 30-secs period between C and B and between E and D were calculated 
to determine the effects of RCCA and RIJV ligation respectively. Because all signals had 
stabilized 60 mins after starting ECMO, we compared F and A to determine the overall effect 
of ECMO induction. The effects were analyzed with the Wilcoxon signed-rank test.  
The changes in mean CBFV, cHb, pH, paO2 and paCO2 at 60 mins after starting ECMO, 
related to their precannulation values, were also calculated and analyzed with the Wilcoxon’s 
signed rank test or one-sided nonparametric test, when appropriate.  
The CBV (mL/100 g) can be calculated from the following formula: 
cHb
ctHb
CBV
?
?
?
69.0
4
 
where ctHb is the concentration of total haemoglobin in cerebral tissue, expressed in 
µmol/100 g and cHb is the intravascular concentration of haemoglobin in mmol/l; 0.69 is the 
cerebral to large vessel haematocrit ratio and 4 is a correction factor, as ctHb is calculated 
from changes in light absorption using extinction coefficients based on the tetrahaeme 
molecule, whereas determination of cHb in blood samples is based on the monohaeme 
molecule (19). 
Because the cHb changes after starting ECMO, the change in CBV (?CBV) cannot be simply 
calculated from changes in ctHb.  
 
Therefore: 
CBV + ? CBV = 
)(69.0
)(4
cHbcHb
ctHbctHb
???
???
 
and  
? CBV = 
)(17.0
17.0
cHbcHb
CBVcHbctHb
???
?????
 
 94
However, because the initial CBV value in the individual infant is unknown, it is not possible 
to calculate ? CBV exactly. Wyatt et al found a CBV value of 2.2 ± 0.4 mL/100 g in newborn 
infants with a normal brain (20). As moderate to severe hypoxaemia is the main feature in the 
pre-ECMO condition, the initial CBV in these infants could be expected to be higher as a 
result of cerebral vasodilation (21). To determine the changes in CBV we used a 
precannulation CBV value of 4 mL/100 g and with this value calculated ? CBV (21).  
For those variables from NIRS data or Doppler examination that showed statistically 
significant changes, we compared these changes between the left and right cerebral 
hemisphere with the Wilcoxon’s signed rank test. 
Furthermore, we tested whether the newborns with asymmetric cerebral lesions had greater 
differences between the left and right hemisphere for the different variables than the newborns 
without asymmetric lesions. The difference in effect between left and right cerebral 
hemisphere of the different variables was divided in two groups: values within the 
interquartile range (between 25th and 75th percentile) and values outside this interquartile 
range. In a 2x2 contingency table this was tested against the occurrence of asymmetric 
cerebral lesions (Fisher's exact test). For all analyses, the level of significance was chosen at 
0.05. 
 
 
RESULTS 
 
Clinical Outcome 
 
All 10 patients could be successfully weaned from ECMO. One patient with CDH died 
because of severe respiratory insufficiency after the ECMO run. Neuro-imaging during and 
after ECMO treatment showed a left sided small periventricular haemorrhagic lesion in one 
infant, and a second infant had a haemorrhagic infarction in the area of the right middle 
cerebral artery. Furthermore BAEP showed delayed central conduction on the right side in a 
third patient.   
 
Blood vessel ligation (figure 1) 
 
After RCCA ligation there was a significant decrease in cO2Hb and a significant increase in 
cHHb in both cerebral hemispheres. CBV did not change. Median values [interquartile 
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ranges] of ? MABP; 0.2,  [-1.5, 0.9] mm Hg, ? saO2; 0 [-1, 1] % and ? HR;  -1 [-2, 0] beats per 
min, were not significant. 
 
Figure 1. Absolute changes in NIRS variables during cannulation and after VA -ECMO initiation 
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?cO2Hb = changes in concentration of oxyhaemoglobin, ?cHHb = changes in concentration of 
deoxyhaemoglobin, ?CBV= changes in cerebral blood volume, L= left hemisphere, R = right hemisphere. 
Because absolute precannulation values are unknown, changes are compared with precannulation values, 
defined to be zero µmol/l or mL/100 g brain tissue, respectively. Horizontal lines represent median 
values; boxes cover interquartile ranges. *: p<0.05 compared to precannulation values. 
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RIJV ligation did not cause any significant changes in NIRS variables. Again, ? MABP; 0.9 [-
1.3, 3.9] mm Hg, ? saO2; -1 [-2, 1] %, and ? HR; -1 [-4, 1] beats per min, were not significant. 
There were no differences in the observed changes between left and right cerebral 
hemisphere. The occurrence of asymmetric cerebral lesions and the difference in effect 
between left and right cerebral hemisphere had no relation in any of the studied variables. 
 
Table 1. Changes in variables 60 minutes after starting ECMO as compared to precannulation values 
 Absolute precannulation values Changes 60 min after starting ECMO 
saO2 (%) 79 (62-95) 15 (1-31)* 
MABP (mm Hg) 52 (43-65) 19 (10-21)* 
HR (beats/min) 169 (164-176) -18 (-25, -5)* 
paO2 (mm Hg) 54.0 (36.7-71.3) +46.1 (+28.3, +69.7)* 
paCO2 (mm Hg) 42.7 (36.7-45.0) +1.8 (-2.2, +5.8) 
PH 7.31 (7.25-7.38) +0.01 (-0.03, +0.05) 
cHb (mmol/l)  8.9 (8.4-9.2) -2.0 (-2.6, -1.5)* 
Values are median (interquartile range), * p < 0.05 
saO2 = arterial oxygen saturation, MABP = mean arterial blood pressure, HR = heart rate, paO2 = arterial partial 
pressure of oxygen,  paCO2 = arterial partial pressure of carbon dioxide, cHb = intravascular concentration of 
haemoglobin. 
 
ECMO effect 
 
Immediately after starting ECMO, cO2Hb increased in both cerebral hemispheres. Also, saO2 
and MABP increased, whereas cHHb decreased in both cerebral hemispheres (figure 1, table 
1). In all 10 infants, CBV was increased 60 min after starting ECMO, in the right and in the 
left cerebral hemisphere (figure 1). In addition, HR had decreased, and cHb was lower due to 
haemodilution by the priming solution of the ECMO system (table 1). 
Induction of VA-ECMO caused a significant increase in mean CBFV in both the left and right 
middle cerebral arteries and in the left internal carotid artery. In the right internal carotid 
artery there was a reversed blood flow direction, from positive to negative (figure 2). The 
magnitudes of ?cO2Hb and ?cHHb were not significantly different between the right and left 
cerebral hemispheres. For the changes in mean CBFV after ECMO initiation, there was a 
significant difference between left and right internal carotid artery (p<0.05) (figure 2). 
The occurrence of asymmetric cerebral lesions and the difference in effect between left and 
right cerebral hemisphere showed no relation in any of the measured variables. 
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Figure 2. Effect of initiation of VA -ECMO on cerebral blood flow velocity 
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?CBFV= change in the mean cerebral blood flow velocity, ICA = internal carotid artery, MCA = middle 
cerebral artery, L = left hemisphere, R = right hemisphere. Changes are presented as percentage increase 
compared with precannulation values. Horizontal lines represent median values; boxes covers  interquartile 
ranges. *: p<0.05 compared to precannulation values. #: p<0.05 comparing ?CBFV in left and right ICA. 
 
 
DISCUSSION 
 
With the onset of VA-ECMO, important haemodynamic changes occur. Ligation of the 
RCCA and RIJV, nonpulsatile bypass flow, hypertension, and normalization of the arterial 
blood gases may all influence CBFV (22). VA-ECMO may alter cerebral autoregulation 
significantly, and more severe in the right than in the left hemisphere, and it can be an 
important risk factor for right-sided cerebral ischaemia (10,23). 
NIRS with the two-channel technique offers the opportunity to study blood vessel ligation 
effects continuously and separately in each cerebral hemisphere. 
Although adequate collateral blood flow to the right hemisphere is maintained during VA-
ECMO, transient blood flow interruptions and cerebral oxygenation changes causing 
ischaemic brain lesions at the moment of RCCA ligation can not be ruled out (7,24,25). A 
temporary decrease in CBFV in the right middle cerebral artery after ligation of the RCCA 
was demonstrated (18,26). With NIRS, we found that ligation of the RCCA caused a decrease 
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in the cO2Hb and an increase in cHHb in both cerebral hemispheres, which could be related to 
the occurrence of hypoxaemic lesions. The changes observed after RCCA ligation can be 
explained by a decreased total oxygen delivery because blood flowing through the left 
common carotid artery is distributed to both hemispheres. Also, oxygen extraction can 
increase because of prolonged transit time of blood through the brain and as a compensation 
for diminished oxygen supply, explaining the decrease in cO2Hb and increase in cHHb. 
Although earlier results and ours suggest a potential ischaemic moment after RCCA ligation, 
we found no differences in NIRS variables between the right and left cerebral hemispheres 
(18,26).  
Some authors reported CBFV changes caused by venous outflow obstruction after ligation of 
the RIJV and related this to the occurrence of cerebrovascular injury (27,28). We saw no 
acute effect of RIJV ligation on cO2Hb, cHHb, and CBV. If RIJV ligation would result in 
venous outflow obstruction, an increase in CBV could be expected.  
One hour after the start of VA-ECMO we demonstrated an increase in cO2Hb and CBV and a 
decrease in cHHb. Mean CBFV had increased in both middle cerebral arteries and in the left 
internal carotid artery, and blood flow direction had reversed in the right internal carotid 
artery. The increase in cO2Hb is expected from the VA-ECMO procedure itself because 
oxygenation increases, as demonstrated by the increased paO2 and saO2 values. CBV can 
increase as arterial inflow increases, as represented by increase in CBFV. This can be 
explained as reactive hyperperfusion after prolonged hypoxaemia before ECMO, or as a 
compensation for diminished cerebral oxygen delivery due to haemodilution caused by the 
ECMO procedure (11). However, this could not be confirmed in animal experiments (29).  
We chose an initial CBV value of 4 mL/100 g to calculate ?CBV after ECMO initiation. 
When calculating ?CBV assuming an initial CBV of 2.2 mL/100 g as suggested by Wyatt et 
al (20), a significant elevation of CBV in both hemispheres was also found, showing that the 
initial value of CBV is not important to demonstrate that there is an increase in CBV after 
ECMO initiation. 
Both increased CBV and increased CBFV can be related to the occurrence of cerebral 
haemorrhages. In this study we could not demonstrate a difference in increase in CBV and 
mean CBFV between the left and right cerebral hemisphere, apart from mean CBFV in the 
internal carotid artery. Blood flow direction in the right internal carotid artery during VA-
ECMO could be forward as well as backward, depending on the collateral circulation 
originating from the circle of Willis through the anterior and posterior communicating arteries 
or from the right external carotid artery to the right internal carotid artery (4,24,25). Changes 
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of flow direction in the right internal carotid artery demonstrate adequate collateral circulation 
through the circle of Willis and have no effect on hemispheric perfusion because mean CBFV 
in the left and right middle cerebral arteries was equal 60 mins after the start of ECMO. 
Others found a symmetric CBFV in the anterior cerebral artery, another distal artery, during 
VA-ECMO (7,22). 
After RCCA and RIJV ligation and also 60 minutes after initiation of VA-ECMO, the 3 
newborns with asymmetric brain lesions did not have greater left to right hemispheres 
differences in NIRS variables or CBFV than those without these lesions. 
Although we could not demonstrate a difference in effect on left and right hemispheres, the 
observed effects may have a relation with the occurrence of cerebral lesions. This study was 
not aimed at investigating aetiologic factors for the occurrence of haemorrhagic or ischaemic 
lesions during ECMO. The aetiologic mechanism for cerebral lesions is most likely 
multifactorial. 
NIRS measures absolute changes in oxygenation and CBV, not absolute values. However, the 
magnitude of the NIRS changes can be compared with usual physiologic challenges, e.g. 
changes in paCO2. During hypercapnia in piglets on ECMO after hypoxia, a mean ?cO2Hb of 
0.16 µmol/100 g.kPa and a mean ?CBV of 0.10 mL/100 g.kPa occurred (30). Wyatt et al 
calculated changes in CBV in relation to changes in paCO2 in term infants to be 0.51 
mL/100g.kPa (31). Compared with this, the changes in NIRS variables found in the current 
study seem to be physiologically relevant. 
To our knowledge only CBFV Doppler ultrasonography studies on the effect of RCCA 
ligation and ECMO initiation exist; no studies exist on cerebral oxygenation and CBV. Our 
study is the first to use NIRS to study the effects of cannulation and initiation of VA-ECMO 
on each cerebral hemisphere separately. We observed changes in cO2Hb, cHHb, CBV and 
mean CBFV, but we observed no asymmetric effect on cerebral oxygenation and 
haemodynamics. We could not demonstrate that the newborns with asymmetric cerebral 
lesions had greater differences in changes of the studied variables between left and right 
hemispheres than those without cerebral lesions. 
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ABSTRACT 
 
Objective: To investigate the cause of the haemodynamic changes occurring during opening 
of the bridge in veno-arterial extracorporeal membrane oxygenation. 
Design: Prospective intervention study in animals. 
Setting: Animal research laboratory of a university medical centre. 
Subjects: Eight anaesthetized lambs installed on veno-arterial extracorporeal membrane 
oxygenation. 
Interventions: During veno-arterial membrane oxygenation the bridge was randomly opened 
during 1, 2.5, 5, 7.5, 10 and 15 secs at flow rates of 500, 400, 300, 200, 100 and 50 mL/min. 
Flows in the extracorporeal circuit between venous cannula and bridge and bridge and arterial 
cannula, mean arterial blood pressure, mean left carotid artery blood flow, central venous 
pressure, superior sagittal sinus pressure, inline ‘mixed venous’ oxygen saturation, heart rate, 
and arterial oxygen saturation were measured continuously. Using near infrared 
spectrophotometry, changes in concentrations of cerebral oxygenated and deoxygenated 
haemoglobin and cerebral blood volume were also measured. Values during bridge opening 
were compared with values before opening. The same variables were determined with a roller 
pump on the bridge with a flow over the bridge at various flow rates. 
Measurements and Main Results: Bridge opening resulted in a change of flow direction 
between the venous cannula and the bridge and between the bridge and the arterial cannula. A 
biphasic response with initial decrease and secondary increase occurred in mean arterial blood 
pressure and mean left carotid artery flow. Central venous pressure, superior sagittal sinus 
pressure, deoxygenated haemoglobin concentration, and cerebral blood volume increased, 
whereas concentration of cerebral oxygenated haemoglobin decreased. These effects occurred 
in each combination of flow rate and opening time. These effects could be abolished by 
installing a roller pump on the bridge.  
Conclusions: Bridge opening in veno-arterial extracorporeal membrane oxygenation resulted 
in significant cerebral haemodynamic changes caused by an arteriovenous shunt over the 
bridge. The decreased cerebral perfusion may contribute to the occurrence of cerebral 
ischaemia, and the venous congestion may result in intracranial haemorrhages. These could be 
prevented by installing a roller pump on the bridge.  
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INTRODUCTION 
 
ECMO is a rescue therapy for neonates with severe respiratory failure for which the mortality 
rate is high if treated with conventional therapy only (1). Since the first patient treated by Bartlett 
in 1976, more than 15,000 newborns have been treated with ECMO, the majority of them with 
VA-ECMO (2,3).  
Although the overall survival rate for newborns treated with ECMO is 80%, complications occur 
in a high percentage of these patients (4). The most important complication is cerebral damage 
caused by haemorrhage or ischaemia, an important determining factor for mortality and impaired 
neurodevelopmental outcome in the survivors (5-7).  
Other than the primary disease, the ECMO technique itself may have an aetiologic role in the 
development of complications. The understanding of the effects of ECMO on physiologic 
processes is important for the prevention of possibly dangerous complications. Our group 
previously reported on the disturbance of cerebral oxygenation and haemodynamics in relation to 
the opening of the bypass bridge during VA-ECMO (8). The bridge is a part of the VA-ECMO 
circuit that connects the venous and arterial sides of the system, enabling the continuation of 
circulation through the circuit while bypassing the patient in case of emergencies. To prevent 
clotting, the clamp on the bridge should be released every 15 mins during the ECMO procedure 
(9,10). In piglets and newborn infants, we found that opening of the bridge results in a decrease 
in CBV and cerebral oxygen supply, because of a decrease in CBF and then a compensatory 
increase in cerebral oxygen extraction and vasodilation. 
The present study was undertaken to determine the following: (a) the changes that are 
responsible for the previously described disturbance of cerebral oxygenation and 
haemodynamics; (b) the effect of various opening times and flow rates on the magnitude of the 
haemodynamic disturbances; and (c) whether the haemodynamic changes could be abolished by 
using a continuously functioning pump on the bridge.   
 
 
MATERIALS AND METHODS  
 
The study was performed in 8 lambs (weight, 3.9-4.9 kg; age, 2-7 days) obtained from local 
farmers. The study was approved by the Ethical Committee on Animal Research of the 
University of Nijmegen. The care and handling of the animals were in accordance with the 
guidelines issued by the National Institutes of Health. 
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General anaesthesia was induced by intravenous administration of 0.2 mg/kg midazolam and 10 
?g/kg fentanyl, and muscle relaxation was obtained with 0.05 mg/kg pancuronium. After 
endotracheal intubation, mechanical ventilatory support was started with a Babylog 8000 
(Dräger, Lübeck, Germany) to maintain normal arterial blood gases (pH 7.40-7.45; paO2 70-90 
mm Hg [9.3–12 kPa]; paCO2 30-40 mm Hg [4–5.3 kPa]). During mechanical ventilatory 
support, anaesthesia was maintained using continuous intravenous infusion of midazolam (0.1-
0.2 mg/kg per hr), fentanyl (5-10 ?g/kg.hr) and pancuronium (0.02 mg/kg.hr). HR was 
monitored via electrodes placed on the chest. The temperature was measured with a rectal probe 
and maintained between 38.5oC and 39.5oC. A catheter was placed in the aorta through the right 
femoral artery for continuous measurement of MABP, (HP 78206C, Hewlett Packard, 
Boeblingen, Germany). Through the other femoral artery a 7.5 Fr fiberoptic oxymeter catheter 
(Viggo Spectramed, Oxnard, CA, USA) was inserted into the abdominal aorta for online 
continuous monitoring of saO2 (HemoprO2 SP 1455, Viggo Spectramed, Oxnard, CA, USA). 
Through the right femoral vein, another 7.5 Fr catheter was placed into the inferior caval vein 
with the tip in the right atrium to monitor the central venous pressure (CVP), (HP 78205C, 
Hewlett Packard, Boeblingen, Germany). Superior sagittal sinus pressure (SSSP) was monitored 
through a catheter placed in the superior sagittal sinus after trepanation of the skull. Mean blood 
flow in the left common carotid artery (Qcar) was measured using an electromagnetic flow meter 
(Scalar MDL 1401, Scalar  Medical, Delft, The Netherlands). Changes in Qcar were used as a 
measure for changes in CBF. A close relationship between Qcar and CBF determined with 
radionuclide labeled microsphere method was demonstrated by van Bel et al (11).  
The ECMO circuit was primed with full fresh sheep blood before cannulation. The RCCA was 
cannulated with an arterial catheter (Elecath 10 Fr, Electro-Catheter, Rahway, NJ, USA) and the 
RIJV with a venous catheter (Biomedicus 12 Fr, Medtronics, Eden Prairie, MN, USA). 
Thereafter, the animal was placed on VA-ECMO. During the cannulation procedure a loading 
dose of heparin was administered (150 IU/kg) and continued intravenously (100 - 200 IU/kg per 
hr) to maintain activated clotting time between 200 and 250 seconds (Hemochron, Edison, NJ, 
USA). 
The ECMO circuit itself consisted of a custom packed ¼ inch flexible polyvinylchloride tubing 
(Baxter, Uden, The Netherlands), with a silicone reservoir, “the bladderbox” (Seabrook Medical 
System, Værløse, Denmark), a 0.6 m2 membrane oxygenator (Scimed Life Systems, 
Minneapolis, MN, USA), a heat exchanger (Cincinnati Sub Zero, Cincinnati, OH, USA) and a 
rollerpump (Polystan A/S, Denmark). Inline 'mixed venous' oxygen saturation (svO2line) was 
continuously monitored between the bridge and the bladderbox (Oxysat, Baxter-Bentley, Irvina, 
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CA, USA). Two ultrasonic flow meters (Transonic Systems, Ithaca, NY, USA) were placed for 
the continuous measurement of the actual flow in the circuit: one between the venous catheter 
and the bridge (Flow VP), and one between the bridge and the arterial catheter (Flow AP). When 
Flow VP is positive, the blood flow direction is from the animal to the bridge, when Flow VP 
is negative, the blood flow direction is from the bridge into the animal. When Flow AP is 
positive, the blood flow direction is from the bridge into the animal, when Flow AP is 
negative, the blood flow direction is from the animal to the bridge (figure 1).  
Cerebral oxygenation and haemodynamics were studied with NIRS. The NIRS equipment used 
was developed by the Department of Biomedical Engineering and Medical Physics at the 
University of Keele (UK) and produced by Radiometer (Copenhagen, Denmark) (12). The 
technique is based on the spectrophotometric measurement of changes in the absorption 
properties of haemoglobin in the near infrared region, depending on its oxygenation state (13).  
Details of our NIRS measurement procedure have been extensively described before (8,14). 
Changes in cO2Hb and cHHb were calculated from changes in the absorption of near infrared 
light at wavelengths 904, 845 and 775 nm. The concentration changes are expressed in ? mol/100 
gr brain. ? cO2Hb and ? cHHb reflect changes in cerebral oxygen supply (15). Changes in the 
ctHb were calculated as the sum of ? cO2Hb and ? cHHb. Changes in ? CBV, expressed in 
mL/100 gr, were calculated from the formula: ? CBV = 4. ? ctHb/0.69.cHb, where cHb is the 
intravascular concentration of haemoglobin in mmol/L, 0.69 is the cerebral-arterial haematocrit 
ratio, and 4 is a correction factor, because ctHb is calculated from changes in light absorption 
using an extinction coefficient based on the tetrahaeme molecule, whereas cHb determination is 
based on the monohaeme molecule (16). 
After cannulation and initiation of the ECMO procedure, the ECMO flow was gradually 
increased to 500 mL/min. The ventilation was adjusted to maintain normal arterial blood gas 
values, and the animal was allowed to stabilize. Subsequently the bridge was randomly opened 
during 1, 2.5, 5, 7.5, 10 and 15 seconds. The ECMO flow and opening time followed a Latin 
square design in each lamb in such way that each opening time is equally often followed by 
another opening time. The duration of stabilization periods between the measurements was 5 
mins. The same procedure was repeated at ECMO flow rates of 400, 300, 200, 100 and 50 
mL/min. The NIRS variables were recorded at a sample rate of 1 Hz using a specially designed 
data acquisition program. The other measured variables were recorded continuously using a data 
acquisition program Poly® (Inspector Research System, Amsterdam, The Netherlands) at a 
sample rate of 100 Hz. 
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Figure 1. Scheme showing the experimental model 
 
RA = right atrium, RV = right ventricle, LA = left atrium, LV = left ventricle, svO2line = inline ‘mixed venous’ 
oxygen saturation, Flow VP = flow between the venous catheter and the bridge, CVP = central venous pressure, 
SSSP = superior sagittal sinus pressure, MABP = mean arterial blood pressure, saO2 = arterial oxygen saturation, 
NIRS = near infrared spectrophotometry measurement, Qcar = mean blood flow in the left common carotid 
artery, Flow AP = flow between the bridge and the arterial catheter, ECMO = extracorporeal membrane 
oxygenation circuit. Arrows indicate normal blood flow direction. 
 
Because release of the clamp on the bridge resulted in significant haemodynamic changes, we 
modified the bridge and constructed a small roller pump that was placed on the bridge. With this 
pump on the bridge, repeated opening of the bridge was no longer necessary. There was 
continuous refreshment of blood in the bridge. Measurements of all the above-described 
variables were repeated in the same eight animals with this pump on the bridge and an ECMO 
flow rate of 100 mL/min and 500 mL/min and flow over the bridge of 10 mL/min and 50 
mL/min, respectively. These data were compared with a zero flow rate over the bridge (bridge 
closed).  
At the end of the experiments, the lambs were killed by administration of an overdose of 
pentobarbital. 
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DATA ANALYSIS 
 
Before analysis, the data of CVP and SSSP were filtered with a 0.3-Hz low pass filter to 
reduce signal noise caused by breathing movements. For each variable, we selected data from 
two episodes around each bridge opening. During a period of 30 secs just before opening of 
the bridge, the mean (baseline) and standard deviation (sd) of each variable were calculated. 
During a period of 120 seconds after the opening of the bridge we selected the first positive 
peak (maximum) and/or negative peak (minimum) and eventually the second peak that 
exceeded the baseline level by more than 2 sd’s for more than 2 secs. When no positive or 
negative peak was found a value of 0 was taken. 
The differences in the values between the positive or negative peaks after opening the bridge 
and the mean values before opening the bridge were calculated to assess the effect of the 
bridge opening. The beginning of the change in Flow AP was considered to represent the 
actual beginning of the bridge opening.  
For analysing the data, a statistical method that took into account the dependency of the 
observations in one lamb was required. Therefore, the mixed linear model approach was used 
(17,18). For all analyses, a factorial model, with factors ECMO flow rate and opening time, 
with random intercept for each lamb was used. This means that the correlation between 
different observations within one lamb is the same for all pairs of measurements. First, a 
possible (statistical) interaction between ECMO flow rate and opening time was investigated. 
A significant interaction was not found for any of the variables. Hence, only results of 
analyses without the interaction between ECMO-flow and opening time were presented. To 
correct for multiple testing within each set of hypotheses a Bonferroni correction was applied. 
Statistical significance required p = 0.05. 
 
 
RESULTS 
 
Table 1 shows the mean haemodynamic changes at various flow rates and opening times. 
Haemodynamic changes occurred in all combinations of opening times and ECMO flows. For 
those variables that showed statistically significant changes, these changes were present in each 
individual combination of flow and opening time.  
Figures 2 and 3 illustrate the haemodynamic changes in one experiment at an ECMO flow 
rate of  500 mL/min and opening time 2.5 secs. 
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Table 1. Mean haemodynamic changes (± sd) during bridge opening in veno-arterial extracorporeal membrane 
oxygenation 
Variable Absolute value ± sd 
before bridge opening 
Changes at first peak 
(mean ± sd) 
Changes at second peak 
(mean ± sd) 
Flow VP (mL/min) 50-500a -1128 ± 90##  
Flow AP (mL/min) 50-500a -775 ± 59##  
MABP (mm Hg) 107.0  ±  10.8 -21 ± 4## +12 ± 4# 
Qcar (mL/min) 97 ± 52 -26 ± 9## +20 ± 6 # 
CVP (mm Hg) 2.7 ± 2.9 +2.5 ± 0.6##  
SSSP (mm Hg) 11.9 ± 7.5 +2.2 ± 1.0#  
svO2line (%) 52 ± 7 +32 ± 2
##  
cHHb (µmol/100 gr brain) na +0.23 ± 0.11##  
cO2Hb (µmol/100 gr brain) na -0.18 ± 0.08
##  
CBV (mL/100 gr brain) na +0.15 ± 0.08##  
Flow VP = flow between venous catheter and bridge (when Flow VP is positive, the blood flow direction is from 
the animal to the bridge, when Flow VP is negative, the blood flow direction is from the bridge into the animal), 
Flow AP = flow between bridge and arterial catheter (when Flow AP is positive, the blood flow direction is from 
the bridge into the animal, when Flow AP is negative, the blood flow direction is from the animal to the bridge). 
MABP = mean arterial blood pressure, Qcar = mean blood flow in the left common carotid artery, CVP = central 
venous pressure, SSSP = superior sagittal sinus pressure, svO2line = inline ‘mixed venous’ oxygen saturation, 
cHHb = concentration of deoxyhaemoglobin, cO2Hb = concentration of oxyhaemoglobin, CBV = cerebral blood 
volume.  
a flow varied from 50 mL/min to 500 mL/min (see methods) 
# p < 0.05, ## p < 0.01, na: not available 
 
Flows in the ECMO circuit 
 
On the venous side of the circuit, Flow VP showed an immediate and sharp decrease after 
opening of the bridge. The flow direction changed from positive to negative, which means that 
the Flow VP was reversed toward the animal. After a short negative peak, the flow stabilized, but 
remained negative during the opening of the bridge. After closing the bridge, the flow returned to 
its original direction immediately. 
On the arterial side of the circuit, Flow AP also showed an immediate and sharp decrease after 
bridge opening. The flow direction changed from positive to negative, which means that Flow 
AP was reversed out of the animal. During bridge opening, the flow remained negative. After 
closure of the bridge, the flow direction returned to its original direction again. 
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Figure 2. Registration of curves during 2.5-sec bridge opening at a flow rate of 500 mL/min 
 
Flow AP = flow between the bridge and the arterial catheter, Flow VP = flow between the venous catheter and 
the bridge, ABP = arterial blood pressure, Qcar = left carotid artery blood flow, CVP = central venous pressure, 
SSSP = superior sagittal sinus pressure, SvO2line = inline ‘mixed’ venous oxygen saturation. 
 
MABP and Qcar 
 
After opening of the bridge, MABP and Qcar showed a biphasic pattern. Initially there was a 
decrease in MABP as well as in Qcar. After bridge closure, MABP and Qcar increased to higher 
values than the pre-opening values.  
 
CVP and SSSP 
 
A significant increase in CVP and SSSP was observed after opening of the bridge.  
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Figure 3. Registration of NIRS variables during 2.5-sec bridge opening at flow rate of 500 mL/min 
 
cHHb = concentration of deoxyhaemoglobin, cO2Hb = concentration of oxyhaemoglobin, CBV = cerebral blood 
volume. 
 
svO2line 
 
After opening of the bridge there was a slow increase in svO2line. 
 
NIRS signals 
 
After bridge opening, cHHb increased, which resulted in a positive peak, and cO2Hb decreased, 
resulting in a negative peak. After a slight decrease of CBV, that was not significant, there was a 
gradual increase after bridge opening with a statistically significant positive peak shortly after 
bridge closure. 
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Table 2. Effect of decreasing flow and opening time on haemodynamic changes during opening of the bridge in 
VA-ECMO 
Variable Decreasing flow: 500 to 400, 300, 
200, 100 and 50 mL/min 
Decreasing opening time:  
15 to10, 7.5, 5, 2.5, 1 sec(s) 
? Flow VP (mL/min) p<0.01 N.S. 
?Flow AP (mL/min) p<0.01 N.S. 
? MABP (mm Hg) p<0.01 N.S. 
? Qcar (mL/min) p<0.01 N.S. 
? CVP (mm Hg) N.S. p<0.05 
? SSSP (mm Hg) N.S. N.S. 
?svO2line (%) p<0.01 p<0.01 
?cHHb (µmol/100 gr brain) p<0.01 p<0.01 
?cO2Hb (µmol/100 gr brain) p<0.01 p<0.01 
?CBV (mL/100 gr brain) N.S. p<0.05 
? = change, Flow VP = flow between venous catheter and bridge, Flow AP = flow between bridge and arterial 
catheter, MABP = mean arterial blood pressure, Qcar = mean left carotid artery blood flow, CVP = central 
venous pressure, SSSP = superior sagittal sinus pressure, svO2line = inline ‘mixed venous’ oxygen saturation, 
cHHb = concentration of deoxyhaemoglobin, cO2Hb = concentration of oxyhaemoglobin, CBV = cerebral blood 
volume. 
When p<0.05, decreasing flow or opening time leads to a significant lesser change of that variable. 
 
Heart rate and arterial oxygen saturation 
 
HR and saO2 did not change significantly during bridge opening.  
 
Effect of ECMO flow rate and opening time 
 
For most variables, there was a significant effect of the ECMO flow rate on the magnitude of the 
measured haemodynamic changes (table 2), indicating that the haemodynamic changes became 
less apparent with a decreasing ECMO flow rate. Shortening of the opening time only led to less 
pronounced changes in CVP, svO2line, cHHb, cO2Hb and CBV. For all other measured variables 
there was no effect of shortening the opening time. 
 
Measurements with pump on the bridge 
 
No significant changes were observed when we used the pump on the bridge with flow rates 
of 10 mL/min and 50 mL/min in combination with ECMO flow rates of 100 mL/min and 500 
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mL/min. No complications like clot formation or rupture of the tubing of the bridge were seen 
during a 2-hr use of this pump on the bridge. 
 
 
DISCUSSION 
 
Important changes of blood flow on both arterial and venous sides of the cerebral vascular 
system occurred during bridge opening. At the moment of opening, the arterial and venous sides 
of the ECMO circuit are linked, creating an arteriovenous shunt over the bridge in which blood 
flows from a high-pressure area (arterial side) to a low-pressure area (venous side). The net result 
is a flow from the aorta to the right atrium through the arterial cannula, the bridge, and the 
venous cannula.  
As MABP decreases and CVP and SSSP increase during the bridge opening, CPP decreases. 
Intact cerebral autoregulation is necessary to maintain an adequate CBF. In normal 
circumstances, CBF is maintained over a wide range of CPP by cerebral autoregulation (19,20). 
However, autoregulation can be disturbed during the recovery phase after prolonged hypoxia in 
newborn lambs (21,22). All infants treated with ECMO have experienced profound hypoxia in 
the pre-ECMO period and might therefore be at risk for a disturbed cerebral autoregulation. In 
the absence of an adequate cerebral autoregulation, the decreased CPP could lead to ischaemic 
brain lesions. 
The aetiology of intracranial haemorrhages and ischaemic lesions occurring during ECMO is 
multifactorial and includes the following: 1) secondary haemorrhage after infarction and 
systemic heparinization; 2) cerebral perfusion disturbances caused by either blood gas or blood 
pressure disturbances; or 3) cerebral circulation changes caused by ligation of the jugular vein 
(23-29). This study demonstrates that bridge opening results in changes in brain perfusion. The 
venous factor may contribute to the onset of posterior fossa haemorrhages, which occur rather 
frequently in ECMO treated infants (30,31). 
Also, the increase of svO2line demonstrates that oxygenated blood flows from the arterial side of 
the circuit to the venous side. After bridge closure, the arterial blood that was drained into the 
bridge and the venous limb of the ECMO circuit will pass the oxygen saturation monitor, 
causing a rise in svO2line. 
Statistically significant haemodynamic changes occurred in every combination of ECMO flow 
rate and opening time. In a clinical ECMO run, opening of the bridge occurs intermittently for 
the prevention of clot formation. The bridge is opened at regular intervals during the whole run 
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depending on local protocols. The haemodynamic changes become less pronounced as the 
ECMO flow rate is diminished and for some of them as the opening time is shortened. As these 
changes occurred in every combination of ECMO flow rate and opening time, they cannot be 
prevented. Therefore, bridge opening of any duration at any flow rate might be harmful. 
Moreover, the opening time must be long enough to fill the bridge with new blood. 
The mean decrease and secondary increase in Qcar was substantial, 25% and 20% respectively. 
Wyath et al demonstrated that mean CBV was 2.2±0.40 (sd) mL/100 g in normal infants and 
3.00±1.04 (sd) mL/100 g in infants with brain injury (32). In our study the change in CBV after 
bridge opening was 0.15 mL/100 g, which also is a substantial change (5-7%) compared to 
normal values. These changes in cerebral perfusion could be one of the factors contributing to 
intracranial haemorrhages. 
There is one report regarding an ECMO system in which the bridge between the arterial and 
venous tubing is altered. Gangitano et al used two high flow 3-way stopcocks instead of a 
bridge (33). The stopcocks are connected to luer connectors in the arterial and venous tubing. 
In situations in which the patient is off ECMO, the stopcocks control direction of flow and 
serve as the connection between the two sides of the circuit. Snyder et al used an automatic 
clamping device for intermittent manual clamping that was parallel to the membrane lung to 
permit continuation of circulation when the lung needs to be replaced (34). This automated 
clamping device can also be used as a bridge, but the haemodynamic changes that we 
observed will still occur. A partial bridge clamp, allowing blood to pass continuously across 
the bridge can probably prevent these changes. However, this can have the disadvantage of 
turbulent blood flow resulting in haemolysis and clot formation.  
In this study, when using a small pump on the bridge, a small continuous arteriovenous shunt 
was created to prevent intermittent unclamping of the bridge. It was demonstrated that the use 
of this system in the ECMO circuit prevented disturbances of the haemodynamic variables of 
the animals. More information is needed regarding the possibility of any deleterious effects 
when it is being used for longer periods of time. 
 
 
CONCLUSIONS 
 
Bridge opening during VA-ECMO results in a massive shunt of blood from the arterial side of 
the circuit to the venous side, causing significant changes in blood pressure and cerebral 
oxygenation and haemodynamics. Although the cause of cerebral complications in ECMO 
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patients is multifactorial, recurrent fluctuations in cerebral oxygenation and haemodynamics 
might be a factor that contributes to these complications. These changes can be prevented by 
using a small continuously running pump on the bridge. 
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ABSTRACT 
 
Objective: To investigate the effect on cerebral oxygenation and haemodynamics of a patent 
ductus arteriosus with left-to-right shunt during veno-arterial extracorporeal membrane 
oxygenation in a lamb model.  
Design: Prospective intervention study in animals. 
Setting: Animal research laboratory of a university medical centre. 
Subjects: Six anaesthetized newborn lambs with patent ductus arteriosus and left-to-right 
shunt, installed on veno-arterial extracorporeal membrane oxygenation. 
Interventions: Six lambs of 140 days gestational age were prepared to keep the ductus 
arteriosus open by infiltration of the vessel wall with formaline 10%. The animals were 
installed on standard veno-arterial extracorporeal membrane oxygenation. With a mechanical 
occluder, the ductus was closed.  
Measurements and mean results: Changes of mean arterial blood pressure and carotid 
artery blood flow were measured simultaneously. Using near infrared spectrophotometry, we 
calculated changes in cerebral concentration of oxyhaemoglobin and deoxyhaemoglobin 
(reflecting changes in cerebral oxygen supply) and total haemoglobin (reflecting changes in 
cerebral blood volume). Also, cerebral oxygen delivery before and after ductus closure as 
calculated. Before ductus closure there was a left-to-right shunt with a mean (?  standard error 
of the mean) of 41 ?  20% of the total body blood flow. Closure of the ductus resulted in an 
immediate increase in mean arterial blood pressure and left carotid artery blood flow. The 
concentration of oxyhaemoglobin increased and the concentration of deoxyhaemoglobin 
decreased, representing an increased cerebral oxygen supply. The concentration of total 
haemoglobin was unchanged, representing unchanged cerebral blood volume. There was an 
increase in cerebral oxygen delivery. 
Conclusions: In this lamb model a considerable left-to-right shunt over the ductus during 
veno-arterial extracorporeal membrane oxygenation reduced cerebral circulation and 
oxygenation.  
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INTRODUCTION 
 
ECMO is a rescue therapy for newborn infants with severe respiratory failure. Most of these 
patients suffer from pulmonary hypertension with right-to- left shunt over the ductus arteriosus 
(1). Soon after initiation of VA-ECMO, blood pressure in the pulmonary artery decreases and 
the shunt over the ductus arteriosus reverses from right-to- left into a left-to-right shunt (2).  
Earlier we studied shunt direction through the ductus arteriosus during VA-ECMO in 29 
newborns. Before the initiation of VA-ECMO 82% of the patients showed either right-to-left 
shunt or a bidirectional shunt over the ductus, corresponding with initially existing pulmonary 
hypertension. After 12 hrs of ECMO treatment, 43 % of the patients showed left-to-right 
shunt. In total, 62% of all patients showed left-to-right shunt within the first 72 hrs of 
treatment. All ductus were closed spontaneously 72 hrs after the initiation of VA-ECMO 
(3,4).  It is well known that a patent ductus arteriosus with left-to-right shunt in preterm 
infants can compromise cerebral circulation, with a decrease in blood flow velocity in 
cerebral arteries and an increase in pulsatility index as measured by echo-Doppler (5-9). The 
occurrence of both ischaemic and haemorrhagic cerebral lesions is a major complication of 
ECMO treatment. To our knowledge, the influence of the patent ductus arteriosus on cerebral 
circulation during VA-ECMO has not been studied before.  
The aim of this study was to investigate the effect of a patent ductus arteriosus with left-to-
right shunt during VA-ECMO on cerebral oxygenation and haemodynamics in an animal 
model. We used an existing lamb model in which, after birth, the ductus was kept open 
artificially (10).  When the animal is placed on VA-ECMO there will be a left-to-right shunt 
over the ductus because the lamb has normal lungs with low pulmonary vascular resistance. 
The ductus can be closed mechanically. From the changes in cerebral perfusion and 
oxygenation that occur after ductus closure, one can get information about the effects of the 
left-to-right shunt itself. With this model we tried to mimic that part of the ECMO treatment 
in which, after a decrease in pulmonary vascular pressure, a left to right shunt occurs, before 
the ductus closes. 
The lamb model is a frequently used model in ECMO research and also for studies on CBF 
and oxygenation (11).  
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MATERIAL AND METHODS 
 
Subjects  
 
This study was performed in 6 newborn lambs. Mean bodyweight of the lambs was 4.3 kg 
(range 3.1-5.1 kg). The Ethical Committee on Animal Research of the University of Nijmegen 
approved surgical and experimental procedures. The care and handling of the animals were in 
accordance with National Institutes of Health guidelines. Six pregnant mixed breed ewes 
obtained from local farmers were operated at 140 days of gestation (term 147 days). 
Anaesthesia was induced with pentobarbital 30 mg/kg intravenously and maintained with 2% 
enflurane and a 1:1 mixture of nitrous oxide and oxygen administered by mechanical 
ventilation (Engstrom ER 300 Respirator, LKB Medical AB, Bromma, Sweden). HR was 
monitored (Hewlett Packard 78330A Monitor, Hewlett Packard, Boeblingen, Germany) by 
using needle electrodes placed on the chest. After shaving and disinfecting the abdominal 
skin, we performed a paramedian laparotomy. After hysterotomy, the upper part of the lamb 
was partially delivered. A thoracotomy through the left fourth intercostal space of the lamb 
was performed and the left lung retracted to expose the aorta, pulmonary artery, and ductus 
arteriosus. These vessels were dissected from their surrounding tissue. The ductus wall was 
infiltrated with formaline 10% to destroy the muscular layer, preventing contraction of the 
muscular layer and closure of the ductus. The formaline was coloured with methylene blue, 
which offered the possibility to check the extension of the infiltration of the total length of the 
ductus wall (10). A silicon vessel loop (Surg-I-Loop; Scanlon, St. Paul, MN, USA) was 
positioned around the ductus without narrowing its lumen. The ends of the vessel loop were 
put through a sheet and fixed with a clamp, so that the ductus arteriosus could easily be closed 
from outside the thorax by pulling the vessel loops out of the sheath.  
Flow probes (Transonic cardiac output A probes; Transonic Systems Inc, Ithaca, NY, USA) 
were attached around the ascending aorta and the common pulmonary artery, both just above 
the arterial valves, to measure blood flow in the aorta (Qao) and common pulmonary artery 
(Qpa), respectively. Both the leads of the probes and the sheath containing the vessel loop 
around the ductus were exteriorized from the thorax. The leads of the flow probes were 
connected to a flow meter (Transonic Medical Flowmeter HT 207; Transonic Systems Inc, 
Ithaca, NY, USA). The thorax was closed. After endotracheal intubation of the lamb, 
mechanical ventilation was started (Babylog 8000, Dräger, Lübeck, Germany) to maintain 
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normal arterial blood gas values: pH 7.40-7.45, paO2 70-90 mm Hg [9.3-12 kPa], paCO2 30-
40 mm Hg [4-5.3 kPa].  
Catheters were inserted through the femoral artery and vein with the tips in the abdominal 
aorta for blood sampling and monitoring of the MABP, (HP 78206C, Hewlett Packard, 
Boeblingen, Germany), and in the inferior vena cava for administration of medication. 
Anaesthesia of the lamb was induced using midazolam (0,2 mg/kg), fentanyl (10µg/kg) and 
pancuronium (0.1 mg/kg) and maintained with midazolam (0.2 mg/kg.hr), fentanyl (2-5 
µg/kg.hr) and pancuronium (0.02 mg/kg.hr). Then the umbilical cord was ligated and the 
lamb was put on a table.  
An electromagnetic flow meter (Scalar MDL 1401; Scalar Medical, Delft, The Netherlands) 
was installed around the left common carotid artery to measure Qcar. Changes in Qcar reflect 
changes in CBF (12). 
The RCCA was cannulated with an arterial catheter (Biomedicus 10 Fr) and the RIJV with a 
venous catheter (Biomedicus 12 Fr; Medtronic, Grand Rapids, MI, USA). The tip of the 
arterial catheter was positioned in the brachiocephalic trunk and that of the venous catheter in 
the right atrium. During the cannulation procedure, a loading dose of heparin was 
administered (150 IU/kg) and continued intravenously (100-200 IU/kg.hr) to maintain 
activated clotting time between 200 and 250 secs (Hemochron, Edison, NJ, USA). The 
ECMO catheters were connected to a standard VA-ECMO system that was primed with full 
fresh sheep blood prior to cannulation. The ECMO circuit itself consisted of a custom packed 
1/4 inch flexible polyvinylchloride tubing (Baxter, Uden, The Netherlands) with a silicone 
reservoir, the “bladderbox” (Seabrook Medical System, Værløse, Denmark), a 0.6 m2 
membrane oxygenator (Scimed Life Systems, Minneapolis, MN, USA), a heat exchanger 
(Cincinnati Sub Zero, Cincinatti, Ohio, USA) and a rollerpump (Polystan A/S, Denmark). 
ECMO flow (Qecmo) was measured by a flow probe around the tubing system (Transonic 
Medical Volume Flowmeter HT 107, Transonic Systems Inc, Ithaca, NY, USA). The HR was 
monitored (Hewlett Packard 78330A Monitor, Hewlett Packard, Boeblingen, Germany) by 
using needle electrodes on the chest. Rectal temperature was kept between 38.5 and 39.5°C 
with a servo controlled heating mattress.  
Cerebral oxygenation and haemodynamics were studied by NIRS. The NIRS equipment used 
was developed by the Department of Biomedical Engineering and Medical Physics, 
University of Keele (UK), and produced by Radiometer (Copenhagen, Denmark) (13). The 
technique is based on continuous spectrophotometric measurement of oxygenation-dependent 
changes in the absorption properties of haemoglobin in the near infrared region (14). Details 
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of our NIRS measurement procedure have been extensively described before (15-17). 
?cO 2Hb and ?cHHb were calculated from the changes in the absorption of near infrared light 
at wavelengths 904, 845 and 775 nm. The concentration changes are expressed in µmol/100 g 
of brain. ?cO2Hb and ?cHHb reflect changes in cerebral oxygen supply (13). ?ctHb was 
calculated as the sum of ?cO2Hb and ?cHHb, and reflects changes in CBV.  
Oxygen delivery to the brain was calculated 5 min before ductus closure and 15 min 
thereafter. Oxygen delivery is equal to Qcar x oxygen content, where Qcar is used as actual 
brain blood flow. Oxygen content is calculated as: (grams Hb/dl x 1.36 mL O2/g Hb x % 
oxygen saturation) + (0.0031 x paO2). From the changes in Qcar and oxygen content, changes 
in oxygen delivery can be calculated and compared with changes in NIRS variables.  
Also, changes in pH, paO2 and paCO2 could be investigated from the arterial blood gas 
analysis. Furthermore, cHb was determined 5 mins before and 15 mins after ductus closure. 
 
Experimental procedure 
 
After ECMO started, the flow rate was increased gradually until further increment was 
impossible because of insufficient venous return. Ventilator settings were adjusted to maintain 
normal arterial blood gas values: pH 7.40-7.45, paO2 70-90 mm Hg [9.3-12 kPa], and paCO2 
30-40 mm Hg [4-5.3 kPa]. Ventilator settings were comparable with so called rest-settings 
used in our clinic during VA-ECMO: ventilator frequency 15/min, inspiratory pressure 24 
mbar, positive end-expiratory pressure 4 mbar, and FiO 2 0.30-0.40. These settings were not 
changed during the experimental procedure. 
After stabilization, ECMO was continued for two hours during which blood flows were 
measured from the ECMO circuit, the pulmonary artery and the ascending aorta. Then the 
vessel loop was attached by using the mechanism described before. This caused an abrupt 
closure of the ductus. Measurements were continued for 15 minutes after closure of the 
ductus. At the end of the experiment, all lambs and mother animals were killed with an 
overdose of pentobarbital. Autopsy of the lambs was performed to exclude congenital heart 
disease with intracardial shunts and to confirm total closure of the ductus after tightening of 
the vessel loops. All measured variables were recorded in a data acquisition system (Poly®; 
Inspector Research System, Amsterdam, The Netherlands) at a sampling frequency of 1 Hz. 
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Flow measurement and determination of ductus shunt flow  
 
When there is no ductus blood flow (Qduct), Qao is equal to Qpa (figure 1). In this case, total 
systemic blood flow (Qsyst) can be defined as the sum of ECMO flow (Qecmo) and Qpa 
(Qsyst = Qecmo + Qpa). In case of ductus flow with left to right shunt, Qao is greater than 
Qpa and Qduct = Qao-Qpa. 
In this experiment, Qpa, Qao and Qecmo were measured so that Qduct could be calculated, 
and related to Qsyst. In this calculation, coronary perfusion and possible atrial shunting are 
left out of consideration. 
 
Figure 1. Schematic drawing of the flow in the great vessels and ductus arteriosus during extracorporeal 
membrane oxygenation 
  
ECMO = extracorporeal membrane oxygenation, Qsyst = systemic blood flow, Qduct = ductus blood flow,  
Qao = blood flow in the aorta, Qecmo = ECMO flow, Qpa = blood  flow in the common pulmonary artery, RA = 
right atrium, RV = right ventricle, LA = left atrium, LV = left ventricle. 
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Data analysis 
 
The baseline level of all variables was obtained by calculating their mean values during a 30-
sec period before closure of the ductus (t = 0 secs). These values were compared with mean 
values obtained on a 5 s period at 15, 30, 45, 60, and 90 secs, and 2, 5, 10 and 15 mins after 
ductus closure.  
Results are reported as mean ± standard error of the mean (SEM). Changes in Qcar were 
expressed as percentage ± SEM compared with baseline level. For each variable, changes as a 
function of time were determined by analysis of variance with Student-Newman-Keuls post-
test for multiple comparisons when a significant difference was found. To compare oxygen 
delivery to the brain, pH, paO2 and paCO2 in arterial blood gas and cHb before and after 
ductus closure, we performed a paired non-parametric test (Wilcoxon signed rank test). We 
considered p ?   0.05 to be statistically significant. 
 
 
RESULTS 
 
Infiltrating the ductus wall with formaline could create a substantial left-to-right shunt over 
the ductus arteriosus during VA-ECMO. Qecmo was 389±27 mL/min and Qpa was 473±162 
mL/min. The mean left-to-right shunt was 354±118 mL/min, which was 41±20% of Qsyst. 
After closure of the ductus there was a significant increase in MABP and Qcar. This was 
accompanied by a significant increase in cO2Hb and a significant decrease in cHHb; ctHb did 
not show any significant changes (figure 2) 
All significant changes occurred already at 15 secs after ductus closure and persisted until 15 
mins thereafter. There were no significant changes in HR. Data beyond 15 mins could not be 
presented because in some animals other necessary interventions had to be done like 
endotracheal suctioning, volume suppletion because of bladder box alarm, and blood trans-
fusion. Then, the observed changes in variables were not necessarily the consequence of 
ductus closure. 
In those animals in which undisturbed observations could be done, the observed changes in 
Qcar, MABP and NIRS variables persisted for over 30 mins. 
Oxygen delivery to the brain increased from 9.4 ?  1.1 mL of oxygen/min before ductus 
closure to 11.8 ?  1.3 mL of oxygen/min after ductus closure (p<0.05).  
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Figure 2. The effect of ductus closure during veno-arterial extracorporeal membrane oxygenation 
  
Figure 2a, effect on NIRS variables; Figure 2b, effect on mean left carotid artery blood flow (Qcar); and Figure 
2c, effect on mean arterial blood pressure (MABP). NIRS = variables of near infrared spectrophotometry, cO2Hb 
= concentration of oxyhaemoglobin, ctHb = concentration of total haemoglobin, cHHb = concentration of 
deoxyhaemoglobin, Qcar = mean left carotid artery blood flow, MABP = mean arterial blood pressure, 0 s = 
value before ductus closure, t:15 s to 15 min = values after ductus closure. Values are mean ± SEM. *p < 0.05 
compared with t = 0. 
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Blood gas analysis before and after ductus closure revealed no significant differences for pH, 
paCO2 and paO2. Also, cHb did not change (table 1). Ventilator settings were unchanged 
during the study period. 
Autopsy of the lambs confirmed total closure of the ductus in all lambs and excluded 
congenital heart disease with intracardial shunts. 
 
Table 1. Mean values (?  SEM) of pH, paCO2, paO2, haemoglobin concentration (cHb), and cerebral oxygen 
delivery before and after ductus closure 
 
 
5 Mins before 
ductus closure 
15 Mins after 
ductus closure 
pH 7.42 ?  0.04 7.39 ?  0.04 
paCO2  (Torr) 39.5 ?  0.5 38.9 ?  0.5 
paO2 (Torr) 125 ?  16 122 ?  16 
cHb (mmol/l) 5.6 ?  0.2 5.7 ?  0.2 
Cerebral oxygen delivery (mL O2/min) 9.4 ?  1.1 11.8 ?  1.3* 
* p < 0.05 
 
 
DISCUSSION  
 
This study aimed to investigate the effect of a patent ductus arteriosus with left-to-right shunt 
during VA-ECMO on cerebral oxygenation and haemodynamics in a lamb model.  It has been 
demonstrated that during VA-ECMO when the ductus arteriosus is patent, a considerable left-
to-right shunt over the ductus can be present. Usually the ductus is closed spontaneously at 48 
hrs after birth in 80-90% of all healthy full term newborns. In the remaining group, the ductus  
normally closes within the next 48 hrs. This means that in humans, beyond the fourth day of 
life practically every ductus is closed (18,19). In newborns treated with VA-ECMO for severe 
respiratory insufficiency and pulmonary hypertension, a period with left-to-right shunt over 
the ductus can be expected when the pulmonary arterial pressure decreases (2-4). A patent 
ductus with left-to-right shunt during ECMO has been reported in the literature. Becker et al 
described one newborn out of 500 treated with ECMO where ductus ligation had to be 
performed (20). However, they stated that many infants were treated empirically for a patent 
ductus arteriosus with fluid restriction and furosemide. Burch et al demonstrated a left-to-right 
shunt at the ductus level in nine of 12 infants. In two of them, ductus ligation was necessary to 
facilitate weaning from ECMO (21). Bartlett et al described that in 11 of their first 45 and 16 
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of their first 100 patients, ductus ligation was necessary while on ECMO (2,22). Martin and 
Short demonstrated an increase in left-to-right shunt during ECMO (1). Earlier we 
demonstrated a left-to-right shunt over the ductus in up to 62% of the newborns treated with  
VA-ECMO. This shunt was often already present in the first 24 hrs after initiation of ECMO 
(3). The fact that this left-to-right shunt can be important is supported by our observation that 
patients with a left-to-right shunt during VA-ECMO had a significant longer ECMO run time 
than patients without this shunt (4). This possibly reflects increased lung flow during left-to-
right shunt over the ductus. Also, Burch et al demonstrated that there was a smaller decrease 
in left ventricular size than expected during VA-ECMO, suggesting that this is related to 
increased left ventricular preload from left-to-right shunt (21). 
In newborns, a patent ductus arteriosus with large left-to-right shunt compromises the cerebral 
circulation. There is a diastolic runoff of blood through the patent ductus resulting in a 
decrease in CBFV and an increase of pulsatility index (5-8). In patients with a large ductus 
left-to-right shunt, diastolic CBF can be reduced, absent or backward (9). On the other hand, 
both spontaneous ductus closure and ligation of the patent ductus are associated with an 
increase in MABP, a significant decrease in pulsatility index, an increase in diastolic and 
mean blood flow velocities in cerebral vessels, and an increase in CBV, also demonstrating 
the compromised cerebral circulation as long as a ductus with left-to-right shunt exists. (7,23-
27).  
This study in lambs demonstrated that ligation of the ductus during VA-ECMO had similar 
effects on MABP, cerebral haemodynamics and oxygenation with an increase in Qcar, cO2Hb 
and cerebral oxygen delivery. The increase in Qcar, cO2Hb and cerebral oxygen delivery after 
closure of the ductus does not necessarily mean that the cerebral circulation is compromised 
as long as the ductus is open. Cerebral perfusion could be adequate at that moment but 
increase further after closure of the ductus. Although the techniques of NIRS, Qcar 
measurement, and oxygen delivery calculations that we used cannot prove compromised 
cerebral circulation when a ductus with left-to-right shunt is present, the high percentage of 
ductus flow in relation to systemic flow makes it very likely that a stealing effect on the 
cerebral circulation, as described in preterm infants is present. Further clinical studies during 
VA-ECMO in newborns should be done to answer this question. We speculate that if the 
cerebral circulation is compromised by a ductus left-to-right shunt, this can contribute to the 
occurrence of cerebral lesions, a major complication of ECMO (28).  
The question arises how far this model with a lamb with healthy lungs applies to clinical 
practice. As mentioned earlier, this model mimics part of the clinical ECMO course in which 
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pulmonary hypertension diminishes after starting ECMO and a ductus right-to- left shunt can 
reverse into left-to-right shunt. The shunt direction depends on pulmonary vascular pressure. 
Although in a lamb model with healthy lungs this might be different from the situation in 
newborns with lung disease, the occurrence of a ductus left-to-right shunt during clinical VA-
ECMO is demonstrated, thereby confirming that also in these newborns, pulmonary vascular 
pressure can decrease (3). Further clinical studies are necessary to determine shunt size in 
relation to systemic perfusion during VA-ECMO treatment in newborns, to see if our findings 
can be confirmed. 
It is difficult to give an idea about the physiologic importance of the observed changes in 
Qcar, MABP, cO2Hb, and oxygen delivery, since with the variables studied one cannot draw 
conclusions about oxygen metabolism in the brain, rather only about oxygen delivery to the 
brain. But we think that the observed changes indicate that there is a risk factor for 
compromised cerebral oxygenation as long as there is a left-to-right shunt through the ductus. 
Over the last years there has been increasing use of VV-ECMO in newborns. However, left-
to-right shunt  during VV-ECMO will have the same effects on systemic circulation as 
observed during VA-ECMO (29). Theoretically, the left-to-right shunt can be less important 
during VV-ECMO since the pulmonary circulation is not empty, causing an intrinsic 
pulmonary arterial pressure. Also, during VV-ECMO, the patient is ventilated with higher 
pressures, which can be transmitted to the pulmonary circulation. Both these factors can 
contribute to higher pulmonary artery pressures and thus smaller left-to-right shunt than 
during VA-ECMO. 
In our animal model, the increase in Qcar was not accompanied by an increase in CBV, as 
represented by ctHb. This can be explained by an increased cerebral venous outflow, which is 
as much as the increased arterial inflow. The increased cerebral venous outflow may be the 
result of decreased pressure in the right atrium and right ventricle due to diminished afterload 
of the right ventricle when left-to-right shunting through the ductus to pulmonary artery has 
been stopped after ductus ligation. 
Some other factors could also influence cerebral haemodynamics and oxygenation. Blood gas 
analysis revealed no changes in paCO2, pH and paO2, thereby excluding these factors as a 
cause of the observed changes after ductus closure. A decrease in cHb, leading to a decrease 
in arterial oxygen content, could cause a compensatory increase in CBF. However, there were 
no changes in cHb after closure of the ductus.  
The anaesthetic medication used in this study is comparable with the medication used in our 
clinic during clinical ECMO treatment. This medication might also affect the cerebral 
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circulation. Yaster et al however demonstrated that fentanyl in newborn lambs did not 
influence CBF (30).  In infants, the combination of fentanyl and midazolam caused only a 
slight decrease in CBFV (31). The effects of midazolam in newborn sheep are unknown. We 
believe that the use of these drugs in this study did not influence the results. Also, there was a 
stable situation during the measurement period. 
The point of discussion is whether the ductus should be closed at the time that a left-to-right 
shunt exists and by what means. The most frequently used method for ductus closure in 
preterm infants is by indomethacin. Indomethacin itself causes an acute significant reduction 
of CBF and CBV (15,32-36). This effect can be counteracted by the increased cerebral 
perfusion after closure of the ductus, but this may take considerably more time, leaving a time 
window of diminished CBF. Indomethacin administration is therefore not an attractive 
therapeutic intervention for ductus closure in ECMO patients. 
Indomethacin also causes a diminished reactivity to carbon dioxide, preventing the cerebral 
vascular bed from responding to changes in pCO2 (36,37). Furthermore, indomethacin causes 
altered platelet function potentially increasing the haemorrhagic complications of ECMO 
treatment (38,39). Ibuprofen is known not to have the side effects of indomethacin and could 
therefore be an alternative when ductus closure has to be performed (40). Although in this 
animal study ductus ligation has been shown to increase MABP and cerebral oxygen delivery, 
ligation is not very attractive to be done in a heparinized ECMO patient.  
We think that the results of this study have to be confirmed in newborns treated with VA-
ECMO. Especially the relation between patency of the ductus arteriosus with left-to-right 
shunt and CBF should be investigated. Based on our earlier study in which we demonstrated 
ductus closure 72 hours after the start of ECMO treatment, we recommend that during VA-
ECMO treatment in newborns, the patency of the ductus should be investigated by Doppler-
echocardiography 72 hours after the initiation of ECMO (3,4).  When a patent ductus with 
left-to-right shunting is present and weaning from ECMO is still impossible, therapy with 
ibuprofen should be considered. Before the time point of 72 hrs, there is sufficient reason to 
avoid a large patent ductus arteriosus with left-to-right shunt during VA-ECMO, considering 
the potential effects on the brain. 
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CONCLUSION 
 
This study in newborn lambs demons trated that closure of a patent ductus with left-to-right 
shunt during VA-ECMO is associated with a significant increase in MABP, CBF, and 
cerebral oxygen delivery, suggesting a compromised cerebral circulation as long as the ductus 
is open and left-to-right shunt is present. It has important clinical implications: left-to-right 
shunting over a patent ductus during VA-ECMO could be one of the contributing factors for 
cerebral complications during VA-ECMO. 
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INTRODUCTION TO VENO-VENOUS ECMO 
 
In ECMO, blood is diverted from a major systemic vessel, pumped through a gas exchange 
device and returned to the body via a major blood vessel. Two distinct ECMO methods can be 
distinguished: VA-ECMO in which the drainage site is a vein and the return vessel is an 
artery, and VV-ECMO in which the drainage and reinfusion vessels are both veins. VV-
ECMO has the primary advantage that it avoids cannulation and ligation of a major artery, 
e.g. the RCCA. Concern about the short and long-term effects of VA-ECMO on the brain 
resulted in the development of VV-ECMO (1).  
In newborns, a double lumen catheter is predominantly used for VV-ECMO: double lumen 
catheter veno-venous extracorporeal membrane oxygenation (DLVV-ECMO). In this 
technique a catheter with two lumina is inserted into the right atrium, via the RIJV. Blood is 
drained through one port of the double lumen catheter, oxygenated in the membrane 
oxygenator and reinfused into the right atrium through the other port.  
Important differences between the VA-ECMO and VV-ECMO techniques are summarized in 
table 1. 
VA-ECMO has significant disadvantages: cannulation and ligation of a major artery, risk of 
emboli infusion into the systemic circulation, decrease in pulmonary blood flow, 
compromised cardiac output due to increased afterload and perfusion of the coronary arteries 
with relatively hypoxaemic blood delivered from the right ventricle (11).  
Major disadvantages of VV-ECMO are the lack of direct circulatory support and the limited 
oxygenation. 
In VA-ECMO heart and lung function are partially replaced by artificial organs, i.e. the 
membrane oxygenator and the roller pump. Oxygenated blood that has passed through the 
lungs mixes with blood from the left ventricle in the aorta. The oxygen content in the arterial 
blood of the patient is determined by the amount of oxygen delivered by the ECMO circuit 
plus the amount in the blood after passing through the heart and lungs; it can be augmented by 
increasing the ECMO flow rate. Usual saO2 values are over 95%. Total systemic blood flow 
is the sum of the ECMO flow and the flow through the patient’s heart and lungs. 
In VV-ECMO, blood is oxygenated in the ECMO circuit and is returned to the venous 
circulation (right atrium) where it mixes with venous blood from the different organ systems. 
Thus, the oxygen content in the right atrium is raised and the carbon dioxide content is 
lowered. Oxygen content of the arterial blood of the patient is determined by the oxygen 
content in the right ventricular blood, plus possible augmentation after passage through the 
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lungs when lung function improves. Total systemic blood flow is determined  by the patient’s 
cardiac output, not by the ECMO flow. The paO2 and saO2 are equal to the values in mixed 
venous blood, in the absence of lung function. Owing to the principle of VV-ECMO, saO2 is 
not likely to be above 90% and will usually be less, e.g. 80-85%. Thus, oxygenation is 
limited, because deoxygenated and oxygenated blood mix. 
 
Table 1. Comparison between veno-venous and veno-arteria l extracorporeal membrane oxygenation (2-10) 
 VA-ECMO DLVV-ECMO 
Cannulation Internal jugular vein + Right common 
carotid artery 
Internal jugular vein 
Circulation 
 
Direct circulatory support  
Decreased RV preload, pulmonary 
blood flow, LV output, increased LV 
afterload 
Decreased pulsatility 
Coronary perfusion with hypoxaemic 
blood from LV 
No direct circulatory support 
No changes in RV preload, pulmonary 
blood flow, LV output, and LV 
afterload 
Normal pulsatility 
Coronary perfusion with oxygen 
enriched blood from LV 
 Oxygen saturation  Depends on extracorporeal flow,  
usually >95% 
80-90% common at maximal flow 
Variables for 
determination of 
oxygenation 
"Mixed venous oxygen saturation" 
Arterial blood gas analysis  
Calculated oxygen consumption 
Cerebral venous oxygen saturation 
Arterial blood gas analysis  
Pre-membrane oxygenation trend 
Emboli from ECMO 
system 
Into systemic circulation (brain) Into pulmonary circulation 
RV=right ventricle, LV=left ventricle 
 
Another factor that limits the patient’s oxygenation during VV-ECMO is recirculation: a 
fraction of the reinfused oxygenated blood drains back into the ECMO system and cannot 
contribute to the patient’s oxygenation. The recirculation fraction is defined as the portion of 
oxygenated blood from the circuit that flows directly from the reinfusion lumen into the 
drainage lumen of the catheter and returns to the circuit, instead of entering the patient’s 
circulation (9).  
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Several factors influence the recirculation fraction (9). First, the recirculation fraction 
increases with increasing ECMO flow. The relation between the recirculation fraction and 
ECMO flow is linear in the range of ECMO flows used clinically (12,13). This means that 
when the ECMO flow is increased, there is an initial increase in oxygen delivery to the 
patient, but any further increase in ECMO flow beyond the optimal flow rate causes a 
decrease in oxygen delivery due to increased recirculation. 
The effective ECMO flow = Total flow – (Total flow*recirculation fraction). 
Figure 1 illustrates the concept of the recirculation fraction and effective flow. 
 
Figure 1. The effect of recirculation (? ) on effective pump flow (¦ ) 
 
X axis: ECMO flow (mL/min), Y axis left side: effective flow (mL/min), Y-axis right side: recirculation fraction 
(%). Recirculation increases with increasing ECMO flow. When the total flow is zero, the effective flow is zero. 
At a given maximal flow, the recirculation fraction is 100%, which means that the effective flow becomes zero 
again. The optimal flow lies between these two flow rates (9). 
 
The catheter position also determines the recirculation fraction and can change during the 
ECMO run, because of altered lung inflation or patient movements. Another factor that 
influences the recirculation fraction is cardiac output. If cardiac output is high, oxygenated 
blood reinfused into the right atrium will move rapidly towards the right ventricle and make it 
less likely to be drained back into the ECMO circuit again. 
The right atrial volume also influences recirculation. With a larger right atrium, there is less 
chance that oxygenated blood will be recirculated and more opportunity for mixing with 
venous blood. 
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Inadequate oxygenation in a patient on VV-ECMO may be caused by a high amount of 
recirculation. It is then important to be informed about the recirculation fraction, also enable 
evaluation of the effects of interventions to decrease it. 
It is difficult to determine the recirculation fraction during VV-ECMO. In chapter 9 a method 
is devised to quantify recirculation during VV-ECMO with an easily applicable bedside 
method. 
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ABSTRACT 
 
Recirculation is a limiting factor for oxygen delivery in double lumen catheter veno-venous 
extracorporeal membrane oxygenation. 
This study compares three different methods for the determination of the recirculation fraction 
during double lumen catheter veno-venous extracorporeal membrane oxygenation at flow 
rates of 150, 125, 100, 75 and 50 mL/kg.min in 9 lambs: 1) an ultrasound dilution method, in 
which the change in ultrasound velocity in blood after injection of a saline bolus as a marker 
is used for determination of recirculation; 2) the ‘mixed venous oxygen method’ using real 
mixed venous blood oxygen saturation, the best standard, for determination of recirculation 
fraction; and 3) the ‘central venous line method’, in which the oxygen saturation of a blood 
sample of the inferior vena cava is considered to represent mixed venous oxygen saturation. 
In all methods, the recirculation fraction increased with increasing flow rate. The correlation 
coefficient between the ultrasound dilution method and the ‘mixed venous oxygen method’ 
was 0.68 (p<0.01); the mean difference between these two methods was –2.4 % (p=0.6). The 
correlation coefficient between the ultrasound dilution method and the ‘central venous line 
method’ was 0.48 (p<0.01); the mean difference between these two methods was –18.1 % 
(p<0.01). The correlation coefficient between the ‘mixed venous oxygen method’ and the 
‘central venous line method’ was 0.51 (p<0.01); the mean difference between these two 
methods  was –15.7 % (p<0.01). The ultrasound dilution method is a useful method for the 
measurement of the recirculation fraction in double lumen catheter veno-venous 
extracorporeal membrane oxygenation and is easier to use than the other methods. 
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INTRODUCTION 
  
In 1976, Bartlett and colleagues performed the first successful ECMO treatment  in a newborn 
(1). Since then, more than 15,000 newborns have been treated with ECMO, with an overall 
survival rate of  80% (2).  
Initially the VA-ECMO procedure was used, in which blood is drained from the right atrium 
and, after oxygenation, is returned to the aorta through a cannula inserted into the RCCA. 
Ligation of this artery caused concern regarding the short- and long-term sequelae on the 
brain.  
To avoid the need for ligation of the RCCA, the VV-ECMO procedure was developed, and 
2,500 newborns have been treated in this fashion. In the most commonly used technique, a 
double lumen catheter is introduced into the right atrium through the RIJV. The catheter has 
two lumina, one for drainage of blood from the patient (venous limb) and one for returning 
oxygenated blood into the patient (arterial limb) (3). Although the cannulas are designed to 
minimize recirculation, this inevitably occurs in the DLVV-ECMO procedure and is a factor 
that limits oxygen delivery to the patient. Recirculation is the phenomenon in which a fraction 
of the oxygenated blood that has just been infused into the patient through the arterial limb of 
the catheter, is immediately drained into the venous limb, thus not contributing to 
oxygenation of the patient.  The recirculation fraction can be calculated from the following 
formula (3): 
 
Recirculation fraction = 
 
Oxygen saturation of the pre-oxygenator blood - Mixed venous oxygen saturation 
Oxygen saturation of the post-oxygenator blood -Mixed venous oxygen saturation 
 
In clinical practice, the pre- and post-oxygenator oxygen saturation can be measured easily, 
but mixed venous oxygen saturation (svO2) cannot be measured directly, since there is no 
possibility of taking blood samples from the pulmonary artery. Although svO2 is considered 
to be represented by the saturation of the blood that is drained from the right atrium, during 
the DLVV-ECMO procedure, it is influenced by recirculation and, thus, not reliable. 
There are two methods for obtaining information about the svO2 during DLVV-ECMO (4).  
In the first, the oxygen flow to the membrane is stopped; therefore, extracorporeal oxygen 
transfer to the blood is blocked. With ventilator support, the same oxygen saturation in arterial 
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blood is then achieved. The oxygen saturation of the blood that is drained from the patient is 
then considered to represent svO2 (svO2 method). This method is considered to be the best 
standard for the determination of recirculation fraction. In the second method, the oxygen 
saturation of blood taken from a major vein, not influenced by recirculation (for example the 
inferior caval vein), is considered to represent the svO2 (CVL method). 
In haemodialysis, recirculation can also occur and limit the dialysis capacity. Different 
methods have been described to determine the recirculation fraction in haemodialysis: the 
blood urea nitrogen method, the chemo-illuminescence method, and different dilution 
methods based on changes in electrical impedance or optical and thermal changes (5-9). In 
1995, Depner et al and Krivitski described an ultrasound dilution method for measuring 
recirculation in haemodialysis (10,11).  This method is based on the detection of dilution of 
the blood with saline. Saline, injected in the arterial limb of the circuit, causes a change in the 
ultrasound velocity of blood and in case of recirculation, is detected again in the venous limb. 
The fraction of the arterially injected indicator that returns in the venous limb represents 
recirculation.  
The aim of this study was to compare different methods of assessing recirculation in DLVV-
ECMO, the SvO2 method, CVL method, and the ultrasound dilution method, at different 
ECMO flows. 
 
 
METHODS 
 
Preparation 
 
The study was performed in 9 lambs (weight, 4.3–6.5 kg), obtained from local farmers. The 
study was approved by the Ethical Committee on Animal Research of the University of 
Nijmegen. General anaesthesia was induced by intravenous administration of midazolam (0.2 
mg/kg) and fentanyl (10 µg/kg), and muscle relaxation was obtained with pancuronium (0.05 
mg/kg). After endotracheal intubation, assisted ventilation was started with a Babylog 8000 
(Dräger, Lübeck, Germany) to maintain normal arterial blood gas values (pH 7.40-7.45; paO2 
70–90 mm Hg [9.3-12 kPa]; paCO2 30–40 mm Hg [4.0–5.3 kPa]). During assisted ventilation, 
anaesthesia was maintained using continuous intravenous infusion of midazolam (0.1–0.2 
mg/kg.hr), fentanyl (5–10 µg/kg.hr) and pancuronium (0.02 mg/kg.hr). The heart rate was 
monitored by means of electrodes placed on the chest. The temperature was measured with a 
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rectal probe and maintained between 38.5 and 39.5 ?C. Through the right femoral vein, a 7.5 
Fr catheter was placed in the inferior caval vein for collection of blood samples to determine 
the oxygen saturation according to the CVL method. The position of this catheter was 
controlled by X-ray. The ECMO circuit was primed with full fresh sheep blood prior to 
cannulation. The RIJV was cannulated with a 15 French double lumen venous catheter 
(Jostra, Hirrlingen, Germany), with the tip of the catheter positioned in the right atrium. The 
position was controlled by X-ray. Thereafter, the animal was placed on DLVV-ECMO. 
During the cannulation procedure, a loading dose of heparin was administered (150 IU/kg) 
and continued intravenously (100–200 IU/kg.hr) to maintain activated clotting time between 
200 and 250 seconds (Hemochrom, Edison, NJ, USA). 
The ECMO circuit itself consisted of a custom packed ¼ inch flexible polyvinylcloride tubing 
(Baxter, Uden, The Netherlands), with a silicone reservoir, the “bladderbox” (Seabrook 
Medical Systems, Værløse, Denmark), a 0.6 m2 membrane oxygenator (Scimed Life Systems, 
Minneapolis, MN, USA), a heat exchanger (Cincinnati Sub Zero, Cincinnati, OH, USA), and 
a roller pump (Jostra HL20, Jostra, Hirrlingen, Germany). Two stopcocks were inserted in the 
ECMO circuit to draw blood samples before and after the oxygenator, so that pre-oxygenator 
and post-oxygenator oxygen saturations could be determined (Synthesis 25, Instrumentation 
Laboratory Milano, Italy). Two ultrasound flow/dilution probes (Transonic Hemodialysis 
Monitor, Transonic Systems Inc, Ithaca, NY, USA) were clipped on the ECMO circuit, one 
on the arterial limb and one on the venous limb of the double lumen catheter. The probes were 
connected to the HD01®  Hemodialysis Monitor System (Transonic Systems, Ithaca, NY, 
USA), which consists of a monitor and a laptop computer (Compaq, Houston, USA), 
preloaded with ultrasound dilution measurement software. There was an injection port in the 
arterial limb of the double lumen catheter 20 cm before the flow/dilution sensor, for the 
injection of isotonic saline. The sensor is calibrated by the factory specifically for the tubing 
set, to maximize measurement accuracy.  
After cannulation and initiation of VV-ECMO, the ECMO flow was gradually adjusted to 150 
mL/kg.min. 
 
Determination of recirculation fraction using the ultrasound dilution method 
 
Measurement of recirculation in haemodialysis with the ultrasound dilution method is based 
on detection of the dilution of blood with saline from changes in the average cross-sectional 
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velocity of an ultrasound beam that illuminates the blood flowing through the tubing of the 
haemodialysis circuit (10). 
When this technique is adapted for DLVV-ECMO, sensors are placed around the arterial and 
venous limb of the double lumen catheter. These sensors can measure blood flow through the 
ECMO circuit continuously by using the transit-time method (12). They can also detect a 
reduction in the ultrasound conductivity of blood caused by an injection of saline, primarily 
by dilution of the blood protein content. The velocity of an ultrasound signal through blood 
(1560 – 1590 m/sec) differs from the ultrasound velocity through isotonic saline (1533 m/s) 
(10). The sensors are connected to monitoring equipment and a computer program (model 
HD01, Transonic Systems, Ithaca, NY), to calculate the recirculation fraction (figure 1). 
Voltage changes that correspond to the mean cross sectional ultrasound velocity across the 
tubing are transmitted to the computer system for analysis and display of peak areas on the 
screen. 
A 5 mL bolus of isotonic saline is injected into the arterial limb of the double lumen catheter 
and causes dilution of blood, which can be detected by the ultrasound dilution sensor as a 
dilution curve, because it causes a change in the velocity of the ultrasound signal. The change 
in ultrasound velocity (ultrasound dilution) is linearly correlated with the dilution of whole 
blood by normal saline. In the absence of recirculation, the entire bolus will flow into the right 
atrium and then into the body. If recirculation is present, a portion of the bolus will enter the 
venous limb of the cannula and pass the sensor on that limb, again creating a dilution curve. 
The monitor records both the actual flow in the cannula and the dilution curves that result 
from the saline passing through the sensors. The recirculation coefficient is the ratio of the 
indicator recirculated into the venous limb of the cannula to the injected amount of saline and, 
therefore, the ratio between the venous and arterial dilution curves is the recirculation 
fraction. The software algorithms use the dilution curves in combination with the tubing flow 
measurements to calculate and display the percentage of recirculation. 
During this experiment, a bolus of 5 mL isotonic saline was injected three times into the 
arterial limb of the double lumen catheter and recirculation was measured using the 
ultrasound dilution method. With the two sensors were placed in series on the arterial limb of 
the catheter, the injected saline passes both sensors and 100% recirculation is detected. This 
arrangement was used as a calibration method for the ultrasound dilution method. 
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Figure 1. Diagram of the system for determination of recirculation fraction using ultrasound dilution method 
 
1 = 'arterial' reinfusion limb of the double lumen veno-venous catheter, 2 = venous drainage limb of the double 
lumen veno-venous catheter, 3 = point for injection of 5 mL saline, 4 = two ultrasound flow sensors, placed 
around the ‘arterial’ and ‘venous’ limb of the double lumen veno-venous catheter, 5 = fraction of blood that 
recirculates into the ECMO system, RA = right atrium, RV = right ventricle, bridge = safety connection between 
the arterial and venous side of the ECMO system. Arrows indicate direction of blood flow. 
 
Determination of the recirculation fraction using the svO2 and the CVL methods 
 
Immediately after determination of the recirculation fraction with the ultrasound dilution 
method, a blood sample was taken from the venous line in the inferior caval vein to determine 
the oxygen saturation in this blood sample, which was then used as a representation of svO2 
(CVL method). Blood samples were also taken from the ECMO circuit before and after the 
oxygenator. In these samples, oxygen saturation was determined as oxygen saturation of the 
pre-oxygenator blood and post-oxygenator blood, respectively. Oxygen flow to the membrane 
oxygenator was then stopped, so that the transfer of oxygen to the blood through the 
extracorporeal circuit was interrupted. Ventilation was adjusted to achieve the same oxygen 
saturation as before stopping oxygen flow to the membrane oxygenator, so that svO2 could be 
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determined. When saturations in pre-oxygenator and post-oxygenator blood samples were 
equal, this proved that there was no longer oxygen transfer over the membrane oxygenator. 
This saturation was then considered to represent svO2 (svO2 method). From the formula 
described above, recirculation could then be calculated according to the CVL and svO2 
methods.  
The mean value of the three recirculation fraction measurements with the ultrasound dilution 
method was used for comparison with the results of the two other methods. 
At ECMO flow rates of 125, 100, 75, and 50 mL/kg.min the recirculation fraction was again 
determinated with the three different methods. 
 
 
STATISTICS 
 
For comparison of the three methods of recirculation measurement, Pearson's correlation 
coefficients (r) and p-values were calculated; p ?  0.05 was considered significant.  Because 
the correlation coefficient only determines the strength of a relation between two variables, 
and not the agreement between them, we also used the method described by Bland and 
Altman to assess agreement between the different measurement methods (13). The mean 
difference and standard deviation were calculated and compared using paired Student's t-test. 
Furthermore we looked at the repeatability of the ultrasound dilution method, since three 
measurements were done with this method.  
 
 
RESULTS 
 
Table 1 shows the results of the recirculation fractions determined with the three measurement 
methods at different flow rates.  
 
With all three methods, the recirculation fraction increased with increasing flow rates. With 
the ultrasound dilution method, smaller recirculation fractions were detected than with the 
other two methods. The CVL method detected the highest fractions.  
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Table 1. Recirculation fraction at different flow rates in 9 animals  
Flow rate (mL/kg.min) Ultrasound dilution method (%) svO2 method (%) CVL method (%) 
150 36.0 ?  12.8 45.0 ?  6.9 62.5 ?  6.9 
125 32.8 ?  9.3 39.3 ?  9.5 54.8 ?  13.5 
100 24.6 ?  9.4 31.7 ?  8.2 39.1 ?  17.6 
75 20.2 ?  6.5 24.5 ?  12.6 29.5 ?  15.7 
50 13.0 ?  4.0 12.4 ?  10.0 29.6 ?  15.7 
 Mean values ?  standard deviation  
 
Correlation analysis revealed positive relationships between recirculation fractions as 
determined with 1) the ultrasound dilution method and the svO2 method; 2) the ultrasound 
dilution method and CVL method; and 3) svO2 method and CVL method (table 2).  
 
Table 2. Correlation coefficients and mean differences for three different measurement methods in recirculation 
fraction during DLVV ECMO in 9 animals  
Variable Correlation coefficient Mean Difference 
(- 2 sd, + 2 sd) 
Ultrasound dilution versus svO2 method r=0.68; p<0.01 -2.4%; p=0.6 
(-26.4, +21.6%) 
Ultrasound dilution versus CVL method r=0.48; p<0.01 -18.1 %; p<0.01 
(-50.3, +14.1 %) 
svO2 versus CVL method r=0.51; p<0.01 -15.7 %; p<0.01 
(-49.5 %, +18.1 %) 
svO2 method = mixed venous oxygen method, CVL method = central venous line method, sd = standard 
deviation. 
 
Using linear regression, recirculation determined with the ultrasound dilution method could 
be calculated as: recirculation (%) = 1.88+0.23xECMO flow (mL/min); r=0.99, p<0.01. With 
the svO2 method, recirculation (%) = 1.42+0.32xECMO flow (mL/min); r=0.99, p<0.01. With 
the CVL method, recirculation (%) =6.66+0.36xECMO flow (mL/min); r=0.96, p<0.05. 
Also the mean differences and p-values for the comparison of the different measurement 
methods are presented. The limits of agreement between 2 methods vary between the mean 
+2 sd and the mean -2 sd (13). 
The mean difference between the ultrasound dilution method and svO2 method was small and 
not significant, whereas the differences between the ultrasound dilution method and the CVL 
method and between the svO2 method and the CVL method were larger and statistically 
significant. 
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The coefficient of repeatability for the ultrasound dilution method, as defined by Bland and 
Altman, was 6 %. 
 
 
DISCUSSION 
 
As expected, there was an increase in recirculation fraction with increasing ECMO flow rates 
in all three methods (4). Using the method as described by Bland and Altman, the differences 
between the ultrasound dilution method and svO2 method were not significantly different, 
indicating that, on average, agreement exists between the methods, whereas when the other 
methods were compared, the mean differences were significantly different and did, therefore, 
not agree with each other (13). 
The ultrasound dilution method is validated for recirculation measurements in haemodialysis 
and has proven to be a reliable method for the determination of the recirculation fraction 
(8,10,14,15). Depner et al compared the recirculation fraction as determined with the 
ultrasound dilution method and the blood urea nitrogen method and found a correlation 
coefficient of 0.91 (p<0.001) (10). When they looked at the difference between two repeated 
measurements with the ultrasound dilution method, the mean difference (± sd) between 
measurements was 3.9% (± 2.8%). Leblanc et al measured recirculation in adults during 
haemodialysis with a 10 French internal jugular vein twin catheter. They found values 
between 5 and 11% with a shunt flow varying between 200 and 400 mL/min (15). 
Traditionally, the blood urea nitrogen method is used in haemodialysis to calculate 
recirculation. Because with this method measurement errors and cardiopulmonary 
recirculation occur, it seems to overestimate recirculation (16). Tattersall et al demonstrated 
no recirculation during haemodialysis in 16 patients with the ultrasound dilution method, 
whereas an average of 12.5 % recirculation fraction was calculated with the traditional blood 
urea nitrogen technique (17). 
In VV-ECMO, a gold standard for calculation of recirculation fraction does not exist, which 
makes it impossible to determine the reliability of one of these investigated methods. From a 
physiological point of view, the svO2 method was considered the best. However, the svO2 
method has certain disadvantages: ECMO is interrupted by stopping the oxygen delivery to 
the membrane oxygenator. With adaptation of the assisted ventilation, the same arterial blood 
oxygen saturation then has to be achieved in order to measure svO2. This approach cannot be 
carried out in infants with severe respiratory disease. For determination of the oxygen 
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saturation of the pre-oxygenator and post-oxygenator blood, different blood samples have to 
be taken at the same moment, making it prone to failure. Apart from not being an easy 
applicable bedside method, this method is time consuming and does not provide instantaneous 
results. 
Nevertheless, in this experimental setting, such a measurement can be achieved. Therefore, it 
is the most useful to compare the CVL and ultrasound dilution methods against the svO2 
method. 
When the different methods for assessing the recirculation fraction measurement were 
compared, there was only a non-significant difference in mean values between the ultrasound 
dilution method and the svO2 method. 
The lack of agreement between the CVL method and the two other measurement methods can 
be explained by the fact that oxygen saturation in the inferior caval vein does not represent 
adequately true mixed venous oxygen saturation (18, 19). The ultrasound dilution method for 
the determination of recirculation has several advantages over the other two methods. The 
major advantage is that this method can be used without interruption of the ECMO procedure. 
In addition, the ultrasound dilution method measures recirculation fraction more directly then 
the other two methods, since it measures the effect of blood dilution in the two limbs of the 
double lumen catheter. It avoids the determination of a third factor, svO2, which is necessary 
with the other two methods. Furthermore, it provides the ability to visually inspect the 
dilution curves on the computer screen. Detection of recirculation by dilution of blood caused 
by a bolus of normal saline injected into the arterial limb of the double lumen catheter has 
advantages over other dilution indicators such as cardiogreen, because patients already 
receive saline and saline is innocuous.  
In our study the coefficient of repeatability was 6%, which is comparable with the 9.1% found 
in the study of Lindsay et al (7). 
Recirculation is a limiting factor for oxygen delivery in DLVV-ECMO. As expected, 
increasing ECMO flow in this study also leads to an increase in recirculation fraction and may 
decrease the efficacy of the oxygenation (4). Information on the recirculation fraction is 
important for obtaining an optimal oxygenation of the patient being treated with DLVV-
ECMO. The ultrasound dilution method provides a rapid, simple, reliable and non- invasive 
method for assessing recirculation. 
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GENERAL DISCUSSION 
 
This thesis presents the results of clinical and pathophysiological studies on ECMO in 
newborns with respiratory failure. 
ECMO improved survival in selected newborns with severe respiratory failure and pulmonary 
hypertension (1). The overall survival rate in our patient group was comparable with survival 
rates reported internationally in the ELSO registry (chapter 2). Although survival rates of 
newborns with CDH in our patient group were slightly higher than those recorded by the 
ELSO registry, this difference was not significant. The major cause of death in our patient 
group was an untreatable respiratory problem, especially in the CDH group. At present it is 
impossible to predict which patients will survive with ECMO, especially for CDH patients, in 
whom respiratory failure is the main cause of death.  
Intracranial haemorrhage was an important reason to discontinue ECMO before the 
underlying respiratory problem had been resolved and this inevitably led to death. Other 
authors also described the relation between pulmonary and cerebral complications and 
survival (2,3). Long-term neurodevelopmental outcome after ECMO treatment is also 
associated with pulmonary and neurological complications (4-9). It is therefore very 
important to study the effects of ECMO treatment on the lung and brain, in order to gain 
insight in the mechanisms by which complications can occur. Understanding the 
pathophysiology of complications will aid the development of measures to prevent them. 
 
Newborns needing ECMO treatment have severe respiratory failure in combination with 
pulmonary hypertension. These life-threatening disorders usually arise due to underlying 
diseases such as MAS, CDH, and sepsis, but pulmonary hypertension can also occur without 
one of these underlying diseases; so-called idiopathic persistent pulmonary hypertension. In 
newborns with pulmonary hypertension the morphology of the lung vasculature is abnormal. 
Their small pulmonary arteries show increased medial and adventitial thickness (10-13).  
The beneficial effect of ECMO on pulmonary hypertension is generally described as “ lung 
rest”. However, it is unclear what this represents. Shehata et al described a decrease in 
adventitial thickness after ECMO treatment in CDH patients. They suggested that this caused 
an increase in compliance and a subsequent decrease in vascular resistance (14). In the study 
described in chapter 3, that compared newborns with pulmonary hypertension caused by 
MAS, sepsis or idiopathic and treated with ECMO to similar non-ECMO treated patients, we 
demonstrated a decrease in percentage medial thickness of the small pulmonary arteries plus a 
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decrease in the cross-sectional area of the media, adventitia and total wall. This suggests that 
ECMO treatment had a positive effect by reversing the abnormal vascular wall structure 
known to exist in these patients.  
Stenmark et al suggested that medial myocytes and adventitial fibroblasts play an important 
role in the abnormal vascular remodeling (15-17). It remains unclear which mechanisms 
achieve the reduction in abnormal vascular structure. To gain better understand ing of these 
mechanisms, more insight is needed into molecular processes. In chapter 3, we discussed the 
potential role of genes in regulating matrix metalloproteinases, or an imbalance between 
proliferation and apoptosis as a cause of abnormal vascular structure in pulmonary 
hypertension. More knowledge about the mechanisms involved in the structural vascular 
remodeling will probably enable the development of therapies to replace the need for ECMO 
to survive.  
  
In our patient group, cerebral complications, i.e. haemorrhages or infarctions, were seen in 
7.0% and 9.1% of the patients, respectively (chapter 2). Schumacher et al and Mendoza et al 
demonstrated lateralized cerebral lesions after VA-ECMO treatment, but in our patient group, 
there was no predominance of cerebral lesions in the left or right cerebral hemisphere (18,19). 
Chapter 5 describes a study in which NIRS and Doppler ultrasound were used to determine 
whether ligation of the right common carotid artery and right internal jugular vein and the 
initiation of VA-ECMO caused differences in oxygenation and perfusion between the left and 
right cerebral hemispheres. Based on the results of this study and our clinical data (chapter 2), 
it seems unlikely that there is a relation between the predominance of cerebral lesions in either 
hemisphere and the procedure of ECMO initiation.  
Nevertheless, important changes in cerebral oxygenation and haemodynamics did occur. A 
decrease in cerebral oxygenation was observed in both cerebral hemispheres after ligation of 
the right common carotid artery. This finding combined with the results of the studies of Raju 
et al and Matsumoto et al, who both demonstrated a temporary decrease in cerebral blood 
flow velocity after ligation of the right common carotid artery, suggests that ligation of the 
right common carotid artery is potentially followed by a hypoxic ischaemic moment (20,21). 
This is in agreement with Peek and Firmin who stated that cerebral infarction in the watershed 
area is most likely to occur during the 3-5 minutes it takes for cerebral perfusion to be re-
established (22). Our study also showed that ECMO initiation caused an increase in cerebral 
blood volume, cerebral blood flow velocity and mean arterial blood pressure. The increase in 
cerebral blood flow could not be explained by changes in paCO2, in contrast with the study of 
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Lohrer et al (23). Simultaneous increases in cerebral blood flow and mean arterial blood 
pressure suggested that cerebral autoregulation in these patients had either shifted outside the  
range of autoregulation in the autoregulation curve or, more likely, was disturbed. If their 
autoregulation was intact, we would not expect any change in the cerebral blood volume and 
blood flow velocity as long as the cerebral perfusion pressure remains within the 
autoregulatory range. 
Disturbed autoregulation makes the brain very vulnerable to hypo- or hyperperfusion due to 
blood pressure changes and this can potentially cause ischaemic or haemorrhagic lesions.  
It was not possible to measure absolute va lues with NIRS and demonstrate ischaemia of 
cerebral tissue (24). NIRS was unable to measure oxygenation and cerebral blood volume in 
the whole cerebral hemisphere. Therefore, we could not exclude that differences in 
oxygenation and circulation can be present between the left and right hemispheres in specific 
areas of the brain (25).  
 
The aetiology of cerebral lesions in ECMO patients is probably multifactorial and it is often 
impossible to identify a specific cause in a given patient. Certain (technical) aspects of ECMO 
might cause cerebral lesions. For example, bridge opening and the patent ductus arteriosus 
have effects on cerebral oxygenation and haemodynamics. The bridge, a safety connection 
between the drainage and infusion tubing of the ECMO system, is usually opened every 15 
minutes to prevent the development of thrombi due to blood stasis. In chapter 6, we used an 
animal model to study the effect of opening of the bridge during VA-ECMO. We observed an 
arteriovenous shunt over the bridge, followed by a sudden drop in cerebral oxygenation and 
perfusion with every combination of ECMO flow rate and opening time. This means that in 
our patient group, these phenomena occurred over 600 times per patient based on a mean 
ECMO run-time between 153 and 176 hours. Such repeated negative effects on cerebral 
oxygenation and perfusion might result in cerebral vascular lesions. In another study on 
newborns on VA-ECMO, Doppler ultrasound showed that opening the bridge caused the 
cerebral blood flow velocity in the anterior cerebral artery to drop to zero (unpublished 
results), which underlines the importance of the haemodynamic changes observed in our 
animal study. Above described changes can be prevented by placing a small pump on the 
bridge to limit the arteriovenous  shunt. In the present clinical situation, the “old” bridge has 
been replaced by a system with two stopcocks. The stopcocks are located at the junction 
where the bridge connects to the drainage and infusion tubing. Now, the bridge can be filled 
with saline instead of blood as was the case in the original situation. This avoids the need for 
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intermittent opening of the bridge and thus prevents any potentially negative effects on the 
cerebral circulation. 
In chapter 7 we showed that during VA-ECMO, cerebral oxygenation and perfusion can be 
compromised by a patent ductus arteriosus with a left to right shunt.  Previously, our group 
has demonstrated that a left to right ductal shunt occurred in 62% of the newborns on VA-
ECMO, and that it was associated with longer ECMO run times (26). Further studies are 
needed to investigate the exact importance of a patent ductus arteriosus with left to right shunt 
in the development of cerebral and other potential complications during VA-ECMO. If a 
patent ductus arteriosus with left to right shunt is clearly related to the occurrence of 
complications, a therapeutic intervention to close the ductus should be considered. It is also 
necessary to define factors that predispose to the occurrence of a patent ductus arteriosus with 
a large left to right shunt in VA-ECMO. 
 
Over the past few years, the use of VV-ECMO has increased as an alternative for VA-ECMO. 
VV-ECMO has several advantages over VA-ECMO. The most important is that ligation of 
the right common carotid artery is no longer necessary. Thus, normal arterial perfusion of the 
brain is maintained and the potential ischaemic moment of carotid artery ligation is avoided. 
However, it is still necessary to cannulate the right internal jugular vein. Taylor et al and 
O'Conner et al suggested that ligation of the right internal jugular vein caused venous outflow 
obstruction and that this was related to the occurrence of cerebrovascular injuries (27,28). 
Walker et al also demonstrated disturbed autoregulation in a VV-ECMO animal model. 
However, the changes in autoregulation were less severe than in VA-ECMO, and no right to 
left differences in cerebral blood flow were observed (29). A randomized study is needed to 
determine whether newborns treated with VV-ECMO have fewer cerebral lesions than 
newborns treated with VA-ECMO. In a retrospective cohort study, Zahraa et al compared 
VV-ECMO to VA ECMO in non-neonatal, paediatric cases and found no difference in central 
nervous system complications (30).  
 
A major disadvantage of VV-ECMO is limited oxygenation due to the recirculation of blood. 
Finding a way to quantify recirculation accurately would offer the opportunity to evaluate the 
effectiveness of interventions to decrease it. Then VV-ECMO can be applied more effectively 
and it may be possible to shorten the run-time and decrease complications. In chapter 9 we 
employed the ultrasound dilution technique as a bedside method to determine the recirculation 
fraction. We were able to monitor recirculation adequately. This enables the evaluation of 
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manoeuvres to decrease recirculation and optimize the patient’s oxygenation. Thus, an 
important problem of VV-ECMO can now be handled feasibly. 
 
In summary, this thesis demonstrated: 
1. ECMO increased survival rates in newborns with severe respiratory insufficiency and 
pulmonary hypertension. Survival rates at our ECMO centre were comparable with 
international data. 
2. The major causes of death in newborn ECMO patients were associated with 
pulmonary and cerebral complications. 
3. The positive effect of ECMO on the reversal of pulmonary hypertension in newborns 
with MAS, sepsis or i-PPHN can be explained by improvement in the vascular wall 
structure of the small pulmonary arteries. 
4. The initiation of VA-ECMO caused changes in cerebral oxygenation and 
haemodynamics, but there were no differences in effect between the left and right 
cerebral hemispheres.  
5. Repeated opening of the safety connection between the venous and arterial sides of the 
VA-ECMO system, the so-called bridge, to prevent thrombus formation, resulted in 
repeated significant drops in cerebral oxygenation and perfusion. These effects could 
be prevented with an alternative bridge.  
6. A patent ductus arteriosus with left to right shunt during VA-ECMO can compromise 
cerebral oxygenation and haemodynamics. 
7. An ultrasound dilution technique quantified recirculation during DLVV-ECMO 
adequately, and offered a method to evaluate manoeuvres to decrease recirculation. 
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FUTURE PERSPECTIVES 
 
ECMO has proven to be an effective treatment for newborns with severe, but reversible 
respiratory insufficiency. However, serious complications can occur. 
At present, we know too little about the pathophysiological mechanisms involved in the 
development and reversal of the pulmonary vascular abnormalities associated with pulmonary 
hypertension. Furthermore, greater insight into pathophysiological processes of ECMO will 
help to avoid cerebral complications.  
On the basis of findings in this thesis, we recommend the following issues for further study: 
?? Which factors determine that some newborns with respiratory insufficiency and 
pulmonary hypertension respond to conservative therapy, whereas others need ECMO 
treatment to survive? In newborns with pulmonary hypertension which factors 
influence reversal of the abnormal lung vasculature?  
?? What is the impact of a patent ductus arteriosus with left-to-right shunt during VA-
ECMO on the circulation? 
?? How does VV-ECMO initiation, with the theoretical advantage that the right common 
carotid artery does not need to be ligated, affect cerebral oxygenation and 
haemodynamics?   
?? Will ECMO patient care expand to other indication areas in the future? Internationally, 
there has been a shift from newborn respiratory ECMO insufficiency candidates 
towards other indications for ECMO treatment, mainly post-cardiosurgery circulatory 
support. Twelve patients with circulatory failure have been treated at our institute 
during the past seven years. This brings up new questions about the pathophysiology 
of the failing heart and thus opens new opportunities for research. 
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SUMMARY 
 
Extracorporeal membrane oxygenation (ECMO) is a treatment that can be applied to (nearly) 
term babies with severe respiratory failure who cannot be oxygenated adequately with optimal 
conventional treatment. During ECMO, the blood is oxygenated outside the body, in an artificial 
lung, a so-called membrane oxygenator. 
This thesis addresses the effects of ECMO on the lungs and brain and is divided into four 
parts. 
 
Part 1 describes “The Nijmegen experience” with ECMO at the UMC St Radboud in 
Nijmegen, The Netherlands. 
Chapter 1 gives a general introduction to the developmental history of the ECMO technique, 
patient selection and treatment. 
Chapter 2 presents the results of ECMO treatment in 186 newborns over a period of 12.5 
years. Indications for ECMO treatment were meconium aspiration syndrome, congenital 
diaphragmatic hernia, sepsis/pneumonia and idiopathic pulmonary hypertension. Survival 
varied between 65% and 95%, depending on the diagnosis. Thirty-five newborns died. Major 
causes of death were respiratory insufficiency and intracranial haemorrhage. A total of 13 
patients (7.0%) had intracranial haemorrhage, while 17 (9.1%) had cerebral infarction. There 
was no difference in the incidence of cerebral lesions between the left and right cerebral 
hemispheres. 
In chapter 3, morphometric analysis was performed on the lung vasculature of newborns after 
ECMO treatment. Other studies showed that newborns with pulmonary hypertension have 
abnormal morphometry of the pulmonary vasculature, with increased medial and adventitial 
thickness. The morphometry of the pulmonary vasculature of newborns, who were treated 
with ECMO for pulmonary hypertension due to meconium aspiration syndrome, sepsis or 
idiopathic pulmonary hypertension, was compared to that of newborns with pulmonary 
hypertension who did not receive ECMO and a control group of newborns without pulmonary 
hypertension. Analyses were performed on lung tissue specimens obtained at post-mortem. 
Compared to the control group, the newborns with pulmonary hypertension had increased 
medial thickness, adventitial thickness and total wall thickness in relation to the external 
diameter of the vessel. In addition, there was an increase in cross sectional area of the media, 
adventitia and total wall thickness in transverse section in vessels with an external diameter of 
less than 150 µm. Newborns with pulmonary hypertension who were treated with ECMO had 
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decreased medial thickness in relation with the external vessel diameter and decreased medial 
cross sectional area in transverse section in vessels of less than 75 µm, compared to newborns 
with pulmonary hypertension who did not receive ECMO. Furthermore, there was a decrease 
in medial thickness in relation with the external diameter and decreased cross sectional area of 
the media, adventitia and total wall thickness in transverse section in blood vessels with an 
external diameter of between 75 and 150 µm. 
On the basis of these findings, we concluded that ECMO treatment for pulmonary 
hypertension decreased the abnormal morphometry that developed in the small pulmonary 
blood vessels. The underlying mechanisms responsible for this are as yet unknown. 
 
Part 2 describes the effects of ECMO on cerebral oxygenation and haemodynamics. 
Chapter 4 gives an introduction to these topics and outlines the risk factors for the 
development of cerebral lesions in newborns treated with ECMO. 
Veno-arterial ECMO involves ligation of the right internal jugular vein and the right common 
carotid artery. In the literature, discussion is ongoing about whether or not there is an 
increased incidence of lesions in the right cerebral hemisphere with the application of veno-
arterial ECMO. 
Chapter 5 describes the effects of the initiation of veno-arterial ECMO on the oxygenation 
and haemodynamics of the left and right cerebral hemispheres in a study in newborns. 
Ligation of the right common carotid artery caused a decrease in cerebral oxygenation. 
However, this decrease was of the same magnitude in both cerebral hemispheres. Ligation of 
the right internal jugular vein did not cause any change in cerebral oxygenation. After the 
initiation of ECMO, an increase was observed in cerebral oxygenation and in cerebral blood 
volume, once again to the same extend in both hemispheres. In addition, increases of equal 
magnitude were seen in the blood flow velocities in the left and right medial cerebral arteries. 
As expected, ligation of the right common carotid artery led to reversal of the blood flow 
direction in this vessel. In three out of the 10 patients we examined, asymmetrical cerebral 
lesions were found. However, these did not prove to be related to differences in study 
variables between the right and left cerebral hemispheres. 
The initiation of veno-arterial ECMO caused changes in cerebral oxygenation and 
haemodynamics, but there were no differences between the left and right cerebral 
hemispheres. 
Chapter 6 describes the haemodynamic effects that occur with opening of the bypass bridge 
during veno-arterial ECMO in a study on lambs. The bridge connects the arterial and venous 
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sides of the veno-arterial ECMO system. In emergency situations, this bridge can be opened and 
the blood flow from the ECMO system to the patient can be stopped. Thus, the circulation within 
the ECMO circuit can be maintained. The bridge normally remains closed, but it needs to be 
opened intermittently to avoid clot formation from blood stasis. In the lamb, opening the bypass 
bridge gave rise to an arterio-venous shunt and reversal of the blood flow direction in the ECMO 
circuit. Thus, the blood flowed out on the arterial side and re-entered on the venous side. This led 
to a decrease in mean arterial blood pressure and mean blood flow velocity in the left common 
carotid artery. In addition, there were increases in cerebral venous pressure, the pressure in the 
superior sagittal sinus, the cerebral concentration of deoxygenated haemoglobin and the cerebral 
blood volume. The concentration of oxygenated haemoglobin in the cerebrum decreased. 
Opening the bypass bridge therefore resulted in significant cerebral haemodynamic changes that 
might contribute to the development of cerebro-vascular complications.  
These changes occurred irrespective of the ECMO pump flow rate or duration that the bridge 
was kept open, but could be avoided by adapting the bridge construction. 
Chapter 7 describes the effects on cerebral oxygenation and haemodynamics of a patent ductus 
arteriosus with left-to-right shunt during veno-arterial ECMO. In the fetus, the ductus arteriosus 
is a connection between the pulmonary artery and the aorta. Newborns with pulmonary 
hypertension often have right-to-left shunt over this duct. During ECMO treatment, pulmonary 
hypertension decreases and the right-to-left shunt over the duct can reverse into a left-to-right 
shunt. 
In the lamb, the ductus arteriosus was kept open artificially (to produce left-to-right shunt) and 
ECMO was started. Subsequently, the duct was closed. Closing the duct led to increases in 
cerebral oxygenation, mean arterial blood pressure, blood flow velocity in the left common 
carotid artery and cerebral oxygenation. 
The findings suggested that during veno-arterial ECMO with left-to-right shunt over the ductus 
arteriosus, there was decreased cerebral circulation and oxygenation. 
 
Part 3 describes aspects of veno-venous ECMO. 
Chapter 8 gives an introduction to veno-venous ECMO and discusses the advantages and 
disadvantages in comparison with veno-arterial ECMO. In veno-venous ECMO, there are 
limitations regarding the level of oxygenation than can be achieved. This is due to the occurrence 
of recirculation, because a certain amount of the oxygenated blood that enters the patient via the 
cannula drains directly back into the ECMO system and does not contribute to oxygenating the 
patient. 
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Chapter 9 describes the ultrasound dilution method as a technique to measure the amount of 
recirculation during veno-venous ECMO. In a study on lambs, the amount of recirculation was 
measured during veno-venous ECMO using a double lumen catheter while the ECMO pump was 
set at different flow rates. The results of the ultrasound dilution method were compared to those 
obtained using two other methods described in the literature (the so-called "mixed venous 
oxygen method" and the "central venous line method"). All three methods revealed that the 
amount of recirculation increased with increasing ECMO pump flow rates. The results of the 
ultrasound dilution method were closest to those of the "mixed venous oxygen method", which is 
considered to be the best standard. In contrast with the "mixed venous oxygen method" and the 
"central venous line method", the ultrasound dilution method was easy to apply and it therefore 
appears to be a good method to quantify the amount of recirculation during veno-venous ECMO. 
 
Part 4 presents the General Discussion and recommendations for further research. 
In conclusion, we found that the survival rates of patients treated with ECMO at our centre were 
in agreement with those of other centres. Major causes of mortality were pulmonary and cerebral 
complications. 
The beneficial effect of ECMO on pulmonary hypertension in newborns with the meconium 
aspiration syndrome, sepsis or idiopathic pulmonary hypertension can be explained by a decrease 
in the abnormal structure of the vessel walls in small pulmonary arteries. 
The initiation of veno-arterial ECMO caused changes in cerebral oxygenation and 
haemodynamics, but there were no differences between the left and right cerebral hemispheres. 
Repeated opening of the bypass bridge, necessary to prevent thrombus formation, resulted in 
significant changes in cerebral oxygenation and perfusion. 
An open duct with left-to-right shunt during veno-arterial ECMO could lead to compromised 
cerebral oxygenation and haemodynamics. 
With the aid of the ultrasound dilution method, the amount of recirculation during veno-venous 
ECMO could be adequately quantified and this offers a method to evaluate interventions that aim 
to reduce the amount of recirculation when the level is too high. 
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SAMENVATTING 
 
Extracorporele membraan oxygenatie (ECMO) is een behandeling die wordt toegepast bij 
(bijna) voldragen pasgeborenen met ernstige respiratoire insufficiëntie, bij wie met optimale 
conventionele behandeling geen adequate oxygenatie bereikt kan worden. Bij ECMO vindt de 
oxygenatie van bloed plaats buiten het lichaam in een kunstlong, geheten de 
membraanoxygenator. 
Dit proefschrift bestudeert de effecten van ECMO op de long en de hersenen en is in 4 delen 
ingedeeld. 
 
Deel 1 beschrijft de ervaringen van onze kliniek met ECMO behandeling.  
In hoofdstuk 1 wordt een algemene inleiding gegeven over de ontstaansgeschiedenis van de 
techniek van ECMO, de selectie van patiënten en de behandeling.  
Hoofdstuk 2 beschrijft de resultaten van ECMO behandeling gedurende 12.5 jaar in 186 
pasgeborenen. Indicaties voor ECMO behandeling waren meconium-aspiratie-syndroom, 
congenitale hernia diafragmatica, sepsis/pneumonie en idiopathische pulmonale hypertensie. 
De overleving varieerde, afhankelijk van de diagnose, tussen 65% en 95%. Vijfendertig 
pasgeborenen overleden. Belangrijke oorzaken van overlijden waren respiratoire insufficiëntie 
en intracraniële bloeding. In totaal hadden 13 (7.0%) patiënten een intracraniële bloeding en 
17 (9.1%) een cerebraal infarct. Er was geen verschil in de incidentie van cerebrale laesies 
tussen de linker of rechter hemisfeer. 
Hoofdstuk 3 beschrijft de morfometrische analyse van de longvaten in pasgeborenen na 
behandeling met ECMO. Bekend is dat er bij pulmonale hypertensie van de pasgeborene 
sprake is van een abnormale morfometrie van de pulmonale bloedvaten, met toegenomen 
dikte van de media en adventitia. De morfometrie van pulmonale vaten van pasgeborenen die 
behandeld zijn met ECMO voor pulmonale hypertensie door meconium-aspiratie-syndroom, 
sepsis of idiopathisch, werd vergeleken met die van pasgeborenen met pulmonale hypertensie 
die geen ECMO behandeling kregen en met een controle groep van pasgeborenen zonder 
pulmonale hypertensie. Hierbij werd gebruik gemaakt van longpreparaten die verkregen zijn 
bij obducties.  
Pasgeborenen met pulmonale hypertensie hadden, in vergelijking met de controle groep, een 
toegenomen mediadikte, adventitiadikte en totale wanddikte ten opzichte van de externe 
diameter van het vat. Verder bestond er een toegenomen oppervlakte van media, adventitia en 
totale wanddikte op een dwarse doorsnede, in longvaten met een externe diameter kleiner dan 
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150 µm. Pasgeborenen met pulmonale hypertensie die met ECMO waren behandeld hadden 
in vergelijking met niet met ECMO behandelde pasgeborenen met pulmonale hypertensie, een 
verminderde mediadikte ten opzichte van de externe diameter en een verminderd oppervlakte 
op de dwarse doorsnede in vaten met een externe diameter kleiner dan 75 µm. Verder hadden 
zij een verminderde mediadikte ten opzichte van de externe diameter en een verminderd 
oppervlak van media, adventitia en totale wanddikte op de dwarse doorsnede in vaten met een 
externe diameter tussen 75 en 150 µm. 
Uit deze bevindingen concluderen wij dat ECMO behandeling voor pulmonale hypertensie de 
afwijkende morfometrie die bestaat in de kleine longvaten, vermindert. De onderliggende 
mechanismen welke hier toe bijdragen zijn nog onbekend. 
 
Deel 2 beschrijft de effecten van ECMO op de cerebrale oxygenatie en hemodynamiek. 
Hoofdstuk 4 geeft hierover een inleiding, waarbij risicofactoren voor het ontstaan van 
cerebrale laesies bij pasgeborenen die met ECMO worden behandeld worden beschreven. 
Bij veno-arteriële ECMO worden zowel de rechter vena jugularis interna als de rechter arteria 
carotis communis onderbonden. Er bestaat in de literatuur discussie over de vraag of er meer 
cerebrale laesies voorkomen in de rechter hemisfeer door de toepassing van veno-arteriële 
ECMO.  
Hoofdstuk 5 beschrijft de effecten van initiatie van veno-arteriële ECMO op de oxygenatie en 
hemodynamiek van de linker en rechter cerebrale hemisfeer in een studie bij pasgeborenen. 
Ligatie van de rechter arteria carotis communis veroorzaakte een afname van de cerebrale 
oxygenatie. Deze afname was echter in beide cerebrale hemisferen even groot. De ligatie van 
de rechter vena jugularis interna veroorzaakte geen veranderingen in de cerebrale oxygenatie. 
Na de start van ECMO werd er een toename gezien van de cerebrale oxygenatie en het 
cerebrale bloedvolume, opnieuw even groot in beide cerebrale hemisferen. Ook was er een 
even grote toename van de bloedstroomsnelheden in de rechter en linker arteria cerebri media. 
Zoals verwacht mocht worden trad er door de ligatie van de rechter arteria carotis communis  
een omkering van de bloedstroomrichting hierin op. Bij drie van de tien onderzochte patiënten 
was er sprake van asymmetrische cerebrale laesies, welke echter niet gerelateerd bleken te 
zijn aan verschillen tussen rechter en linker cerebrale hemisfeer in de bestudeerde variabelen. 
De initiatie van veno-arteriële ECMO veroorzaakte veranderingen in cerebrale oxygenatie en 
hemodynamiek zonder verschil in effect tussen de linker en rechter cerebrale hemisfeer. 
Hoofdstuk 6 beschrijft de hemodynamische veranderingen gedurende opening van de brug bij 
veno-arteriële ECMO in een studie in lammeren. De brug is een verbinding tussen de arteriële 
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en veneuze zijde van het veno-arteriële ECMO systeem. In noodsituaties kan deze verbinding 
worden geopend en kan de bloedstroom vanuit het ECMO systeem richting patiënt worden 
afgesloten. Op deze manier kan er circulatie in het ECMO systeem blijven bestaan. De brug is 
dus normaal gesproken afgesloten, maar moet intermitterend geopend worden om te 
voorkomen dat zich hier stolsels vormen door stase van bloed. Opening van de brug 
resulteerde, door het ontstaan van een arterio-veneuze shunt, in een verandering van de 
bloedstroomrichting in het ECMO circuit. Hierbij stroomde het bloed aan de arteriële zijde 
het lam uit en aan de veneuze zijde in. Hierdoor trad een afname op in de gemiddelde arteriële 
bloeddruk en gemiddelde bloedstroomsnelheid in de linker arteria carotis communis. Verder 
stegen de centraal veneuze druk, de druk in de sinus sagitalis superior, de cerebrale 
concentratie van gedeoxygeneerd hemoglobine en het cerebrale bloedvolume. De concentratie 
van geoxygeneerd hemoglobine in het cerebrum nam af. Opening van de brug resulteerde dus 
in significante cerebrale hemodynamische veranderingen, die zouden kunnen bijdragen aan 
het optreden van cerebrale vasculaire complicaties. Deze veranderingen traden op bij iedere 
openingstijd en ECMO pomp snelheid, maar konden worden voorkomen met een aangepaste 
brug constructie. 
Hoofdstuk 7 beschrijft de effecten van een ductus arteriosus met links-rechts shunt tijdens 
veno-arteriële ECMO op de cerebrale oxygenatie en hemodynamiek. De ductus arteriosus is 
een verbinding tussen de arteria pulmonalis en de aorta. Bij pasgeborenen met pulmonale 
hypertensie bestaat er vaak een rechts- links shunt over deze ductus. Tijdens ECMO 
behandeling zal de pulmonale hypertensie verminderen en kan de rechts- links shunt over de 
ductus Botalli veranderen in een links-rechts shunt. In deze studie werd bij lammeren de 
ductus kunstmatig opengehouden zodat er een links-rechts shunt bestond, waarna veno-
arteriële ECMO werd gestart. Vervolgens werd de ductus gesloten. Sluiting van de ductus 
leidde tot een toename van de cerebrale oxygenatie, gemiddelde arteriële bloeddruk,  
bloedstroomsnelheid in de linker arteria carotis communis en cerebrale zuurstofvoorziening. 
Dit suggereert dat in de periode van links-rechts shunt over de ductus arteriosus tijdens veno-
arteriële ECMO er sprake is van een verminderde cerebrale circulatie en oxygenatie. 
 
Deel 3 beschrijft aspecten van veno-veneuze ECMO.  
Hoofdstuk 8 geeft een inleiding over veno-veneuze ECMO, waarbij de voor- en nadelen ten 
opzichte van veno-arteriële ECMO worden besproken. Bij veno-veneuze ECMO is er een 
beperking in de mate van oxygenatie die kan worden bereikt. Dat komt doordat er recirculatie 
optreedt, waarbij een deel van het geoxygeneerde bloed dat vanuit de cannule de patiënt in 
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gaat, direct weer wordt gedraineerd naar het ECMO systeem en niet bijdraagt aan de 
oxygenatie van de patiënt.  
Hoofdstuk 9 beschrijft de ultrasound dilutiemethode als techniek om de hoeveelheid 
recirculatie tijdens veno-veneuze ECMO te bepalen. In een studie in lammeren tijdens veno-
veneuze ECMO met behulp van een dubbellumencatheter werd de hoeveelheid recirculatie 
gemeten bij verschillende ECMO pompsnelheden met de ultrasound dilutie methode en 
vergeleken met twee andere, in de literatuur beschreven methodes (de ‘gemengd veneuze 
zuurstof methode’ en de ‘centraal veneuze lijn methode’). Voor alle drie de genoemde 
methodes werd gevonden dat de hoeveelheid recirculatie toenam met een toenemende ECMO 
pomp snelheid. De resultaten van de ultrasound dilutie methode kwamen het beste overeen 
met die van de ‘gemengd veneuze zuurstof methode’, welke wordt gezien als de beste 
standaard methode. De ultrasound dilutie methode kan, in tegenstelling tot de ‘gemengd 
veneuze zuurstof methode’ en de ‘centraal veneuze lijn methode’ gemakkelijk worden 
toegepast en lijkt daarom een goede methode om de hoeveelheid recirculatie tijdens veno-
veneuze ECMO te kwantificeren. 
 
Deel 4 beschrijft de algemene discussie en voorstellen voor toekomstig onderzoek.  
In conclusie kan worden geconstateerd dat de overleving van patiënten die in ons centrum met 
ECMO zijn behandeld overeenkomt met die in andere centra. Belangrijke oorzaken van 
mortaliteit zijn pulmonale en cerebrale complicaties.  
Het gunstige effect dat ECMO heeft op pulmonale hypertensie in pasgeborenen met 
meconium aspiratie syndroom, sepsis of idiopathisch kan worden verklaard door een afname 
van de afwijkende structuur van de vaatwand van de kleine long arteriën.  
De initiatie van veno-arteriële ECMO veroorzaakt veranderingen in cerebrale oxygenatie en 
hemodynamiek, maar zonder verschil in effect tussen de linker en rechter cerebrale hemisfeer.  
Herhaalde opening van de brug, nodig om thrombusvorming te voorkomen, resulteerde in 
significante veranderingen in de cerebrale oxygenatie en perfusie.  
Een open ductus Botalli met links-rechts shunt tijdens veno-arteriële ECMO kan leiden tot 
een gecompromitteerde cerebrale oxygenatie en hemodynamiek. 
Met behulp van de ultrasound dilutie methode kan recirculatie tijdens veno-veneuze ECMO 
adequaat worden gekwantificeerd en dat biedt een methode voor de evaluatie van handelingen 
die worden uitgevoerd om de hoeveelheid recirculatie te verminderen als deze te hoog is. 
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DANKWOORD 
 
Wat door anderen voor mij al geschreven is, is waar. Het schrijven van een proefschrift vergt 
veel energie, maar de afronding ervan schaft veel genoegen. Zoals voor de klinische 
behandeling van patiënten met ECMO geldt dat het bij uitstek een multidisciplinaire 
aangelegenheid is, zo geldt dat zeker ook voor het doen van onderzoek. Velen hebben een 
belangrijke bijdrage geleverd aan het tot stand komen van dit proefschrift. Ik vind het 
belangrijk hen daar hiervoor nogmaals te bedanken. 
 
Mijn promotor, Prof. Dr. R.C.A. Sengers. Beste Rob, het  was een uitstekende beslissing om 
jou in september 2001 te vragen om mijn promotor te zijn. Op dat moment was er om dive rse 
redenen een stagnatie in de voortgang van het onderzoek. Je stimulerende inbreng, oog voor 
de grote lijn en ruime ervaring in de begeleiding van promovendi zijn van grote waarde 
gebleken. Je motto: “ik heb geen drempel”, bleek keer op keer waar te zijn als er ‘even’ snel 
iets overlegd moest worden. Voor dit alles mijn bijzondere dank. 
 
Mijn co-promotor, Dr. K.D. Liem. Beste Djien, jij stond aan de basis van dit proefschrift met 
het idee om de NIRS techniek verder te gebruiken om klinische vraagstellingen rondom 
ECMO te bestuderen. Onze samenwerking op onderzoeksgebied werd vooraf gegaan door een 
bezoek aan je ouders in Indonesië, hetgeen heel bijzonder was.  Ik heb heel veel geprofiteerd 
van alle kennis en kunde die je hebt opgebouwd rondom je eigen onderzoek. Of het nu ging 
om praktische aspecten van metingen, theorie over de cerebrale circulatie of vragen over het 
bewerken van een grafiekje in Axum, je was altijd bereid mee te denken en zocht met groot 
enthousiasme mee naar oplossingen. Ik hoop dat wij in de toekomst nog vaak samen aan 
vraagstellingen kunnen werken. Ik ben je bijzonder dankbaar voor al hetgeen je hebt gedaan. 
 
Mijn co-promotor, Dr. F.H.J.M. van der Staak. Beste Frans, wij hebben de afgelopen jaren 
intensief samengewerkt op het ECMO gebied. Ik heb grote bewondering voor je 
deskundigheid en systematische benadering van vraagstukken. Dat laatste geldt zeker ook 
voor het bewerken van de verschillende manuscripten. Je bijna encyclopedische kennis van 
data heeft hierbij zeker ook geholpen. Ik hoop dat wij nog vaak op hoogte de effecten van 
hypoxie zullen ervaren. 
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Henriëtte Wilbers, verpleegkundig ECMO coördinator. Beste Henriëtte, jou in het bijzonder 
ben ik veel dank verschuldigd. Gedurende vele jaren heb jij een zeer belangrijke rol vervuld 
in de zorg voor onze patiënten, de protocollering van de behandeling, het initiëren van nieuwe 
ontwikkelingen en vele andere zaken. De vele experimenten waren onmogelijk geweest 
zonder jou steun. Op het moment dat dit geschreven wordt is er grote zorg over je 
gezondheid. Ik hoop dat er toch ook weer betere tijden aanbreken. 
 
Drs J. Hopman, beste Jeroen, je inbreng in de verschillende manuscripten was geweldig. Een 
opmerking in de trant van “wat je eigenlijk bedoelt staat er niet” was altijd weer reden om een 
en ander nog eens kritisch te bekijken, waardoor het aan waarde won. Ook mijn worsteling 
met de verschillende registratiesystemen wist jij altijd weer in goede banen te leiden. Voor dit 
alles heel veel dank. 
 
Collega’s van de afdeling Neonatologie. Beste Berty, Djien, Ethel, Katerina, Louis, René, 
Sabine, Viola en Willem. Enigszins woelige tijden hebben wij de afgelopen jaren mee-
gemaakt. Toch was er bij jullie een grote bereidheid om klinisch werk te doen op momenten 
dat er metingen moesten worden gedaan of geschreven moest worden. Voor de ruimte die 
jullie hiervoor geboden hebben en de belangstelling die jullie voor het onderzoek getoond 
hebben wil ik iedereen bijzonder bedanken. 
 
Prof. Dr. D. Tibboel, Beste Dick, jij bent één van die mensen die in staat is verwondering om 
te zetten in een onderzoeksvraag, hetgeen volgens mij het kenmerk is van grote 
wetenschappers. Ik wil je bijzonder bedanken voor alle stimulerende ideeën die naar voren 
zijn gekomen tijdens ons frequente overleg. Natuurlijk dank ik je ook voor je ja als antwoord 
op de vraag om zitting te nemen in de manuscriptcommissie. Ik hoop dat wij verder samen 
kunnen werken op de manier zoals in dit proefschrift in gang gezet is. Beide hebben wij 
vastgesteld dat de afstand tussen Rotterdam en Nijmegen niet (meer) 1 brug te ver is. 
 
Verpleegkundigen en maatschappelijk werkenden van de afdeling Neonatologie. Ik wil jullie 
bedanken voor de samenwerking die het mogelijk heeft gemaakt om tot dit onderzoek te 
komen. Uit de ouderdag die wij jaarlijks organiseren weet ik dat er ook vanuit die kant grote 
waardering is voor jullie inzet en deskundigheid. 
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Medewerkers van de afdeling ExtraCorporale Circulatie. Wat zou ECMO zijn zonder jullie 
medewerking? De onvoorspelbaarheid van de momenten waarop ECMO behandeling nodig is 
heeft grote weerslag op jullie organisatie. Desondanks kunnen wij toch steeds weer gebruik 
maken van jullie expertise, ook in onderzoek- en scholingssituaties! Als leden van de 
klinische werkgroep nog een bijzonder woord van waardering voor Dr. Patrick Weerwind en 
Herman Zegers. 
 
Collega’s van de afdeling Kinderchirurgie. Beste René, Paul, René, Marc en Ivo. ECMO heeft 
de samenwerking tussen onze afdelingen een goede impuls gegeven. Bedankt voor jullie 
bereidheid om tijdens operaties toch steeds maar ‘even’ een paar minuten te wachten totdat de 
NIRS signalen gestabiliseerd waren! 
 
Leden van de manuscript commissie. Prof. Dr. F.K. Lotgering, Beste Fred, dank je wel dat je 
als voorzitter van de manuscriptcommissie wilde optreden en voor het door mij zeer 
gewaardeerde overleg. Prof. Dr. M.H.J. Brouwer, Beste René, hartelijk dank dat je lid van de 
manuscriptcommissie wilde zijn. De afgelopen jaren is al bewezen dat er meer indicaties voor 
ECMO zijn, dan de in dit proefschrift beschrevene. Ik hoop op een verdere vruchtbare 
samenwerking. 
 
Dames van het secretariaat, zowel van de afdeling als van de staf. Jullie zijn in veel opzichten 
onze steun en toeverlaat. De deur staat altijd open en dat hebben jullie geweten! Sorry voor de 
vele onderbrekingen als er weer even iets geregeld moest worden en het liefste onmiddellijk. 
Corrie van Wolferen. Beste Corrie, op fantastische wijze geef jij leiding aan het secretariaat 
van onze staf. Verder ben je de computerexpert bij uitstek. Zonder die kennis kan eigenlijk 
niemand een boekje schrijven. 
 
De medeauteurs van de diverse artikelen, de medewerkers van het ‘dierenlab’ in het bijzonder 
Theo Arts en Alex Hanssen, Jos Evers van de afdeling Fysiologie en iedereen die in welke 
vorm dan ook bij “ECMO behandeling” is betrokken en daardoor een bijdrage heeft geleverd 
aan dit proefschrift, wil ik bedanken. 
 
De paranimfen, Dr. Ben Semmekrot en Drs. Berry van Suntenmaartensdijk. Beste Ben, je 
hebt een belangrijke bijdrage geleverd aan mijn opleiding tot neonatoloog. Van collega’s zijn 
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wij vrienden geworden en die vriendschap betekent veel voor mij. Wij moeten nu tijd over 
houden om wat vaker de route Radboud-Ooij hardlopend te kunnen afleggen. 
Beste Berry, studiemaatje van het eerste uur. Om allerlei redenen zijn onze gezinnen met 
elkaar verweven geraakt. Laten wij dat nog lang zo houden. Ik vind het fantastisch dat jij 
vandaag mijn paranimf kunt zijn. 
Mijn ouders hebben altijd het belang van opleidingen benadrukt en hebben mij in staat gesteld 
deze te volgen. Alleen hierdoor heeft dit proefschrift kunnen ontstaan. Pa en Ma, mijn dank 
voor alles wat jullie voor mij hebben gedaan is niet in woorden uit te drukken. 
 
Lieve Len, zonder jou zouden er een heleboel dingen niet zijn. Dat geldt zeker ook voor dit 
proefschrift. In alle opzichten heb je mij als mijn maatje steeds gesteund. Zoals al vaak 
gezegd, zijn er in het leven maar twee dingen echt belangrijk: liefde en gezondheid. Laten wij 
dat zou houden. En nu: UTTMV!! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 195
CURRICULUM VITAE 
 
Arno van Heijst, werd op 20 juli 1960 geboren in Mierlo. Na in 1978 zijn VWO diploma te 
hebben behaald aan het Pius X College in Almelo, begon hij in dat jaar aan de studie 
Geneeskunde aan de Katholieke Universiteit Nijmegen. Het artsexamen werd met succes 
afgelegd in 1985. In 1986 was hij werkzaam als arts-assistent thoraxchirurgie in het 
Academisch Ziekenhuis Leiden (Hoofd: Prof. Dr. HA Huysmans). Hier werd zijn 
belangstelling gewekt voor intensive care geneeskunde en extracorporele circulatie, niet 
wetende dat die twee zaken later nog eens samen zouden komen. Vanaf  december 1985 werd 
de militaire dienstplicht vervuld. Het grootste deel van die tijd was hij werkzaam als arts-
assistent anesthesiologie in het Militair Hospitaal Anton Mathijssen te Utrecht (Hoofd: Dr. A 
van den Bogaert). 
Van maart 1988 tot oktober 1988 was hij werkzaam als AGNIO kindergeneeskunde in het 
Academisch Ziekenhuis Nijmegen (Hoofd: Prof. Dr. GB Stoelinga). In oktober 1998 werd 
begonnen met de specialistenopleiding Kindergeneeskunde. Van 1 oktober 1988 tot 1 maart 
1990 in het Canisius-Wilhelmina Ziekenhuis te Nijmegen (Opleider: Dr. PMV van 
Wieringen). Van 1 maart 1990 tot 1 oktober 1993 in het Academisch Ziekenhuis Nijmegen 
(Opleiders: Prof. Dr. GB Stoelinga en Prof. Dr. RCA Sengers). Op 1 oktober 1992 werd reeds 
begonnen met de deelspecialisatie Neonatologie (Opleiders: Dr. H Boon en Prof. Dr. LAA 
Kollée). Op 1 oktober 1994 werd deze opleiding beëindigd en vanaf dat moment is hij 
werkzaam als staflid op de afdeling Neonatologie van (inmiddels) het Universitair Medisch 
Centrum St Radboud te Nijmegen. Sinds 1 juni 1997 is hij coördinator van het neonatale 
ECMO programma. 
 
